var title_f27_57_28560="Radiosurg radiother";
var content_f27_57_28560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Radiotherapy and radiosurgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) In radiotherapy, radiation is delivered to both normal and cancer tissues. The therapeutic efficacy is derived from the increased DNA repair capacity of normal cells relative to tumor cells when repeatedly exposed to small doses of radiation. In the illustration, the dashed line represents the radiation field. The solid square represents the intracranial space. The striped circle represents the tumor volume. In this theoretical illustration, both the tumor and the normal tissue receive 2 Gy of ionization radiation. B) In radiosurgery, multiple, non-parallel radiation beams are converged on the tumor volume. The radiation received by the normal tissue in each beam path is minimal relative to the point of beam convergence. In this illustration, the dashed line represents the radiation field. The solid square represents the intracranial space. The striped circle represents the tumor volume. The tumor volume receives 8 Gy of radiation from four radiation sources while the surrounding tissues receive significantly lower doses of radiation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28560=[""].join("\n");
var outline_f27_57_28560=null;
var title_f27_57_28561="Deep morphea";
var content_f27_57_28561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F77587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F77587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Deep morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The areas affected by deep morphea have a cobblestone appearance with subcutaneous atrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28561=[""].join("\n");
var outline_f27_57_28561=null;
var title_f27_57_28562="Patient information: Nausea and vomiting in adults (The Basics)";
var content_f27_57_28562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/62/32738\">",
"         Patient information: Dehydration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/34/34338\">",
"         Patient information: Diarrhea in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/42/30370\">",
"         Patient information: Motion sickness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/3/9267\">",
"         Patient information: Viral gastroenteritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/54/22371\">",
"         Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nausea and vomiting in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nausea-and-vomiting-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30481847\">",
"      <span class=\"h1\">",
"       What are nausea and vomiting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Nausea is the feeling you get when you think you might throw up. Vomiting is when you actually throw up. These two symptoms can happen together. But sometimes people feel nauseous without throwing up, and some people throw up without feeling nauseous first.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30481854\">",
"      <span class=\"h1\">",
"       What causes nausea and vomiting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common causes include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Food poisoning &ndash;",
"        </strong>",
"        This can happen if you eat food that has gone bad. It is basically an infection in your stomach. Infections like these often also cause diarrhea. Other kinds of infections that affect the stomach or intestines can also cause nausea and vomiting.",
"       </li>",
"       <li>",
"        <strong>",
"         Dizziness or motion sickness",
"        </strong>",
"        &ndash; This can happen if you're on a boat or in a car, or something else that moves. It can also happen if there's something wrong inside your ears that affects your balance.",
"       </li>",
"       <li>",
"        <strong>",
"         Medicines",
"        </strong>",
"        &ndash; Lots of different medicines can cause nausea or vomiting. Some examples are antidepressants, antibiotics, vitamins, birth control pills, and pain medicines. People who are on chemotherapy for cancer treatment or who have been under anesthesia also often have nausea or vomiting.",
"       </li>",
"       <li>",
"        <strong>",
"         Pregnancy &ndash;",
"        </strong>",
"        Many women who are pregnant have nausea or vomiting. They usually call it &ldquo;morning sickness.&rdquo;",
"       </li>",
"       <li>",
"        <strong>",
"         Gastroesophageal reflux disease (GERD) &ndash;",
"        </strong>",
"        GERD is condition that causes the juices that are in the stomach to leak back up into the esophagus, the tube that connects the throat to the stomach. It can sometimes cause nausea. Plus, people sometimes confuse the leaking stomach juices with vomit.",
"       </li>",
"       <li>",
"        <strong>",
"         Problems with the stomach or intestines",
"        </strong>",
"        &ndash; In some people, the stomach or intestines do not move food along the way that they are supposed to. In others, the intestines can get blocked. Both of these problems can cause nausea or vomiting.",
"       </li>",
"       <li>",
"        <strong>",
"         Migraine headaches &ndash;",
"        </strong>",
"        Some people who get migraine headaches have nausea during their headaches.",
"       </li>",
"       <li>",
"        <strong>",
"         Alcohol",
"        </strong>",
"        &ndash; Drinking too much alcohol can cause nausea and vomiting.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30481861\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if your symptoms last longer than a day or two, or you have severe symptoms. You should also call if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have chest or belly pain",
"       </li>",
"       <li>",
"        Throw up blood or something that looks like tar",
"       </li>",
"       <li>",
"        Have a bowel movement that is black",
"       </li>",
"       <li>",
"        Have a fever higher than 101&ordm;F",
"       </li>",
"       <li>",
"        Have a severe headache or stiff neck",
"       </li>",
"       <li>",
"        Feel very tired or have trouble getting up",
"       </li>",
"       <li>",
"        Show signs of dehydration (meaning that your body has lost too much water). Signs of dehydration include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Feeling very tired",
"       </li>",
"       <li>",
"        Being very thirsty or having a dry mouth or tongue",
"       </li>",
"       <li>",
"        Muscle cramps",
"       </li>",
"       <li>",
"        Dizziness",
"       </li>",
"       <li>",
"        Confusion",
"       </li>",
"       <li>",
"        Urine that is dark yellow, or not needing to urinate for more than 5 hours",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30481868\">",
"      <span class=\"h1\">",
"       What can I do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Drink lots of fluids, if possible",
"       </li>",
"       <li>",
"        Try eating, but start with foods that have a lot of fluid in them. Good examples are soup, Jell-O, and popsicles. If you do okay with those foods, you can try soft, bland foods, such as plain yogurt. Foods that are high in carbohydrates (&ldquo;carbs&rdquo;), like bread or saltine crackers, can help settle your stomach. Some people also find that ginger or peppermint help with nausea. You should avoid foods that have a lot of fat in them. They can make nausea worse. Call your doctor if your symptoms come back when you try to eat.",
"       </li>",
"       <li>",
"        Avoid strong smells, such as the smell of perfume",
"       </li>",
"       <li>",
"        Take medicines with meals, if possible. But check the bottle first, because some medicines must be taken on an empty stomach.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30481875\">",
"      <span class=\"h1\">",
"       How are nausea and vomiting treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have been vomiting a lot for more than a day, your doctor or nurse will ask you lots of questions to try to find out what might be causing your symptoms. He or she might also:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Give you fluids through a tube that goes in a vein",
"       </li>",
"       <li>",
"        Give you medicines that control nausea and vomiting. Some examples include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?32/50/33573?source=see_link\">",
"         Prochlorperazine",
"        </a>",
"        (brand name: Compro)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2806?source=see_link\">",
"         Promethazine",
"        </a>",
"        (brand name: Phenergan)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?33/45/34517?source=see_link\">",
"         Metoclopramide",
"        </a>",
"        (brand name: Reglan)",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/24/24965?source=see_link\">",
"         Ondansetron",
"        </a>",
"        (brand name: Zofran)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Schedule tests for you to help find out why you have nausea or vomiting, such as a stomach x-ray",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30481882\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       Patient information: Diarrhea in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/42/30370?source=see_link\">",
"       Patient information: Motion sickness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"       Patient information: Dehydration (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=see_link\">",
"       Patient information: Viral gastroenteritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"       Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/57/28562?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15733 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-BF0A88A09A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28562=[""].join("\n");
var outline_f27_57_28562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30481847\">",
"      What are nausea and vomiting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30481854\">",
"      What causes nausea and vomiting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30481861\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30481868\">",
"      What can I do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30481875\">",
"      How are nausea and vomiting treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30481882\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/42/30370?source=related_link\">",
"      Patient information: Motion sickness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=related_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/3/9267?source=related_link\">",
"      Patient information: Viral gastroenteritis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_57_28563="Histology nodular melanoma";
var content_f27_57_28563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 375px; height: 278px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEWAXcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAopCaaW5oHYdmmlhTS1MLUikhxakDUxjzTc0XKUR5eml6YWrjvHHjD+wSlnZwedqMqb1L8RRLnG5z+fFOEZTlyxNIQcnZHYs+RxWRq/iHT9MgaSecOy5HlxfOxI7YHf614teeI9WgS6bVtRmlaTrg7eo4UAdFx2HXvWNFHea/MFRZLeFfnZVbHJ/iYiu2GB+1N6G/sGj2C3+Juhtlbx2tXHUMytj8jVXWfifp1su3TYnu5DzwRjH4GvNdV07RdBsoTqcp3Sfd2rgE+nGada3mgWoKIqXLrII3QPu2nOBx3+lV7HDp3V2P2Kjuz0vRPifpNxbZ1bdp9yDjYQWUj1DD+VdpY6laX8Sy2dzFNGwyCjA8V4TJbaZeozKph2sQWTOODycEY9KP+EbntzLNZXkkcezcGQkEkDoR2qZYejLWLcQdH+Vn0Dvpd1fPugePdV8O3sf9qXL3WnHIlSb7yDGQV/Lp71euvjbPJLIljpQVP4JJH5x7ioll9a9o6oy9nJaWPdN+DSJMr52nJHBHpXznd/EbxhqbvHYEww7cb4YAW9znoPwrPTx941v9T0+z065YPZhpZ5QgJkU8BXB4PNP+zqnVor2MrXsfT4bFAb3r55tPix4qsi8N9b2d3IpwC8ZjOfQ4NdhoHxYhmmWPWbQW6sM+bH91T6cnn9PpUzwFaCva/oQ6Uluj1jPPtTkJwM4z7VzvhnxZpHiNZf7Lug8kTbXib5XHvj0963w1csouDtJWZk0Sg5p2ahDU8GkS0SqadmohTwaZDQ6ikpaYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACijmkzQAE0ZppakLcZoGkDcHrTSeaaWyKbnFItRHH61G1NZvemF6RooisTTd9NLc4phapuaJEd1exW0U0krgCKMysM87R3r548SeIJL/AFa5v2xJcSt8keeFA4UdegA7+vrXtHj50h8MXszR7nVNqsFyUycE14P4Y00ahcSSysNpHmPz27AV6eAjFRlUl0Oiikrsit7afULoBEaWZj97sv09BXToZLR0trKVUiiHLo3MrFerccAU67kmhuLW3023gTTzzMxzubg4x/nvWc1x5ovrNbd43jXbmXAEm4EAj24xWtWt7TS2hU59EJfxLc2TOJtylWVZQQ+P9rnI+lNi0KylsIg0bLJswHB27+Pv4HG73q7Yx5sYjclVmZA25F3KzdMD2rLns7yXUEjN7PBaSKJZmYfdI4wOwyQePes3Z9DO5pXdhHa6JcSrqEyrAA5jQ8ykEE5HpmrTeNVvbmJZLWWCYFITEijLsw6nHoOv0rC8VyQSww/6xJywVQpGAGzkt+BOK1ontdMsiUQRWagvvc/Oxx3yclqm19xre6Itf+xas7rcp5TwLvOGUB1JHQk84zj1rHuk0uxhWaC1h4jV1DsWkBbO07f1rWntLSZ7W/vH8kWqGUREbjKhGR8vscE/SqkF+t4/m6YYp3VkJkkUALnILDjGQOg7VopyS5U9jRVNNThLjxZqlzqaxWcJ2Kx3IGOScc8jpnBr0LRNZtodPMsyPcao6qJiq7FHTjP0NZmm6PFbatfiKAKCiNE8g65OcE98YrQiSHLwTS25lmY/u0fYxT2GcnjvTUrqzM7uJsxNb6kqDUrU7lyI5AcEc4yfwqZfCVk7bTeMj46Mo5PUc1TjiSOGBLeRmAO1A6klgBjk/h1xVqB7tcXSPLCS5jYEEA4OM4Pap55R+F2H7R9Tmbi3v9GvluYxNbTwSfu5lBAODxz3Br1/wt8RLC/tIRqMiw3BGHODw2e47fXkVxX2uG8H2O5l3QOrxhcHgjvnuc9PpWTrPheSxt/tdpK0sanGRw6D147VpNwxCUauj7hKCqarc+hbe4juIllhdXjYZDKcg1MGr578KeLb/QLlIpZCbctgiQkKfqPX3Fe4eHtXttZsRcWpII4dG6o2M4NefXw0qL7o5ZwcdzXVqeGqNcA0/PpWCMmh4NPBqIGnA00Q0SUUgpaZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUmaAFpppCaRmoGkJnnmo2PFKSKrXVzDbRmS4ljiQcFnbApGiRI3BOTn2rK1nXdO0iEyX91HEB/DnLH8K4/wAY/EG1trFotKeRryRisZC4JGcZGe3vXlFxbXFzKbrUS7MDkoSSFHU89z+vNddLCcy5qjsvxOiFO6uz0jVfi1YRA/2bay3PXlgQPyH+NYbfFrUWy0enxlecjaRt9+TzXNNK0IU6fYo6Y5ZmUDnjvznPapzK0TfuwhJOCrgHP4dvp710xpUFooX9WacsDs9L+KsE8YF3bIkwPzIH2MR6jPB+ma7vSdZtdTUm2ly6gFkPDLn1FeDajoUVw7TJi3RfvIRuzx1qpaXmpeFtSie3uGWMHKnkqVz0+ntUzwdKqv3Tsy5UmtYnv3iiXboF+TH5o8o/J6//AKuv4V4R4fuFGoX8SIIjJv2Rc4yDnH6Hiul1z4t2y+H7g/ZjDdYxtZDJGy/xDtyRnrXGWdxHNetqdtE0UbFSqA7ixYfz/wAKMNQnTpzVRWuEOxpTPI3hLbLbTR3Sqq7O6Hd29qryaSbMQNcTyXd5HOH27jnHOOCeSQR9MVNrDzLBbpDP5ct0+3IbG0nkFh3AxzUlxBaXUCidppCgX5h8pJHOP0/GklqQVtV1CCz1G1kneVNibVTacEkjPtxx71pxzmYgmNhEkRIQZBGOM4P6ZqOSNZXglURCNZlkKMMmMYxwex4rN8V+cIYJ7SYIElCMdvzLnGP8+9EtAWpY0rU11WVrlrVkmt1Oxn5QnoORxkmrEmmvc3Aa6KFSoGxhkR+rKQfvA/hjFJaW66fLttQSwwj5GA7DgDHbA5zVwSDhQAoD4DdNy44OPz4p2sO4l2Uu1IV5FngYMrrgMORx7gjtVKwgZNQkWF7dI5VVmhEewgDgluOvJ/KporhkvGBKMZACkII+5nBY+uf0xVLSoXa5upZSPslxNJvMh2Nzxge2AP0pAmXI1ubcsXffKzBlbBKKDkDYn046+9ZXi2yDTfaPL5i2FSflJIboPTk1q2FvHbWduqKVG07AWORz05/nUjWkE+nvZt5xWXcRK3zMrHOT+GTT6XQdSw0bzRjzk+R4w0mGwy+i/rnINZPizVJrMaZNBPJHCHbcSN4xhQVOO/XFM8Orc2jGyuFkdY0OHJJOMkYxnrgZqzc6dDrFsbS6cKW4SUdVYngY6f8A66Tu1dC62N7SpbW6trSeKN5N6IQuQABnqSO5/GorzXNQtby0+z2sESRAvdQu/DjOQEbPzHHb3/CnWUpjtYtPImjESCE7o9jMMHawPc8cfWq+sw7NHnzstjACEuJiDt/rk8/SonrqNaaFnWIbDXLRLuFmWZ0AQtypGeh9D2rP8H+IL/w5riqXQRlfLeGQnD47Z7EdjUv295IYJmaRldVcYGVPGeP5VV8RW8d3f2MaR5luVDYxgcniumk7r2c9i4yU1Znv2naxY30CSQXMXzD7pYAg+laKketfO0/hK7gz5RE3lqGYRsc/lWj4X8c6r4dvFh1WSa807kOko/eR+4Pp7VyvBKSvSlfyMJ0WldHvQPFPBPvWbpGpWurWMV5YTLNbyDIYfyPoa0FNcLTTsznaJgadmohTwaZm0PopAaWmSFFAOaKACiiigAooooAKKKKACiikz7UABppNBNMZxQUkBOKrXlzFaW0lxcyLFDGpZ3Y4AFQ6jqVnp6I99cxW6udqGRgu49cCuB+M14k/ggm2lWWGSVMmNsgg/TrV06bqTjHo2bQhzOxi+KPiu0geHQ0KR5x555Y/0X9a5S3+3a5CbqfVpVaVydseSFPv35rltLtPtt2IWZVGCRzgYFba2dqvlm189iw3GRTtHt09a9qVOlQXLDR/edqpxpoqPHJpuuwG/DOCfvsTyMcGrmp6jDiNXedfPlHzhSQuMHBx2PSo9f8AENm1pBFc2wdBujbzGIaMqDn8eB371DbwSqmRJnTljMsMpOcAj7p/z2rGU/aavdDdpaIvSMq7k3pGWJLEpxgcY9s+vtxWVqd9JY2EksPyyL8yRhCcjI5Ht7+pq/cXsl5c2ktu6hUC740QOHHTAz3z60k+bcx211G5aWRlRGcAKuMllwCD0otdGMVZmVBeW9xapZsXtpGj2tKXO6RupVfbNa8Mtpd2Kw3axsI2CsEJ+QnoVPp9az/IidAyXllJIxKqjDBOScgHGP8APepbG1iFyLpXCwcLIyjI4Hy49sd/r6UnHl1NYVNbIzvFljFtFtFAiwXCMwY5J+XGc56VsaKYk0CAHKlXLH3I4rKv2junNzvlZkjaMb8E7d2QTj1z+VM0vVZNPd9qRyxPyyN29x6VpyylTt1NJao376FfIWWYKT8wV1QvlWwDjHPSq2mia6ihW5uy1vayZt3HBkIA4J/T86fa3cMjrdWysropBO/LIGIycd+nX0otrvT7i5ubeW5RD5m8KsZyGIGR2wCRxya5rWdmYu9rFwQpLbTRs6xzYB2tyyjHc+uaikRJ3S1kIQSN8+VBztPAHbqKpCeQ6xPZqot0VT5V0R7Arz3+lWXeeBJFkSNmVySVwXYDPGB2x0ovfYSVty48KNcGZoGWVVYkL91i2ASffrVO+h+02slnKfKcjh0bJyOQRj04/CiFxLtiZJHDJvJVgMDsDz7/AF4qFUZYEEKsXiGB5jZCD/ePPQ07dBsv2Rgs7OLEaPJGFRRGMkcYz7Z5PPU1MJITbiaRFQSBWMcw+4T/AHuwOcVVSR2fEKx+WDiQtjHTrTLiQT21wtwqeTIpZ3kzhgpA7cnjmk9NRLsWoo7iA2yGSWR1yJWc8uMHv9T2xUSgTOkABJVSSd/XAOTgn9Kjhe4ljaOO4C5i3RER4CHOcn2x09faoLt5pbRWsDt3yKrsyjIHUkfr+dNOwMfr1rNctp72kCwhZFZmGA0fAAx9en4VWi1e6u7y3tYoIrZxud0wHUqcYbPXP1q7qN4r6ZM06vb+UG2kvjf05XnHJ6A0lvIltDBJ5S/aJv8AWSxg8sWyeOw9am2orXNliRE6lFmk3Bsgkj/61U7tGv7FIgicASqrgHkHggnvjtTLXzHUhpI3fLMp/vj29frSM8NlZSOrCMId+0tnnofXtim9gsMtftMms3jxJBFhEBhjYMwbHJCjgckcmr8MYPiK13yEizhDTuTkqecL9earaHqOms5uEECCcgMeQ8knTJH54qtPrtrYTzWsMTTTmQPJgfMxB5wcckemMe9TF8paSWp2E+vW8d41t9rhhunUMiM+CD754/CrGqaVa6pYrPcSRMTuHnRsMjAySR3Ga4ZNLj1LUZb3UZ2u7WdgImwV+UfwhR9B83Q1v2H2PT4EhWCV1DCUsxJLMOCxxxz6VnFSVmtGHO7lr4Ta5/Z2utpkrkWt3u2Z4AkH+PNe2Ka+cPGWnJAGvNPl3wvh1KtgxsOQBivfPD12t/olhco+8SQIxOc84Gc/jRjYp2rR66P1OepGz9TYDU8GoFNSKa4kzBolBpwNRA5qQGmiGh1GeTQKKZIUUUUAFFFFABRRRQAGmE1S1jVrLR7RrnUbhIYlGcseT9B3ryDxj8S59TtmtdCjmgVzgSMMFlz3HX8BW9HDzrP3Vp3NadNzdkekaz4z0HSbn7Pe6jCs+M+WvzEfXHSuP1b4rWUU7RadbNPwQJM8E/y/WvOJNE1K4i864AEjEZDv8xHAyB6DNU/GHhyfTfDl3PHcM95EN0Yj5XAPU+3X8q7o4bDw+J3Z2LDxirsx/jL4v1rxI2kWsyxwwJKZowgw2SdoJ9ame51KSxNj5sr2kp3mI8gsP4hV/wAK2MSadAssrXD31uGcMoO3IJBBPP8A+uto6ddRWthKswglt4XjcqOcE8Ee9dCqxpLkS2NYU42vFGTDawi3064SNROjBZ1JwSDnqPWnwTuIpXKARL8qxopDYJ4z7e1PvtPilWcswty2Q7HH7zjg/wA6rrbm3txGqs+QHyh54wAQp6D3rFycpXYT1RXmtYLmd2eHYxbKuw9eenbBqayWe9sL+a6KsAGdPKGPMTBGNvYdqp3c7G0kS3PUKrJ1ZASAeD1yKhhtJrm0jcS+VPgA8kblz0IHqAaU1rZBCNtyrCGtUiNmm9rgcbpMADHJb3FXkRBBLjEU/miJDtHQj17Z9aoWENzHfhJQi7M7O+RknHucdvarlxcNLkNKRA5G0MmQOQOvGO9XSTasOdl03JbeJDarLHCwlimHzrPz1zyp98DIx0q24geBICXAnl3tGDzuBOBzyRyfwqqJLdLiKEMY52HyqwOSPr6dfzq5PAjWk0ZBkkjAkRgpLZH49aVR6aEU4+9qLaxqkhV1AgLEENgYB4x+dU4tBMl+yMrLaA5Dn09PrVixuGudPR7uLY7t80bjO3/a6dDV2GULYzbVcMMPg8jOcce9S6klt1NI6rUr6nZWkccSw+ZbynhHVSRnoN2Kgt/khne9WDNscNIvXaRyWC9e2M1PdAXjRlm+Qk71U8Fe6jHb3qCGH7PZmG3iiQAFfmbIx/tHqTiod7WYc2txs1yZ7q3iEmN53QOMDyyRnLA9eAePxqZsxzSMw3SPgfe4J456ccVS1C0luTAwYuqA/J94Ix4BBHcAY+lXo2McKiYgGOPnaMIPf36VMdL3Jl72wwGV5UT92IdxLOr/AHe2D6+lUnlun1J/JgR4zhf3jjIUnqP5+9T2M6OFlLIkciF1ZupwTx04GOaI7kYiQAKR8vmYwD7DPJ/CqbuRYktobi2tIUvnZZAG3OhyCAPvc9/SpLqaOKyhG17lWUJhz87lvp29arS2kUpH2h5ZXUEBZGJRR/uj61bmDW4hjmZmUqSWYZYjsP1+tLzkNLsRG+tYGlS/mBCMhXYTlSTjBxx+FPdYYWzbrJ50a7RjLDk5x9Pequn2sMX78qZJZcSPMy7XIzkDHpzUupma3QGK6h8xkXfjK7Qc8hcdep5NF2tWNa6DYzf3M0Zv0htrUEEqRufOOhHbB7+lXG+0RzRyRSRr8rF1YfeXsc9uaYzossCSqksuNwCsOMD7x9R2z7027LopltIY5C424M2MHrz+vX0o2vcOXsaluyx4UoBMo2Lu44HcY6cZqrrZC6Z8jKouCI1aYlQpJ5JPXp/Kl8sz36zLlSUGRkgu2P1xRcJDfWJWSFWkXG1ZFLdzye57ZpO9hK3U5y3u57gLFAScytHDtbYIcKAWPHAOf1rQPh6Sa6Uz3Q+Z18xBIGyccgHHoMfjVzw9psdq10A/mTCTe838JB5zz3z29qqo1899CzyukDszeXNtEpwONuORnsBUpJ7iuzR1HVZrKSSHS4lmkRdp4+6Nvy7fT0rV0u+nmtYJrm2Ec6rgB+AeOSB/jmuV8UGaHTWa2kUSSlVfcuPNJ6Y9CO/tWlovlWWmwW9zhJztON3mMNw4467ehzRbV3FbsaOrpGuizTuUjeRlXy1/PPvx/OvUPhIznwFppZsg79vfA3mvH9ct9+kWVyJEaEqUTB+Z885x/nFbXgr4jXui6d9jvrNJ7eIAQLGBGUUcYI7nvWtSjKrQtDV3CcW0rHvYPHFSLXG+HfHuiaxtRJ2t5zgGOYbcE9s11yt6V5U4Spu0lY5midKkHAqEH3qVTQjKSJBnFLTQadTMwz7UUUUAFFFYXjLX08O6LLdld8v3Y0z1b39qqMXJqK3Gk27I1b69trCAzXs8cEQ6s7YrzbXvitDDdNFotp9pjTrNKdob/dH9TXn+ojW/EzPfTedcpk7RjKofQVuab4fsZNH/ANJWVbmaIFw4wYyMjgV6McNSpK9R3Z208Mt5HP69q2p+LbubUJopDEjbUjUHbEPT3PvWlpunW1pHYajbzyvLKrBl2DGccj2xU1vHJDDaxiIARIRvyQd2euPpU0aJAjsGZEdvM2p6kck1tKppyxVkbxslZETSzGdTPIrfKOM9B2//AF1z3iOZ49PvRJH5iyQvCEQgksQeue2MHitm6vYDG96eVVcZJztwcdPrWVqCmRGZo2WcjKSHHH0BGM89aiKV9SXe5haHGIJiLcFdhVGkjPAAAABHbitPXp76XTnhjRpY3KrlH2tgdeOtYuhRPbzyxsgjnYsz4AcqwJ/LIreimjVigk5KkhWB65z/AFPpV1Y31ZcXrYzor2e1sYLaW2liRTtV5cE89M/Tp60SyOrb8MCJMckY9x69BnFO1CRDBL56eZGq5O8cBiPl96zrpH+z+RJGtmsiKg2dDn1I7daIp62RXJazuTM6iXMMe12AjICcuME9uKhWSVjhlWJI3DMm35m75Pp9KuajbxD9wP8ASJzGNsnCqo9sVzl+8lvbK1qMLIwV945iYHAP45JzVxkrcxVSLjp0NiZ4/tJnkkkchgfJ3ZXcO5Hvn9Kii/fmNYziNjsYbs4OSe3asxo3JtUlkZyOCcYJwT1/z0rThLt9qjVAskn7to0GQP8A6/59apJJXMJO7LRzNcfvHlkEY2g7eFXJ6H61oFXjZWdcFP8Alp/AMjqMVStZGdBDFKUVzuZsYwnGQPc1ekjCoyI7LAgJ8snBIPY+p/wrGT1sjZKyu+pHaSGVP3M2QSuQxAB5xnPXJonlY/vEVXZGxlf1ORUV3axX2PtKBjEgZGiG04U52j3qCPThBeQ3EIYRONrgcg8/5/Gs7u+xPuotLHDJC0IYDPBIOCeOxHPpTEhis7RYRG4hHBAUvjPJJ5/Gneb5cjsNjEDaxC44/WldmSJmsgi3BOdrnhjjGOKJdwSQ8bEtVSLbsYFgwAwQemAOvai1ZwcTyguMlWde3p0FRW5nWKI3OwSgDhfl+YjkD0571HaGZLdhdEBw2GYtyF+v59qASTVydLYTMUAkceuQMeoH+e9QTTvEyyyIGaFyQyqSFX1x1J6A4qe2mZld13eTu/dkD7wx1Pt71GWVpGM0bJJ18xc9B1/z3qdyWraFETNDKpXDW8u5lyCh3Ferdz7Cr6lZr0pHlooY/L+aMsQfZj3/AF4rFl1BLPUrsI4dbcrI7SDcqEkcKT0HIqzbXwnvY7ZnjMRaR0wwYOu4j+QHHvUXRVtC1Mz21gTIEkIGB5ZyBk4Uc98Yqldq761PE8qxWsMKr5sq7Qz43DHqcZ4q7fakt1K1okcaSIgcCRflHPQ/kOKo6gwurdp44y8h+ZHwODjGcH0qndq/YWidjfDC4QXCCNZjlDKxyQCNx6fUcVn6hJMsMn2OzlYhhuYLgEY+9j2H60RGa201TOhjkICFg3KsT94H3qxpgSMtbOCXTB25DeYGPIz9eaewPVC2XmwReTJco7Z3opbeQCPXg+1T3tub/TFjdhDuY42nJf6Nkd/wpLdYnKbY0EoBAx8xyM4APQc/54qyrywIRgOiIWO75Qq/4c0WVrMSQkSvaQNDbsxQ5zu+Ytzn0psdz58qyMSyIWVmJBAbH04pkymaAgTSRNvDjy1BxjjGO/FUZ7qWy05SyRRCORQoyoLc5IwM88UXtuJ6k+uWltJaNcX0IedG2Q+WSgYk/KCOc59anFmy24uobZm1GOH90CxLKwGCQCOvPepbSa3v1jnSWeNIsrGso2qf9r0JwcVowM6SuYQmU3PszyWOOCewNQ1ox9VYZq0yTwWenW8QfWcqxfGPKPVsn1qbxJZWlvoVva28PmXbyYD/AMTn+JiaLa3t7ScixkJupjvklY7iq/ebntj9av8A2pL+3YywOhiLGMyA5I9R9av2nK1bZa/15FJ9jl9T8Py2MXmrNHujjDsFbL446D0r0v4S+KxfWCaXeMxuY87HJyNo7E9jzwK4NJ0aHzFkWC3JZGQ5RTwc8HkjP51ytmNR02M3BQwLcSExll5Kg8da35frMHCb16ESiqi8z6yU81Mh4rwvwv8AEbUNOWNdXBntOgbBz+fUfqK9g0HW7HWrUT6dOkq8blB5U+4ry6uGqUfi27nHODjubC07NRq1PFYmLQ6ikBzniimSZPifXLfQNKkvLjLH7qIOrN2FeIyXOr+ML2fzblc7TJ5LnCAZ6Ctv4q+I7TWP7PWwl8y3Qu+c/ePTOPStSwsrWK2s7myt1EskHMsfbI54r1KEPY0+Zr3n+B30KXKrvcy7UNplpFZRksfwMYboeRz/APqpst4WBEhYPCcM+Bh/Xpzimav5Uc7CPEakYlLDPJ5H0PGap3UsSEncsb7eIyd28+uPXim+7OlbuK3GtNKtujQOcYwRkbRnqc/0qG4uWgeNgsm8yBFVRxk9CcnkcHioYZ4rtDbRhyJUzK5BXbj0Uj14q3cJFJEdqOIQPm28bcDsPXmgLWS5iHUQLiVjjeGALhV4ABzx05zisrUpEjCOtyrowZEQZ3HJAyOucY/nV94xAxjEm2NUULHnJwDn8zms9yEaH5G3IxMewgKOcnGe9NIzcovRkbahLchorqKKO2QDa0dsiNIMc8jnOcH0qGacRRyvHEiQRrzuGDkDkn2psHnSOktsdimUI+ccY7E9u/Tip4YYxIzzASQSQyhB/CjEABcHrxnn1qtjSMY20MkM1zAzFTFHIAp8znBUA5z6YJ5pFuUaS7aRox5gyHOXz2AVenHWo5SRLbxwp5/2ltzRunAyPmVvbOKgvI2jDq/mxhV2eSyDO4EnjHbHHFa2WzG72KzagI2k80eduwSrZBHof0/Wqnly3c7I06oJGwAEJ2r2bHU455H40uEktvMkdg6FQxZc+XyO/U9ait4kNvILuO6nDKwQRY2htwwXPZQM05wU1oJVGjba1iKTjzWlwfvrkfLjrjt6Yp1lEv2790RIS28R7vmwV657/jRaRSTWYWRoHkhPlAE4aQHGDj0H9Kt3FjqEQVFmFuz42uU/HAxWTlaO5pyx3CKT7JDKNQcRgnKgoCegO3/e96dBsuoYp7cSDGdruPmx349frWJp8khjunJDyRkgboxvY8btp9OoronFwzJE5PnbRtPVsHkcYx/SsVd6sV77ED75ICUdVRuASM4/DvTgWitgdzOVbcRxz6fT/wCvUE88tlas7rHNJnnLYVQexJ6nn0qmYry+tpJUniiibGIypLkdMEmnzEOPcspdi6ZmWBxEQQxI2nd1xnvnmqF8zXixzWN2IIzhXV1Crnud3XP/ANenaRZ3EF2Zbi7kZfvLGzA5OOo9BxV2eRGtrhDC20APlsEE4xxU2ckOKSItEkRtO8xo3HlN5eWOSxBxxzzVtT5oZWAEKHZwOMenv3rNMcc1rHDJ8oBVt+3K5ODkHtnFOvLowvHbrJC8kmRtB4XPOT/hVbfEK6uWdUd4bLZE5b5lIRcn5c8gcH8qp2F5PLcSq0z7UIGIkIXPo2e35GmtbTaikDTXTwrCA3yMUdweQWA6D9a03lUzNPKgdNigOuSeB1z0zis9W9dipNK1tCldadauUeR5ZAz7zs4HUcP6jj9af5dpaXkYtYRuk3cogwCOuCemak0yaDUUdY5tsjqfLZgR+A9f/r1U0dytvODMkg38MMhkH8QOepprl5rIhttalm+LpZySwRxicAbyeSw7gn39aq6VfxXEQdYHSJCFVXIGDjke4zWmH2Dy1XO7KgY4IPQY79TWPd6gzXcNlNZFWY7WwAI8Dpj9DT2kRLuaUTeWUjVBITzIckjPbr16mpYLjbEsuCjtkIH6oAeMn3qDT5zBPHBIshVoncO3XI5P5ZAFN8O7ozPE8hky2FyvAznA+hFDetiulzU+zFIZRBGrTu24LnZlseuTiorCW6j3Le2oiccrMhDAgYyuM5x3ptvdG2lVLeKMlpAC0g4B6HvwcciqbS3djq0keoPFudfMRmOQB/CgHuD2qb6h0NyKOKBxGAA3DDPGSR+nFRyxR/6VNfbJS3yqOMIpA6L1yfzqrEQ7xyxyQozqFkOMlscgHsBVDWZZxNvVxESwUzh+xwdq+v05qnbqK2hq28cUcnkpbsqRnIRkx8pGc9cdc+9XppWOnz/Z4y1wxA2IADnPGT9K5K21C+mltzFe3RHmHy9w+UADnIHTjt611do5VVLXC4VslkX5mGO45x1patbAmr3GabmPUr7yUSORwnmFD8pJznnueDz9K0Z5XgmO3MkDARkDGE57559aypLed757mK4B35+RHxIORtXHp1zxU1vM6M8FwkbSIhckvnHfkY6cikvMHFvYuWtnNNIsN5KxHm74tqg/J1UkDgYpbq0bWXknBCwRZjtVkHMh7yN7elLFNNBE++QO3mbQFBwQPbHXnt6VoQXxdyoKGfYQrk7gvU4Y+nSnGTWqKUbMgl0VNQuLWwRxFDBbj5sZ3OevB75rNSDW/C987abPLH5Q3mVEygB65B4rciuJJo1W4aJSwYeWPvFsDkHPGM1q6bJaS2q6bIkkqvEdxJLqxHUbu5zVxryWj1XYdk1Zna/DvxSnibSWaXC39udkyjofRh7GuuFfOWm3Nz4O8WhopiLdnG4ZGChPGcV9D2Fwt3aRToCFkUMAe1cuKoqnJSh8LPOrU+R+RZFFFFcpgfOtj4flNxMssW+9tiC9mcKZYz3U+tdba2U+mS+VZ3dyINgdbd8bUzyRu7d617h7DcZ54yk0alAwOSD6Z61iXssm5pfMjWGVNhkzkKv06E9K9aVWU9z2NFqyrqc0cqssjBpXyp2qQVwfxxjPWqttatDYXBO1p8ko8mCfY8fXpRBdK0/lyqTHGVYKTjfHzu/A5HWhowqYLuowRgcAj19Qai1tGauafvRKPloiB3uZZcscK5BIPoDjp15p+4gl1U47gEjIHcfj2qqot7oxyGK4Lplt5JCucDt+HBpZmLyB5JpmQYwox8xz39Ktow0vqR4M7MzIQnlkgbhkHPI/kap3MTRt5k6ssYBCtxyfUZ74rVjVfllkVAHK8n5efr7VnTTpaXlrYSNGr3BwPn3EKPXPQenr60k9SnT5tepVaC4M7OWmaMYygUfKvXdn19aozy25aT7SHWHJD4BwMYx+PTitDKRpDLEQWkUNhj8xHpjtk0XCf2fGy3cMcn2ht4KtuUMOiuOgfpwetVzWWhdOneSjIpahb3OnSy24ZmeN9sYK/KB1V/oQeKq6ja2V/aw3pka3vYgRIFBwoHJbaT1J6c81p6jevPqEkkKMyTS4ZkIByFXKgY4AI4HpWfrFxDqFwLWSOC3a4ZlZUX7uByNo7+/6UauKbRbhb3ZbkMOkNLBGVXLlRIBL8u0E4DEE8dRkVkyxWqTzB5HaeYFQ6KRGv4c+1bGm20TwPBPbRzqWO1nyXPOM7h9OlMEM+m3W0wLHHKgyW/1bp3+vIqoyv11QShymdaxmI7kVxjlSOcA9sda14ZJsnzJ5MBwEUNnB7kfWo7i2KQpEmGEjklApzjqNvYgc8U9ciUERuskYCKT0XGOSe/X9auUlLVGNrPUtCC3aW3SSYlk3GKPhVQnGWz35qFpJ4JlW3KyyxksrbeQT0J9sHFOnha48xoPKjm3rsDkgsMEvn2zxUbh5JRsLCWNvlVeAwwe35Vgkth2Et0kW3zKFLSMSTkAr2IHvxirDJiMY/djvkg7fTgdP/r1UMflW/wC9/co7ZYRnaxJOeDVmQyPGPlGzBBOehHTk9eKZFmMt7eGJrdQNxIVMR8Ejrnr7k1JeoioQYg6yAncoGcY7j2qK0BSOM7QSUBJGAW9Tn096dOyPMqRjbISf3YPyqO9K1nqU20VktknvIBGxdo8OQvZcdce1U55rezYTXRkBnJJKLgkZ4J9OO1aSJtQeVvV5PlZx1NQXAgijW0aONkRVXDjsec5/Lp0qZJrVCTTRQXVBcTj7NG0ol4bzIjll7BTWiWtrmCO1HnoGfLoqFQox90tTI0C628ygKIohsboC3t6YA4qa4RvNGXb92oCGP+MYz+PWpSbWpUnZ3IVhghtI7eIeXGCScEkH0I9KLJvtInjkMaKvCO3Ug+p6HpT9+bOJ7n90FBlPPRR1P05qtb2/2rFwYJIsv5quxVcjsQO7e1UrbITTirmhmSO4Xy0VXIZvLzw3HHI6VmWqgwx/aWEm6XKB1JZTwcA98Hv6CtTzI164WTlc9dwJwDx+GaZMryxPErKxHzOjHAx1yp+uOaTvugVnuUZ/9HuIbh8tskLuPvbV5BPsDUt3YyTByjyxsgDLtYBjn+63qARx3FWUtEudJZLueP7RK5OfuZLMcD8uoqW6t51ggMVxtk43MqjBCjoO/PSobvoO1lcfZJmOOG78kS7SCYzjeezH9M8daillnMkysq+bvAiRwOQPTHPfmk+0m3byhFbvuJ3ASbSCSMt90k9O/FW/LZ5DdCHyxIPly+GI7E+g6VSethWQ3CwwKioN7hsKRkMe4Den/wBapYbO3tNWjlv/ACt/lqIEbB8teucZ68jmorRHbMhBV2GYhjdt55xnipkt1uHMTKPPcYQIMuCOpJPQcUSQXXYtX9rp3lqDbgxxTGQ+XhdpxknINQiRYfM8qSOJmGY/MHr39+3apPBl0NJj1K1t4ILmyZysgzyrY6hj1479qbPFAYJJYvMWMRnC8Mdufuj1PvUw00exLTettglljSSC7umgN5tKqu8L8xGMjPQnP4U03ayyFDLKjIw/dyYUyHtyeSPpwajZ7edrW4zvZSuUkU4xjgn3GOv0zVx7QG5guvJZvLG0OWyF6npg4+ppq9y2rq7CCPd+7e18liGLFm3kZ44HvzUiyKyw4G0BijHGN2OMn1HHSlkggLJLK0hib5j8xA3dhn/PSq1yl5d3Qlt5mjsXIMoIyGwcHHfke1VfqRKJqwXVsYGDBtiqTtHzHBOM8Ct7TzChWWCNt5z8wGQM5rDhRHm3oWcOMpsIUlfUHqavaPOYyjeYyHBBY/dyeuR6+lKequhxT2MX4gXNhOsItYd8y/K8qD5AB1GehP8AKvUvg7qTX/hNY5JN7277OTkhSAQP51yGtNYQ6DcxXEMKW0aFYScZLkcYHY1x/gfxBd+HNSjmgdjbMQJ0PQj1rZU/b0HBbozxFJzjpuj6aoqlo9/HqenQXkWPLmXcuDniivJas7M8x6HktwZZGeFlBdXEo2kH6ZOPbn8qi1CUMXCrGUI27N2Mf556VKV8lSgGXZvvqMYGcg8dar3KbihlYZ+8FzjJz6enNeorXPYqJqJiXkS+davG5eUjMYBxnkfLkD6fhV+BZA6GParHJl3nHGOetR2Fms9jeXzsoV5nSFVUj90o259vw96mgRF0+O2SKMyxfKzodpds5+bgcD+QpzetgjC8Cq838MB+Uvh1fjd6bR37UgV54w2WwTyNuCvvn8KS9821KNDG8ocY8uEghjxuXJGDn+YHTNMvZUt5lSCZhGY1GPm4yMkc9MdPzqPQp2itSVLQz26hmRYSp2kHdsPPJH1zj15qpcaUZJIZmWOSWIFQ0i5OCOT7H0NPlcQsThiy/MjRjJAP8+akjvlV4klcFk3cAgbsnGcdgcmh83QdNxbuzHaMxxFGCvICVJjOct1B55BqK5/tK2jntrgLJZXmJSvAaVlGFLHqAPwqzLdna8TWBFzMGXzCCB1zk56MAP5GoYLZ7Wa5Kzi4jUMqtyylVxzzyfvH8qtS0u0NKzsiDyx5Eb2qq6tKY5DIp5PHzBfc4H41TE9vcY8+2tzdIhT5gWPPXcAfm56emRUyRSpfSI3NvdbQED8o+cqfpwQKLe2htfEFjcXEeFkRmkRnChtmG2n9DTskmrlSnKUrsisvIYJcRRKDjYDKTvD9Qp564wfxq3dXchDWghAMRUtv5xnqD6H6VBrUBnj863UJbTSeZFMgyXQ5PPvx3qG2n8uYvtSXahBPGRu4Af1FSoX95EqrfREy4xPJckJG22PByxDEnH8sZx3qGIuu9ZLYRuMqQ3O89ePzFTTCK5CBF8mVgPlZuN57AnoBx1qa2+S3uy8c0aSAk5HTA5AJp6xVxOXPoyKEQGCRTGRIMqGYjOT6n600SStLg7ImUfw43Z7Ek+uD0qVLdcyKylARgOZOXzj5ce3PNPsY4YrklonZ9gB342sBx398Gk2tWgXNa1iKGMpamNndUkCrtUZY/T2z6U63hKTbLpdhkc+WPUADk+3A6Uzy3h2SrIfMYdOoOfr2/wAKr3M8cExhhckWwMrc5Jyc7SPQ1LutmWuRLVWt1LJ8q2Rgz7dz/N6EDoKVbcQTRzMFMhyCM87TnqTUKS27WlrOZX/fD95byEhonPAAb0zznpTZHV98cwV3IAGc4UDB/nVr3jnm7BBLi4Qs6CNGJ2Y68njPpVW9095r6WSZh5ryL5cnIGO4qVhGI2llK7gNi5GOozzipo1F1bIZJHdJCArCTA3dqUkr3LWqSGLLJIXd4g6sDsZTnOByOOayo7WV545FkaGGOQMAclg3fn0rVS0h09vMVGHzNubOXycjOfxqOLM8TzyCIpISyoF+ZT7nvwDxU7tXFJaW7DpHlVkdCAOh3cqOf/1GkVXS4DqT5gIVivAYH09gMU2ZitsoUiMocqMZBPpzx371IT+9glZ081cghTuyeAB16datpX2Ju9EO2IrvNtdS+1pAc/N26Uk0kTrHFGNrOQNhYqdwHUd/w96vTBvs+EBZ/TPAx1BqJ4l84ROu759yPjJB6n+fWouW49iraXTzEkwxAwyeXtY9T/eq/AP9GR5G3TM7Fo16xjPAH4Y/OqUaMvnqx24YNGE4KnpknvmrUOJ7ZDvJkjO7BPyuPT3o9SX2Qy4t4pt6wSE/KGOcqMZzg98euKs+czTPDMw2f6uJV6EemT9Oas2VgJIcu7KzMcYHRcjjn1xUd7axwTeXh/L8vBYnueFGeuev5VCtewtXqVVWN0dnLw2rEJHGxxle4APb3qW6VVlR4biSQJhVUHlf85qf7KwZRcTchvkUKCwBHfP4U21smeOJ5TtLMcnGGAHoBxziq5ktbmnI2rJEunyKbyUiLCqu5sHHbHJPv/Kob0zpFN5ECvFCEYAOMEgEN8uckcgn6GrEscC+fK85MAy0oHc9ge3THHqajYO3npbtLFKrqYpMZG1scD16n2paNqwarVly7iVPJkjkgYxoHKRDAOemfb2+lIhm8tgdpbAPXhyM5Bx2qjPaWJmtJmi8o+YyyLLlSUxkA46sMVOTMlqkzcxBiXOQQFPAJ/rSivvHLV3bLO4pJ5pcCKNgdq5+bj0781LFaFtRkupCJdyllBY4Xjpx6+9Ng/49hcIpecKIXQPtRVJ/+scfWpI/tDIfmUbWwp6BsnIHHtQDvrqSzzRz3kanylmWPLIF6EYBwO2P61PaCOzEybFMTOrqdhPHfj1zUDyYJm2KHUKhdzhVHO7B79an2ieB9hIErHyTjlM47Y4Garp5GLvey3NZltb9WhvYYpbdgCNx6Ecdvw/OsvXPD1hLHNDp2ILx0CwoxxGPU9M9KqymW1mMIy2wAlnYlCMc/T6ZqnqmqhPs9yykypIqwwxkbnYMcLn1P6d60pwkmuVlc0mtVsdj8BNXniTUvDuoNme1lLxZPOOjD1xkZ/GiuU+DcN3F8VLi91NYjNfRyBEiGI4QAW49emM0VzY+Nqt+6TPOrx5Zux1UbqIYnuMiQYRVPUDA/r/OsW8Tz7xmnDhABtK4PI5+o5robuyW6mQjcHTIyWA68Vzd/EYFmuIvMk37c7GDfOABgc8Z4PTvXRC1z0qkpSjy2LNtcpb2RtpNxVHK5QZJ74Pp9ayprx5LhmYhDvJ2Dklf61s22lXUjOBGVON0hxkKuM5PbNWrfQdPRP3l5FdB2GZIG5jX2BGG7jj1pOUU9SYqdtzAhvRFBFtWR5IMhWAG4gn5hnOOnH5UzUtTOrX42W8CRt8+0cZAGMZ6D2FdRL4at7l3fTr2CUW+SIyuMoc85/mMdq5q5tnVDPZRJOYjicBsDZjrjt1H/wCulGUJPRalNSkveexnwO3nxRyRAb5TtCA9uvWnSW7WdzHPJJhIo2B3cgZPXPp0596ksI1vNasoptltbJndIXLBFKHue24CoJ9yGVVllwzDO5flOcgYI96tJ3J5uRW7krxPcW8lxJ+6kjz8hP3uwHuTzVS3m33EzyyqjyoyAYAAOQBx75zVSdlSIxebvVTkZzvB6n17d/enxskZMq5mdG2uMAYYkYyB/kc1XJZMv2zckys8kf8AassLxIVEyqrNywG0An2I6/U1HqiXhhMUcSySl1jyx555BX64x045rSRxaals3vILlAJkMfTkkMw6e34Yqvqdre3F7He2YNtCZvLd422uBs+WQ+mecfrSv+Q3vdMuapcx/ZrDT4nkj2NLLMFXKyOc8Y7kAD9ayWlknu9zESCZT87AAMQOQAe/A47U/TLB4bXTBZn7UZlcLGQdw2seTjHYn3OOlRmSSIt5cDOdzYIYIoBwD15OfWiNorQykmnZjBcR2sQgmXmaQtGzAnBC5I/nWysE6Wf763MohYo5GcRyYyAfTIx/KsPTneQyagt7FIsKsUhCnMangk7u/wBK0LC+vriJLI3kohfBMYbBY8+nJyM9ajWS5lsVzN+pILQrc28jb3Kgs7Z5PXhR2xmq9wj3Lxn5wj/PLG42ybRj+EdM1ZlmMF/PHKpMaEvEzP8AKwABwf8APaqS7raTzVLuZTgqOWfnoM9zTgm9S3JJWKu64Omn7SULI+wfKThe5JHpRHGkKGHJ6ByR8xbrnB+hra2EwSTtCsSIjOivw3IwQcVhZI+ctjjtzjj/AD+dVDW5FaTej6El9FM0CRnqTgjGSOePp1qHRBtkih8rDF5JHJ54H+P1q2sZuJCFYRnhS0ueAR/+qn6PEhmF1LcXEdpHmAQxr29ST+HPNTJ2CnFSepK+6OJ4Y981wT5rAdRn1/A9PaqUtnFKx2ROjKd4MZ2kE9DjkfpWjqF+JLhp4o44DIqxkRvv6dwfoBmqF1e3EbFTAkjscwI/DEHqD69uOtG6u0NskufNaREdnQcdFDE8e4NV57iezCfIq28kiiRX9+Nw7+mc8VZtXupI1Yu0gRSw+TAj7Y9zxzUdyi3e37VDCXkcBF9SR6DmlvYbVmTS2iXMPkzLuKkSLtbr3x9KgjtmMqZiAVg+FAOSRj+LsKs39o9sxhljkF4WKLEmDngHkemCK2Tok2maXJfX10tvIqDAkZmTce2Bnj8M1MpqK33Kcb2dvQwZY4rMgsZjJIwDLnoc/wBQKfGdrhpC6v8AeUup5HpVq30+W+SyhSe1eeSZ5AXbOIsYUevzEn3wKtaho89vDdB2CrbONwLZ+UjOV9ee1HtFawcsVNJvczABNG4CMHR1Viw2jcc9CevFLpd5HpuqSRz27SGaMxpCxPl7iOcnsPpzmrU0UIcFJGksHLPA5XG8dM59c1UncAmdIlwsq5RurEdunrz+FDTkhOUbmm2pzxW5CyojlwqKxwQep57gYqtd3DvABHlMMfnL7t5659hT5mSZUdFiklJ7kjI5xg9qmhtYr3zlh2xvEp356AYzyR169qlWWskE038GxFBcSpFIS6JjLFjk8ev61JLcxTT4Ro3YDjacZ745qgbW4RIVXbLPN87AAkDBGBnPA9j1q6YYLPPnRrJNJucsPlCAd+e56elP3b3CXO/cWpRkuZJLbFskk0czEGIICCemc9h7d8Vp2sbNZtHbQyyOGUMgJySCMgE+2OlVY5jHAI5Pk3gO7KARGqk/KD3c+3Sr9jLI9j5pZVSYgwLGMN0OTjORnI5oknuNWhoncScwxu8l2WkkLnGByBjHHpgU9Ymt5o4njaSMDdhRhSD7/wB4ehpto5ltpzG3nQxuA6KpwpHUA45Pc/SpYGxAB5rbWzy6f+hY4xQroU7acxI5WZ4/LMseW8vhc5J7j29DSNEqRRyK9wUiBfcF7gdP/wBdSwb7hZ1PzNgFGPHy9hxTmulaU20UwVkQuWIypGeh9+KE3ewnbcgTzDD5hc7JflCLhlHHbjvV+AeZGgaMFkcZUnaQe3Tr2qvbQ+Y6tFvjgDHeo+6/fcPoc1t+HdQg07UJm1EC6hWIxYbB3EYZc+9OT00M7u3MtTIija5t5LRZHWR2bdv+8D1AJ9BWq+kadc26LqceBbjeJvuheOSG96jtXWS4nult1E0gACg4WME5xnPYVrL5N9axAwi6iR8gZ6MP5/SlKTRrbuUPC6W7fEzRJ7G3aK1KSojNkb8ROMgHoO3vRT/Dl5czfE7Ro7uMW5xMUgDZKjynwWPqeeKKwxd7xv2/Vnn4v416GpcusoAO4IGZeV2kDb97J7D2qWxnaKyt0dRJcRp5cvGwOB0J7HjHXrip5YzJbBWgXdwDubO455PPSofPihjJiUOGRkVgjPg4zxWjd9Ees7OPvFDUdVHlStPLGYj8v2eL5QcZ5468d6wX1RbzTozbwT4yCJIl3NjH3Pl4XPT24q3cpFqRScCeJll8pmQYYMmMhc/Lxnv61o3sS2zX9ofMgSdCHMIG9XxkKuOBk8mtPdj01M0nLZ6FbwxIb+x1t40W4eCJIxGgzt3H5gcHkqOPer9jpbJY30ltGZJfsxhYGVt7KQMtt7jI/CqnhkTaexlEjRwNGNwQhcydt3uf51d0Kab7TeXTTm3lhYsy7cs44+UDp0zx9KxqPVtFyi4qSZyLaTbzWE4FzHcXW5QGX/ljICNyEDqMEEE96oyQqpFujSXCvjMcWSy9+cDhh7V2E9vppNzNHJMn9oODcqkW193OOQePwqrZNafaLN7dWjkimjKTovzkK3zhugwQTyRWqrPcy9jdanN3dvGkah0eIMRITIPmAwOB2GcDg81SfTTBfRqqusaK0ki7vvKRnk+n55/EV3Hiy5sp72cJFEiwvsOE++/Xn1zxisbUEleRXYxGaQYaRCeMrnAHGegBHQY4pRrNouFBJKTMe40z7PolzFeqZb2QpLNK7f6sDhFBHQnPTHasi8dJJ4reKRDbAluEIL4UcnPtk46AnpxXTW1hD9lt7S9W6tzLCHM0PKmU/dBXuAM89cmsGTSLpboszYxuJZuhA/qfetaco3bbJlGTdlsZ9lrc+kgizljjlkwCxXcRkANsJ78dav2Vr9p82W6WWJQzMqv8zc9Dn64q3b2iKbT5vNhjBwjgZBPOf0/Dird5vW3lEIcOflAAycnJ4H0BOaTneWnUHBRjeRzlmuj2zSZW5kjBzJKgOC2Tzn6Hp0qyLe2EM0lqhSNYshkfc8g6AA9iMYIx3qkqTkTG2D/ZYvvqBldvTke9a1hFDJBDDbqq+f8AuiCP4j938cgVrKCitGZvRbEVooltkBjUzCNlTJwOOPy/wqHTII5GSSXieBg4bf8AcOcdR7VBNKY1itbYqt5J8kW8cAb/AJz7nj8q0b+38ickqqAtg7iQDjOOB13VL6psqkndNIg1gOrxzRArb3CHLkNlvmxwfbjis+1UxwksrLHgrnuW7YH511+iXH9saStqlt5dz9pdojyAAAPnPsT1+lVJ9Na11SaJJi/luDJujGGbGSVA4xz9azhWVuVlVKTU+W2plRaQk4X7WpEOdioxzkD+I8dau2M1pY28MEsMkz793lsQDIc4GPYdajvp0WSOGBwSpLyb+R2wv4dzUEd8hlZH+dmcFyxwUUYO1fT60crkrsalGK5UV76DZeLJcOs2x8NKr7Q+PQjjk1HrNw97dWQsrFkngA3+Sc7sdMZ5yOfU1fSe1TSp7JQ1vicSROy5woB5P15qva3Wq6ddkwxmI7MrI8SsZUIJ3Z6gYp7K/VCinKSS1RYsmtptb06G/Vk86EvMwXaW+8AxxwOmKdaJb2cTXr27ieUlLZRzuycDj17/AMqy75Xn0xxGSWEZjjI5ZTnOD+tW4XaG1jSRJXCKQS2FC55z+P8AKlKLa0Y6bjF+8jUvprCfWILuQRxvGiFirDJA5znoOfxq/q/iCx1ewMU9pOiLIrKZsAN9MHnrXOJbw3NwVtrlICVHySPkg56AjgnHOKrvteTYpknAOV+QKceuPbHSo9lFta7EOTbTfQ09M1eDTtVsbT7JbXBnmUvM4wyZOMjtxireoTwajqk86q7GFt+dvocAVkwSCCa5nkVxbojbZCAzAEAEf571bu7SeNVCiJEcCQFX+9kYBJ7DFDilLfUnrzpCG3aV4rRJjGXJYLg7IlHLE9vXn6VXFmFLStI0uAAjFTyAQTx6+/WrvltNA0ZuGVsdQN2Pb3FWLKxlisszSxu7kHCjGM/4YFLm5Va5t8cuZqxQCQoIlDshVR80h6scngdR+NU/sN1cTxzxXMCQqS3yynzJFHUY/TmteW3jPmB4hK5ZcjoCB905p1xaxr5Jby18t/nYMcKAvIH50ua6NY3pttW/r1L+oWMMEwkt1Z7ZoA7RrhRz2BPp+dYlwCwMaRo7bQByOQD0z7c0WEjXU+2KNEs1/iYEMzZ4P0x+dbb2VoXtJImicecDLhtpjI64GM//AK6L8mktTHkloyjcSWdxiSJP36KPNSQnB4ABzS/YRcWc09kyh0XlZMZ4Hbr7d6lu1TzZ1t4naCYh5FfIIIwfzp5gxA0iyvHCyYKfwtnjnPpVc1loZ8l3Zai6RK9nZWrQBGtA5kHdQxGWI74yKbaI7JcLKHI8zcu48H2qSzjkuvNhtEQWqRGUy/wxjouM8bhz1q7BcQx2RhVT5SD/AFjHIfgc/r+tQ3a9jaK95LsU7uFiztbKS+wfN3B5weOw70yAzw21s0yW2GHOMnc2c5I9DjvV1kke7CQYiQgMAGJJwef8+lOWyaaS4aUh48KyKV4yB7etNT01KcLPTqLJd4jt4o45ZLmZDIyKuAhxnaT0FSsI40LFf3zx7tncN2JA79KtQ2s8k/mSSsgljU7RwU46Ej+VaFxFa+erQyNKqrtDsuMH29qSkkJ3+ErQqFjy0fXqoGM+9XbCRG3Bd4VW2/dxz/h71FDDxuIJ5wCeMCoNT1mx0mKRnuo2uDH+7jUhirY4PFNJydkhSaRV0O8juvjRpaw5PlLLG5zkZEL0VkfCSFrv4h2dy0p82JZZpMqTv3Iy9eg5Ofwoox8VCcYrov1Z5eLlzTPSZJ/KfzxIFj2sshPIOf61kGWVHiltI5pYckKyPtC4JOc545GOM9a0Z9Pku5opJGPlbtypGOCD6/X1ponIuhD9n+zru2RfNuTHHX/ChWPT1bsjIlj1B9XtJ792a0jL7tr+YVUgc89/w9at3kJjvZIrmUs4QMDj5WBHXPc1duIHdSrthZY23Fl3gnPQg1QuI+ViGQikFmI6k9MZqW7l01bXoQwqkUMSQMkYVWdlx68nJPU96hDlrmJt8wSP5jtPyt9Dg9KszWxt4BBOHgmKbwowXY9QPx/Sq9qJZUe6DpHa28bFzI+FUDt+tI1TuuZ7DZD9q1CLcRGqsQwbj8c9u/50ae0L30aW4XdyNrKcMMEDnHTmrLaVcS2krmJooSC/mvyOe4B6jBqhayg6lFAyLK5BWR9+NgJGCrdicfrRutDN6p2Zl3loi+ezKzhmJLBidp9fb0pLe5SfajxyxxoNnzL949M5/XPvVuGzFssm9iZJGJcsQG6+vr2qwbVbbT7czFo4SdkZLDe34dSfw707qxs+mpnX25C+QF2dPTHf+VZ2rTyxLIVVSNoIdjgHnHIrQu3glCWe540ICts4bg9z+dLqmkf2nbJGgdVBYRMF+bjHUd6cGk1zbCrX5dNGc1qC6hpVxDNdGOaOVBNHLtA3J0+Ujv7VdmnPnJjd5BTf15B445+pqa28LX13PDa3twZraDOyMBhtB5I5+7nr3qS+05rfCXEbRoFwVJ+7zxj1/pW0pwuluzlVNtWOUnuRZ3U0TZ2t8wJbqKn0jdLNaxo2PMfzBz1wf/rVoN4curqN0eJZ4k5XcwSSMfXv0qKysUS7E8XJQLCrHIRAfQ9T1OTjn6c1s6kHHTcfJKXuvoHhrT1+0S6regSXPkGKKPbgQL64P8RxnPvU67rtxdSR+ZK7BlGceUi9CfUnJqTUsyWa2sd1BBJGd00pbbxkAADuec496h0qC7/tK0jnLGxEv7x1YEhPXj6frXM3f3mdUIezje5uaPeTWN2ZvJMg2bcf3R1rE8Q6rcR/uJLdIkYmQTRxEZ3dCSO/bnFbEQiTXDepMbewtm+VEmZlmOSAAB+HHNU9VX+1Jla83wzD5iy48sKOVUL1PpzWcdJXsZSgpS107nMLaRPKrRI8SkfMjk/e55zjp7VM1jdRQiVpBtMW6RtpYEDgcDkmun0a0hlukt1UytHyytjv0LVHq7m2u40BEeMxhcBRx1Jrd123ZGfsoX5TF0yzadZxY2j3MigswZgr7cD7oJ569Kt6Yx8mWSD95I6lJYZGIIXoNpP+RVzQ7h9OjleIoZpFYmQjhMnOcdTgdqr6XNZwm4LTO80uPLJj5TB5LDOOc1m5SlfQ0qJU1JN+hBpNlDqGpPbSjZNICwQH5YzycHt7etQ63pSfNbsuSrHcnU4UZP6U3wsE0/WzPI7ugk3EnpuK4xn+VaWqD7Vq88zSuYmcYKgZAwP8/hVTcoztfQzioyei6fiZK6ZDPBIJFkh8vKiF2CliMcsPp3+lXLSxa3Gd/wAkZKjdGDs7U1bWK41zUJWDcKJFBOFfj+Inqcn+VPZXaxiv9QdLWad96wpLu2gjq349AaHK+lyeVx6EWniN7cxSnMgUl8Z+Y5yevbtU93OwZSiGYv0OOdgAwo9Cc1aNnFGiXAOxov3Wf7wIPB9e5zWfLIlp5hSfbJkfIh/hA68+/apupSugbtBqT1FMssbvGF2yqNojYDHB547Ht+FS6NqDXOoPDcAqkRJJAGJBzwPTBGKqQpLOkEsjGNnBYlznIx3PY8gUmg+eviAs4DRqREWc9cgkNn0HFVKKafcypSfNY2JJSt5CUb5OT8o6kjnJ74xTb5VFuYJUPlzOJGbgZB/hB9eg+lR28V0t9JbxBZwDlHP3Qx6Y9aul5UuzFJAhTOBIw3Egdl9KxWh0VWlZIz42la4kZTiGPam1c8YxwOx4pYJ2nupS5bhyFBTA9ef8au3sCtBtXLKxJK989doxVKztvLVVVZEPTaVPTqBzVppxuQotSsjSJVTuaNSewbnn39qck0PzQecgK/LxwST1x/8AWphIhDFg0i9Bxms2WOVL+N4ZgFDLkMM/L9fy6VMI82jHUbg+ZG/aWsctjFb2pmbyAzMRx945GR3HFQzQXipEYFUWiHdIcZaUd8dsZ/lS2k8587y97tKAjPwpZfQZOR+XNN1EXdxDbWKXMikOX2KdmO+MDoOvPqaIppkKbbdi0SXYCItG5HDADcB36jipotoKlZ/N3dcNnHPFMjhe6hmiilMXAIY4zuxzgYyOh5qaxsX+xrISRIpJljc8EcDIPp60tLFTquMttCeJtsJedygOcDrn0qWIbohhWB2ElcfMcDpjoM1Sg2vdNtQ4ICjHp7e1asW2PBd/m9B/hRsW1KWpw+reILy7ikhRI4IDkMu0lwPQ57/SuUtLGe/u444kLujlwIieR79BjvXsGoWNpfxGK7t1kAOVPQ/mOaSysY7Wxkt9PijtchkEi8kHHUk9cGuyniowj7q1MHCSdmY/wanVPEMUc7xiWSR9kRYhhiNvmA79xRVjwLo72fj/AE1/OluZI2l8+Qx7IwTE4G0nqeee1FcmOalU5l1R5+K+M7a/jvFMcDzFd3zuGyzHI9ulVLkJ5C7gcKMsSM59MD14pzLc2ly4liLyqQwCkNvOc4IPAx9aguHeaZpY9sUsg+baQQuOuD0zTR68E2vIto0bJNvZQ+0FAW3ZzjP5CsTU5FMFpPI4aOEqVi5PmKDnbjHv17UXEFyiqLMREyFgzPISdo7A/mKsRaZE/hdVvZjDcSRh0ET/AOrIPf1zyPpS21KtGG73KMt3czSveFisrSArzkKM84Pf61p3tzA9r9k0sDGS0m5fvE5yx7cVg2mp3jtBpq2USafExjWRmw4PVmyT83XpjpW5qdutnO8DnLZ6L8vykctx/nilJW3LkoppW1RRkka6mS2luXuNq5CF8LuA4HPH4Vny2F4uotNMxW3Nv9xjt24JDHjqT/Soc/6THaWex5+f3ZJY7epAHr3rUtpoL29TS7krHfquyMg4ywBLAjHGQeDn1o1QTfs3otBNJt478nzby3t5YxtGYyCR0zkn8KqTJOD/AAyIoADgE7c/0OM8elLqtrdWk/kTRFsEsFTcygeuRx36GsLR21HU9WaEWYEaL5sbpHjdg4yPwNCV9blQjo5J6EzxSRZiM0aqCdrMclT6ADrn3NWWu5pbOIzmRZFXaXHXr2H9RWj4ksrvTNMMlrYF59oZrhsFBx9zjkZJxk8CoPA9ulzbMdZX/TL354ypKhcL91fyOTUuSa5i+dOHtOiMKz1ie9vVskEyMSMMATuA4yB/WoX1NxORAXuHhfy23RYDDP6EelbF9HAsFwluPs16h25LNmRcklWB+gHWs+xYx2Y+2QyJBjd+7Kj5vbP4/wCRVxa3SKlyv3rWRNd6j9t1S2+0SS/Y0bLRYG5jjhWA6rntS6lD9i1G204albkA+dcQKh3rn045HT6VY020lt5/tZEZCAyLITuAODgH3zjvXPT3Ly6zdX1zGwe3iJ35AZy2Bj3Gcn8KStfTZExpuUuWLLOtaA8Uv2p7/Md1tMWYiyIwJBPJ6+1TxQ7bW2SNZPOkbczoMFgT2HQd60rqObUdG0GyWByk+2a4GdwUHqAeoPf8TTPE0UB1+3itA8X2WJVAjYgY64H09/WhSbSizNSvLllvqV5bTy2aSK2eFU+U4y23kdz3x/OqDyNLbzhJIY7kcpCzgMQc4P1OOldit+bjTI4o3hEpjPmLMv3vx6VxeqWe6VorwOhX5jtATb6cjJIxRTd3aREZSlGy3Rr+FrBdOl/tWc7JLhSsxkOWwP8AIp2uanbXU0ubRGSJTtd1+Zicfl/Os+O9hiuFtUJMjKMAgkknpj2qS8hSS7ZHbcynbhRn5vwpW967G4XnzzKUgR0jljHlwqN8mBnP51WntXuYFlt32yluhO35R0AFa88zfYvskcSRxow+Xy8fNnpz9KrW6R+QjSZZ0OduBkHsKuMmtUVJKS1RnGy8uX94wlkxvxnack9RT7C1l3JA7kzyyAmR8EIoJyD09qu3U1tYNHJcK8pYkBFBPln8On40lzZrJ5XLBZiWXeCuMdetNzckRTpqLbbsmVWV7hp7d0RQ33HV8hseo7dqupHFqP2hY40Y2yh5CMED0Oe/So4IoWuF8k5dfkO09Tn9elEUbQXErxQtGpXLKuBu5GP8alvsPk311JJ5pL27nlukR4W+QKFGMAY5/GotZgUwRm2G+SGJzLgAj5SvA9ev0qxZNtumieLYQxYx46Ec9PX+tQwOYixjZiPKcZf1Ix17etJOzVjOdJOL02MeGeW3guJrvyGCph1HBIxgfoMcVPpDGe2j+VleX5zzkgdqrxW7P51upEkhGx947cc+wzk471uSRW8MapZRthQqbjg5/wDrZ7e1aVGlojOgrSuyZFdFDx7VUHO5ug9ST61PYj7SI2AVnZSyJu+bnvj1IxVee0u5mjLrmzMgVkVsNKfTHYGuosLe1tLS3GpxQpOjHaxHIH19hgZ9a5pSsjWpJJK2rMDyZLYuDlVJBCkfdOOTzUFs7uXjtpJVjYksqgKp9evWrt076hq8YmdDHI/7sMu0KFz82c9OnFVUCSXV6ZZ3ePcYkkChsoRnavpyOcVUdtRrbXcMfaoXkCbApwqlwfyI61LcyXpEMFlKqMUOTJ0XHOfTpxUsMarZRxWdusUAOCOVCDuSKjkVxe5VzJCh4xwJB7j86dx2V7DLa1upLguJt7Y4UoVY/XjmpBOLe8heULG7DALdCOe/6U/TPPEYNy6psUZ3ff3HsMUt/BBeoig48vDAH7uR7d+v5076mul7S6EiQsMTSYeRySoZclRgZx6VE0sf2xFXzJJJZApRW9R6dK2T5cmnPE6o1x/AyHAHGOeB+FVJbHzbqKSY7kUr3x9SffilF66kaSumLaWoFxLbWe5tnLSZGNnXj+VWPtEW5lQghVzwOeuM07U0ge6ig0938qePd5wyNox3x15qxb28aRxRhRsCANjrnqf1xTvfVkJ2SHxxfwkq+4cAHoKkVNqopyuDgZ7n+tCw+cSN/I+6OhWpY0LyFSAVIIPcGi43G7uavhbLavExbj5hjPU7TRTfDVqqavakjHlszIB2yjD+porGrueRjf4i9B1tYjUtOW7eZ7bn7ncH6dQar6h5lpG8gjErKoVMkAk9s/nk1Na/6LbpAsYnlldgGiXr6bscfiKivLKRJ4jebs525ZcAH37HNdHU9OMmpavToVLK4EkWWcxzxgMzRYCgcjIPoc0y9mhgiV7kCOdRtBYk7mPQfU0oS2iE9lEF+ynDSLIDyTk7VPpz3qNraKREbduZBhR95frtoZsuVyvYpXaxRhC0ZDlstsGPm6k/lRJJI8Zt+DFtDhvl49T6884z71faaefDSeUwQBd20KMAcYrGBYarF5Bjbail1fkIpyVY/THGM9aFqU9d+hHHB9nuIp7WEpIDjzEXDY9SfXrxV6XdBrL3dvJDLchc+fvG8AjGcHk8DHFThrcTsImLYA3Ngrk96wJovmk2RhgzjYzYyeeV+nOcflSWrG3zK5qNrPiCzkjkkRbjzmbAZhtzgDAAxwu3nPTrQ2r6xLKWjexDsgXz1CltuM4XHb61ialMl/ptnHZzrKLctu3nKhmxkn/D0zWnqNw899Alj51wjBY4yAyxyS45Zc8KvpR7PpYzSgrNpa+RSQXMkj/bZHc7jllc8j3ySP0q9p99Fpu+4itFuGi5lld8eWvQKvYH2ArPns57HStcu7uZd+nA/ulGXaQ4xkH+Hkc96Ymo2MWlzRSStKwj2F+FJkI7D2yRmk1fbU2m4zWmxrpDbeKrz+0LCYC3fYt1C+d6456dM9O9Z2ow/wBk396RAjWx3BYmlBJBHoDn86yNM1m806yS0sJIovm8ySRV+aQnAGf85one81R96TEXKrjewxvBP3SMZIqvYyTtfQwhJxl3j+gI80azKklwkDx+Y0XUFuw9hj1qCxt/NMJcyLA4L7wxJVOnU9skccdcmolgv8uJ5NytGRkLhSf/AImmag946QxSj/RIx5axxJiOJsA8ZwSeme3NaqPmXOTtywWrG6b40uLS5EcMQeLLFVZsHJ79OcDtVv7dJqGrJqCrIzlWEi7eCenH0x/Kqh0zSZI2nVJ2uwVIijOFwO56+nb8qv6VJPBiODSZFhZygXONnvz+P6VU1TavBGMXKnJ825Yhu8hEEWGdiqoybh+A9P8ACpNUWCQamsab7iTMsZB5HQdPTAx7VXWZFufP8popURmAcjkg/dHpmpp5ljiFxczJCJHVU54OfQ9/SsHGzNuZS1RuaDpySaWQ0flM6qfMBDHvxmsq0CQairDa6JJmQZ544yDWvpl0HtJbEFQQp/eJ83JPfH5Vi3iG3aVWZVMeQx7Csle7uZRu5SUiv4iMsl35Y/eTyjerIM4X1z7VTlu40nWPy5mD4ClYyQc8ZPp0PNOtvtE2oMZwiRQRKFB+9IxB69scjpTbVLnzcswmGw75EAwrY4GPr1rRKysbq1rdiaOD7Lay27TI08wI/cjIRQcqM+uRmrtmypaKkh/dWMB8o7g5dz1z78/rSRW6x6c7+YDJuAVdwY4xyfaqkkJKEKzKHzkAcfhU3voZtKb1K9nqMTW4jnf7NJIXwY0PyIOMEH+It0I9a1vDen3UdpA92UML3DHZIOVU9Bn8Kq2lqXIuEhMUaII2BIPckH261uSzfaoLdJFjkCDfsY4JKnuKU32JqSsuWPUyJmUXLOihVEuE5ycDn+dZ1zutbW4YrnsOO56fzrQjwsIWJRvXsapQiaeNre7dWMf71yAVyg9e3XHTtTRrDTfYqaNC8t8zxqDyFIToADgfqTWxLDGzySIY96LhWLnk9iB0/HqKrRXRWURQLszG20KvMhBO1fpyauySCMJG8hjcDaXzkru9fr05ok22KS7aEVvOkE9s7PvhQtJ5ZXPUbfx5GefSriXgv4p5Z/MO3OwHjIx3+vpWRcv9nCJFGTLnZtVs7QO5Pv1q1NEIbZQq7GkQK5Y5z/kjihpMn2a37i6YhS7R72Qja5kURjLEH+H29M1b01BJD+7dY4hufaVJL+uCe/bBNV4Yo43bMYLIArO/RvQEnirS3UMMEUEwbM0g27c/OewPtmh67Dk3dtEU8Ml7pVtJAWiJ3mWNiB93p9c1Nbqrad++l8q9b5i0fK464/pRJHbQz7Jx5DJlQCvAJPb8aWO1k3O++NjKwj3njametIN1ZlqeBY3fZyO6tjeDjv61Xu1R2QyO6bDuBT69CD16Vr3+mwWGlQ4uA8iMQhHORj7vHXms6zUvEO2RtbnnJHalF9UKDTV7k0V1Fkyq0hVV3Zx2x14/lTInWa2imCAxO4Dl22lV/ve/0qHQoo41u7aP5vLA+VuXK5xnHTitKK3dkZMQRRxNvUSkfvFxzjpjmqdkW2ouzHt9tktI5ozmN8RqzDAABxgH0ohQrOCsqttBDDcevt/WmGYfatkxYKoyq8/KOxA6VcUKtqsajDKwYPtAbHof8ad7GUoLqI6SxRCeBwz4LBCByauQYKrIoAaTqPeszWrg2Vm0s/mIDtTIJzjPUCprS+EkUgkJilt1Bk82Mr2zkZ+oovcUVGMrHQ+HG8vV7aOVo1c7gEB5J2nOKK1/DdiBFFdzKwlIO1XXBXtn8aKwqO7PIxc1Op7vQwWLwxI8J8pRli3TB9vxqpb/AGpA7yXjsWbIRmLdGyGyea0ba1MmlzXdzIoliYKIwMbfY+/NULu3STy3ldtsisAyvhv90YrpTPXTUm7en6lu5eEeRO21lZcYB5Ynvj3rO+ymxsLdbeX51dziVsbkPIXGMkjkCmTRRmfcixusUvzJuxujxgA+hxzx6Vb1Zba9eOHT3jWNIy+1+cMBwuR04PvRsFrWX9f1qUIXtLqzL2DBgR5jHZjaT056npWJHYpP4kn1V70IHiWJY8EcDgn654q6yXBt/NWEJHuKtls8YI3jHfp9KfLbbIvOuGUO69NvUg/e49cA+9N6HRFqOie4lvMYb+N7gKbBnfLx8swx0/lVO9kW7nklt0S2tiSMEbieMdexqSWymgihifKwMu6ME888/hUUsg82zg+xq4KEQ20DYMm3hiffI5Jqba6F8sV726/r8THg0SGe8jNxceXaON8iMeFx06dc46e4qHxZdpbSWhsBKkttOHgLZZUwf4x3+nata0SB5UkuUSNC4fLg/u89OfwOKbPthvLnz5eLgKDlQxVQSTjPfOOa0c22rvYVOCjJuweL7+/+0wfamsoneOKW4WyZmMyBsqCSOFJH5VjyStqUltbXcEKWCM0iJboE3MOgHc8mtizsI7iQyQWkl85fLXFxN5ag44XAPI/+sKydbtrnTbfFzNZxXly/lCFZAoXtz3wMjAGB3pRlGKtHcVKlzSUJWViSKddUe4tFnhtLe3XpAoGGHHJ/GtfwDo0Fj5l5qV032qWQrFBJIMbSOCR1JIzjNcn4fMp0a6lvBGnmt5cbxDaDGCMnjqSwxk+9aEE62d1ZHy4Wg3gxzbxkAHn5Qc8YPPrUS1VkzoqULwlCGhP4hSMalLFosX2qFWAfAwsZYnIHHQCoIIonjmE20t5h+cEhSABg46+o61oyy4ubq4sREkM0ucsSW2gcYPbP8zULX1vplyxe2S4uGj8rOc7FYZPt+HaknZWIXNy2W6+8zNNgn81WjilaNAS77NwySMD6fyrQ1CD7RoymSFI5xKY5IVYZYnG1sn24GKtSXSRafGkBkSEDJGMAHrzj655rLm1K3YpJIA2MNC0YLE+pPpjANPVsmV5vmtsMj1xLMw2mrwvNbsdqyxJmQYxgFjwfp71PqWkSRxJcLE+wEvGrJz9AucDr1p97JDLNaT3FqJ445AyrJ/qS5OdxI7iuiuNZe9gMbQxlOkhBP19KHKUdUYVFZxcY+pxelandxajZ2dtbS291dkJ9okGwH1469q9CGln7LI1wVlumQ7mjXAY4446E+5rk57WOXW4NwIfdmLPIPfaD2xW9Frk0UEokjDMoxGuOh9z3rKpeWqIrrms6at3OYtGJupLVY5YnVQx8xcZB9D9cjmn6RbiO2EMSl0gBkdnboCc5A/wqaW5mOuwLEySSamFeaEnBjkQAED2I7fjUt0Vg8y1tdscpDh23Zxnjj8OK0kOMnJNFRgjGTauxiCc9ATk5/QUy0uVvmjmhkH2YRxsSUYY3MVGfxH9allURsmyNndsBEGDzxkn0H86S1ddP3RKirBOQrJjdjGTwfQe3TNLSw5KW6C0mmOpeTefNFn5YwvzMPXd1rpbWCG8tXublz5Zyr7sAADHOaj03S1nhNw7hG2kIQwbGR/e/xpt5pVtqNsNLMhPlMrSsr43AHuP6VlKSbsjCpOLfYxr+ZFnBtAq2bZVMRct6kH1+tbGj6On9kXCSrIZLgsTuPzDsPpWpqK2EKwveyRQLBzGWfaF4xWHrFhf2knnaY262b52G7kNj7xJ7e9Lm5lZaCU/aJRWhnoRFMUUsSgOP9pwMZ9jzWcItQudSiV3tbcJIMmVhsbHTr949cDtzXTL9hvPD6TCcuYSjSTAAFm4JB9u1c+sMd5C91FbK0jf6nzBuwueuM9+SK1i+5vTm7N28tS+8sOj35R2R/lJlVE+Rif4f5VXurotfNHcQrBAqiTBUYznjH+FTpiSyj1Cbyyg4jVziTPTGCP1qGRond0CO0jqJSBztz6/lQlqVHletvmWr6w+yyKXl3eYoZtvRgegI9KrOzwJaXCK7zwuDhH2dxz06e3pVq882WGOVpFk24Cg+54/Dr60+4QqBsBMgBOQe2OuKa0CLurSEjuGup5vtcysC7SxuB0Bzxz26AUtpK8mCVURqD8zdM846etQ2Hl3TSOhDjcQGBIyo/QnIJq7cuZI4mSOJ7ZBvO376kdQQDyOcjPrS2HJW91FF411SNwpxCoCsJDtG7sRnn34rr9MvtNgs4LeSJW8hcBkGecYJ6DrXOpC0cCpIsSk5wFx+f/1ver0Q8lVUNhhnOR94HiiST0InHnW7I7KCaTXZJYrlUt5flMUZBwmcZY9OPStNrcMjIoEk6bkJ+8GGcZH+FU2j3x+TCUD4+7swG9ic02CF4UkikxvBYmNMrgEcgZwck8/lQ9R2JYbCRgs0zL58beXsQgMVzx7HFWbWSMWMl5MjhSu9kIwQAeoBqk9wtu9qoVhG42Zz8wJ4BFaEZYwz3CGI2kah3llbChWJGcnvRJ6EzlZe8afhUR3sgMVrOICuWmmQMky56deCCPfpXRNolk+qSX00Yd3Ckq3Iyv8AFj16VDYSWmhadY207xwq4IDDOwtjceffmrGhyzXDXMsksksO8+SzxlPlJz0746A8cVz31bR41STbcjXQ5APrRSrRQczOQv8AeNMikHkNDIefKOSrH3JIrOlaOzud0ckizffK7sgH1/zxWXp8WyW2hjuJJnnfzJppAFBUDBwvO05P3q21jtppLdI8ecoZZIXJKvjvn9a7nHlPdivZ6PUqwfaP7RiuRLE9usJIjcBmLMRn6EVHGApwoAd3ZlxyzAdD0qxb7YplWMojjJUbskd6iltGBilI+UE7WYH+eR/WpZtFe9qRy7oYDIQTs3EoR3JGB+ORVHS1gnS2SRnjjTJLEn523ZAI9O1WruR5rxY8J84BCEn5x3Ptio3imj8x2G5EJ2pwWYnt7Clsikm1YyNYguZL1Z5JGhYsWbByWwe34DFQTyfZdShvLYJHOuFIJyR2x6YJ6/hWvaWgCi6mBSVyqEsMlDjPX/8AVVGaFZZY1eAzR+ZubYQrnbyOvUHFUn0NotJO/QgTy4Lq5hRY3JCzMJXPJ9/yAwfeqkTpeXk0rxGVhkvIDty2eVwOg6/lRJA6R3t1cxstwjFo4n45A4/DmrFhA80UABG2MbiUICF25zz1JotpdlpqPwmcEltXuZS3n3LMJbYoTtC4yAB2AP6DvmoBBNO9zJcXcMjwIrSSy4O9m4A5HB/likuLidpd1rIsxWRo5nOGVv8AZDf0HpTriKO20s21ysUb31ygZyCCwHcDPQZB+tHQ0cbNPqMhtGtINMaAL5tysrwq5wFQKSCR/vDgn8aybQaZcSaNc29o9xfIXkuWeTarbifkb0GckH0rc1SO0gnvbeSSSQxBolKpk/KOOh4BHNRW8UkiLK/lNLEnlwKqj5B6ZHfHWpd3qy4Sjy3X9b/5j/B9pdaDc6lCx8mO4ywSQeYABzgenX3p0UUUlxNbtMY2gfcsbdSW5JA/z2q5ari3WSSV3VDllcYGe4XHaoLSRp2N1cSHzPuBmX07dOlLfUylLVy6kF1Cn9pNtJitWw32cDIwD/ET19cVcaOKVrmS1iTaw8rce6jtUEwO94gSrO24t1wCf8KhtpFVbiOFXKD5QSM+Zk9v/wBVFuwm21qTRRCSyRJFCTs7KpIwGUdCMcEYpmnvIkLCUeX5e5SwUlTg+voak0m1mieOaREWWTf/ABfKq+w9RzTr1Y5I3SLYzRqSABjHPOfXOaHvYzUlsxtxJM8aMtvI6SHEcyYAz+J/UVZ+zSNLH9nZTEyCRlOBhvp1/Km6gTcQGJGbfFEfLjJwAVGQBj1xiodLieWDdcPl1Ifao98jPH+cUuhm07XJfCumxaLq13cXVzJtYM5WQAhGJyT656/hTLoi/wBZuLq2jjS2YBY3L4WQnq/t9KZrFzEWMgEZVzy0knDkdeO3NJZG4u2kka22+Xu8zdHhASOMAdB6E0rP4mSqdnzt6sSSFXlit03ReWdrlfmz/FjPTk8ewqO0h+02InjjYBJCFMg+97/SqUVjquouoS4ljdhhxaqQOB3PoCR0rtPC/h6XQYjELtri3kUF45EGVb1BHalOXKVVlGnD4rst6LDENOePb+6yeo4K4rLtLIpc22o2wBi8yRNpJzsPRl9/b3ro7sOsOyOItGQQ21gCox2B61y3mXDTMnmyNFG+IhnIAHQ596yhd3Zw07zuyh4ihe/nspJ0JVWYOXTAXHqfX3rRS7E+hNatGWLZjZH5JTuxx0FUBA08xjSSZZHHC8gPg5x9fzqvFqIuL1Ut5GlmkJGYjkooPIz7dPxrXlurdjqcLpLsRXuomCN1YolqSu5EUjA6A4A/Q9aX7Ys/7zfuji+VVH5Crtrp1hd2t81rHdvPA/mBXm3KW6HB6np3/CovC2lPJqLKkJjhZG3llOCh6Lk985wRyKq6s79C/wB2ouW1irDqDPdpAiRzzs+XYNsC59++MVcbfb3rJA29WAVgQpKr0LZPXntxWpa6FYaNc7i7tEp4YL8xk67SemMVal8llk1K3iAuXkCIBxhcZ3e/1pcy6bClUi7cq0MPUkktwsYgxNgFA/R8dTx/D0+nNFss81xHI91GkABDAKSCcdvXmrN9PJcTtcNJ5rxooDuMA+2B1z1qOylaAOzeS1026OMSD7wPPy/401sUk3Emjj+zNdbJIn+0FcI42KhAGSCB35NN0/S52nvV8iSNXfAkboBjjB6Y61HpcGo3MtwZ9u2GMMGYAh2z2z0x1/Cr+juj2NwVa4llKESRFgFK93Qcgnjnp3od1sTUahdFbTFivpES2aKZ0Y8Icqcck5P0rQVFuJ2hQbJV4IznqOPoaTQxYwRvBFctbyPkRs4wFB6/d7+9TRxpbSOjzLGzNkSuPvY9e9J7kuopP3SOG0kjvh+5kMartMPOTxWhJdQpaF3igXys5eVipCjrzweOabGq3Cgyny0jx+9jPA54yoq5qGjw+IbdjY3MUc7x+XKsik8dCcDGO/NRJ9yKk0tZFSCTTpbqx2w/azL81tI7/J8wzkjHQVYvtPs7nRb/AE/WLuGG+QB5ZseXFgkhSoyMgYPH866fSdDhsSqAJJDGoEYZcsuPetOfTbK6LG5tYJGYYJZASfxrNvXQ8ypW966K/wBngv7C3RpA1rtUnsZBxjPoD1rTRVRQqgAAYAHaiONI41jjUKigKAOwpwBHSkcjYoGKKB16UUEnDaLZiys2+0lvMZSrIUA3McfNnOe3NVL+O8a4jZpkSOZVjJSPAiIP3uOxB/MVrII5fMzL8vcAZI9x6cUyS7tJI5PKZ5JGkzxkbB0AwR0ru63PdU2pXtdjNP023i8TAAOJ48yhgxCvkYx9cc4x3puoX39qTyxO37qPhRHxyDyee2eKnC2d5Z7ZJ5vPXnCvnaAe/oDmso3vkXxiTY0cqfJK3AXn5gfpj9ahK7uTBSnPmkrtKxHqEm0rKjrHNGBHuI3bix4znoeP51WV1t1eaTmRgMsvJ7YX29fxqyEWG8kmSRhKmffbxgkde3eo7m8UeXBD5Tvnem8dDgj9ao6o9kjPvbs/ZZ5GuHgjVWIRwuAR39cnpUunW08+mJqWnyqn2Xl/NP3jkEgDGFx+tULaSaTWVtby9MjvHiSHyQVQN79KtancPaS3OiW6mCNyyM+0l5VHA+X39R+lDT2RU/5Y77/LqVr65hMjvcXDhpxho4lBI6Asd3OPwqtDPY+dBE1ibiJTwWlZd2OMkA4JxnqKpajpKotuLOKPMRLK5cqFODgHcemalvrmM6LGttYpHqG3Y0kMpYEgfM3Xr3zQ0raGygmklf8AL9SfW7BbCaewddlv5q3KCMDDAZx26cmqnh+S2TUys6RyrJmN2ZCWjBBwDnsen41saZDbajoMNtfO9rLax+Uk/ZkBwAw65yetU9Q02WLU5rdQsk3k78QrkFR/j1FRf7LCnOKTpyevX/MwNC1JLn7RYXTf2fMJWiE7dAhzyMj72BjHqK07GK3t9KlEEsxlkkLR3FwOCxPzMff27ZqG80tkR7y+t5ItvCq/yHaRnPr+PXFSW8/kQQRyW+1Tklj0xjOfp06U3qbzinrB6FN7XWYRaTW2pIYXMguLdVBJ5wABznOc+2K3YLYQaHN9udVdiREpBBxxw3681ls3nzNtZBEpG4eZhyfTAHT3ot5XAeBpMhvu7z3/ACxSadjOcXLX/gEMwuPs0r5BZny21R04HQdhjirEKLHbwxqA2CG+XGfpgVZgZ7aGV5ZtigHMUf3hxknJHH15ojYXNhvtptnkgPEBECXXuM+2fSght22KV4HkKBeGyA4PJHfOKNPhitLYNcs8sshOPVvck1PHJFC6ERFs8li2dw5pYJGupE2xEyMSUkyTtHf68UeQm2o2aFkhSNUdGfIPO8Y4Prj09aTAMZ3spGcl1Y8fU1r3diy6cLsHCKg8tVwxkYngjrXKaTdz3viY6dPHFNIZEkR7NsLGqnLKQeD7jsaS1M1Lmi2uhNcWgu7eCMxiNgCY4zyxx/EQec8/pV9PtcEDwwCW4jiGLiSJApZj3OepHtXV3elQL4gTWbhkCQwlcuThTnr+tPn1mytwwQM5yMBBw2ev4+3Ws3UctkYOvdJRV/8AMpeGWWZU8tFRYE2gFPnOe7EcdunNaepz/Z7VijqshIUc+pqHUdWt9O0/z4ombPCoqYx7kemf515vfa5dbLmZkVmdhtMZwxBPdjxj6fSlCjKq7nNKzlzM6/Vb+eW+t9PiLSlxkyIMI2e2elZeoRmK4kRiX6AlflKsOwNPgdLW6uGhMiQBjKvmcgEDAAx9M896rWd/b3265cPJljllBO456/T6VcY22O2EeVaLQqTp52oNIxlO1srnIOCOee35Vsabb2VlHG4i2yjLDGCoOQRz1+tFjHAfM+1SNH8oEYVeS3uOuM1Wugy3kIZhHbltzZOCyjj+dVvoOUudcpJKs1xNL5cDW8zSeaHyQx+gHbr61pjXLmCKNTGofP3dh6Dr+JrDv7N5IEIuZoNjeYHt5NrE8YBzXQardWV4lvM0cjyRjhW+UE9mOOvNS0nbQmcU7X1RlzT3d+8lzt3RKcSqMEj6gdPTPess6jPHqixzBZrcJsMCjYyDgDDHoevXrmtRZ5ofPFnlg6hJVB5yB1+lJbyySwrhQzZy7sclTVo1hFR3V0TvCFQsjvOpdUX5fmX2OOmOKdGrRyqxMZZWIUgZPPHH+NSKy24VhGiRSHBP3RJ9cfzFRvcRzXW1VTyinQnO0+/vUq5C7LYHG6SYkMmMfdPzEen50+OeS0jUQho0SQeWFHQnnH68+tR3AnJgdSqAYVsjO7jPB+tMdpIpkUuzR7ScIMHd6n2qkrjaUjevdDS9tnvtMkWRiMmJRgDjkL+tQWY+1JDblxI65aMkAN6FD9KTSLqVZxJasUkJAC4wCPfP6Vo3WnpdPNdaamXLfv4AcSRP/eX1z6flSV1pI4pJ0pblae1e0a3QxsjHn7pzx1x+NavhyAPqokklKyBSVQZGef1rKvbuSB4/t8EsMhASWR1IVh6k/wBRTPDz39t4jnF3GRFbthH3jypQw6qfT/A0pLTUqU+am+56YgqVBXP+GdQe/a8Gyby0lz5rtwSf4VGOgroU6Gua1jx5qzsOooopmYhUbt3cDFFLRQBgrpNzmRmFqWfq3IJ4wOgpn9iXGSd8eSMD5zx+lFFdPMz01OS2IV0G8Eschmh3LjIDMM8dzjmmN4cuWunkd7eSNjuCMWwp74470UUuZlqtNbMqx+GtS825uJpbNpZBlYlLLHkdFPGcetQaR4JuYoL2TU77z7y4dXAjYiNSp47fh04FFFNzaQqtepFWT7Ed/wCD9SvZC00llICpXYXYbsnoSF7dvepZfCF80rzK9r5rE9ZG4B7Z25ooocnY2Vaae5k6p8OtQ1O9kmvLq2kQLthUSMuzPUkbTnvirmoeBLlZ2GlfY47dY1WNZpXyG7scL/Wiild6DWKquSXNpb/Ijm8Das9s0Md9ax52jKluQP8AgP6e5qx4i8NeI7iGCLQ5dNsz5flzytM+91C4AGE4x160UVLk3uVTqSc02aen+G76fw9DZeILiC7uwuJJY84J9uPT2rnLj4c3whkigubdgchWlkYlVz8oA24AAxRRSTakzCjiKkJtRZO3w9uliheK4tvtOMSsSwB9MHGajPgDUtinzrFpCpVtztj6j5aKKakzeGKqtasQ+AdT8p0EtgQy7f8AWMP12Gom+HmruCGu7ONQMARSON3rn5ePpRRVczsDxFRdS9/wgNwtkVzby3JBAZpmVV444CHP6VBD8O702Ekc93bm5aIIrIzAIc5IHHQ9OlFFRzMyeIqct79R8fgnXI47eNb+zEcI2heeABgAfLxT9H+HA0zU4LyGW33RbwOMEhh9KKKUptIirXnZq+5q6/4Yvr/T2htp4Y5SeCXYD8flOaybjwPqlw3M9nEuAPkdiTjvnb14ooog7RIp1Zxjox194K1G7b5v7OUBdgId87c9/lqgPhtevITPJYGJYwixqzYLZzuPy/pRRVKTS0LlNlibwBqEk43yWTWylSE8xlLcDOTs9e1Sp4GvwgUDTolC7fLjd9pA6fw/yooou7F+2npqJJ4G1OWWMmayREYk7ZHJbjjqMCmv8P71rtJfPtNqjAG49P8AvmiijmZHtprqTHwRqJPM1oVPUGRuf/HaYfA2pCZ5FmsiWUpgswGP++aKKLstVp9wHgXUhn9/Z5Of4m/+Jpr+A9QZg4mst4G3lmwR/wB80UUczG8RU7jv+EG1KR38+5tnVlCj94wCgc8Lt45pdM8DalZRT7riznuJBsEjFhsQH5QAB19TRRRzMTrz+G+g+38DXsj3f9o3Fs6MoEOwsSD3zkcfhU8Xgy6WDyzJbDucM388UUUczuSq023qQp4J1GK4DRTWSxAZIBbJb8vT3/CpbXwnq1pcyeTNZLCYWjUh3DAnnptxweQetFFXzNk+1nJasNQ8G319dRyPNAmxQCwmcmQj+8CMetaUHhy5TbI7W3mL0QFtn06Z/GiiolJ2JlWmo2uamiadNZNcGcR5kIO5ZWfJ79QMfma1gKKKxOCo25O4veiiigzCiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of a nodular melanoma, demonstrating a large, pigmented dermal growth without an epidermal component.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28563=[""].join("\n");
var outline_f27_57_28563=null;
var title_f27_57_28564="Joint aspiration or injection in adults: Complications";
var content_f27_57_28564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Joint aspiration or injection in adults: Complications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28564/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28564/contributors\">",
"     W Neal Roberts, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28564/contributors\">",
"     Howard W Hauptman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28564/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28564/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28564/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28564/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/57/28564/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A needle is inserted into a joint for two main indications: aspiration of fluid (arthrocentesis) for diagnosis or for relief of pressure, or injection of medications. In practical terms, almost all injections into joints consist of a glucocorticoid, a local anesthetic, or combinations of the two. Adverse outcomes from glucocorticoid injection are uncommon, but several are serious. These include iatrogenic infection and three serious types of atrophy (ie, tendon rupture, nerve damage, and inhibition of chondrocytes leading to glucocorticoid arthropathy) (",
"    <a class=\"graphic graphic_table graphicRef74660 \" href=\"UTD.htm?14/25/14747\">",
"     table 1",
"    </a>",
"    ). The last of these is more of a theoretical than actual risk of glucocorticoid injection.",
"   </p>",
"   <p>",
"    The complications of joint aspiration or injection in adults are discussed here. The technique and indications for joint aspiration and intraarticular and periarticular injections of glucocorticoids and intraarticular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1719?source=see_link\">",
"     hyaluronate derivatives",
"    </a>",
"    , as well as the choice and frequency of agents for injection, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link\">",
"     \"Joint aspiration or injection in adults: Technique and indications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONINFECTIOUS COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tendon rupture is most commonly encountered when undiluted glucocorticoid is injected near the rotator cuff or near the insertion of the long head of the biceps tendon. This complication may be more common with the posterior approach, which can be directed upward in the direction of the subdeltoid bursae and rotator cuff, than with the anterior approach, which is only intraarticular (",
"    <a class=\"graphic graphic_figure graphicRef53450 \" href=\"UTD.htm?28/61/29663\">",
"     figure 1",
"    </a>",
"    ). Tendon rupture can usually be avoided by sticking to one size of needle and syringe so as to be able to recognize the higher resistance that comes with injecting into a tendon.",
"   </p>",
"   <p>",
"    Nerve atrophy or necrosis occurs when glucocorticoids enter the nerve sheath directly, an event which usually occurs only with carpal tunnel injections that come quite close to the median nerve. These injections should be performed by a subspecialist with specific training (eg, a hand surgeon or a rheumatologist). One would think that injection of the nerve would be quite painful and would, therefore, be uncommon. However, once the perineurium is pierced, the pain may be moderate and may be accompanied by a burning sensation. In the worst case, permanent nerve injury with a claw hand deformity ensues.",
"   </p>",
"   <p>",
"    Other minor atrophies can also occur. These include skin atrophy, hypopigmentation, and dystrophic calcification around joint capsules. Hypopigmentation around the injection site is the most troublesome, especially on the wrist and hand of deeply pigmented individuals in whom it takes years to resolve (",
"    <a class=\"graphic graphic_picture graphicRef74337 \" href=\"UTD.htm?8/13/8402\">",
"     picture 1",
"    </a>",
"    ). Thus, such patients should be specifically advised about this complication. It may be possible to reduce the incidence of hypopigmentation by switching syringes and by flushing the needle with a small volume of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    before withdrawing it.",
"   </p>",
"   <p>",
"    The risk of bleeding complications in patients receiving therapeutic anticoagulation is low and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link&amp;anchor=H8656865#H8656865\">",
"     \"Joint aspiration or injection in adults: Technique and indications\", section on 'Approach to the patient on anticoagulants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Glucocorticoid toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraarticular glucocorticoid injections do not appear to have measurable effects upon the rate of progression of osteoarthritis. This was illustrated in a study of 68 patients who were followed for two years; no discernible effects upon cartilage depth, either chondroprotective or destructive, were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects related to systemic absorption of glucocorticoids can occur, however. Among the complications that can be seen are ecchymoses, menstrual irregularity, accelerated cataract formation, and osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two other clinically meaningful systemic metabolic effects of have been measured [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suppression of the hypothalamic-pituitary axis lasting from a week to two weeks after a single injection",
"     </li>",
"     <li>",
"      Increases in blood glucose for up to four days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A rare complication, but one with major clinical implications, is osteonecrosis (ischemic or avascular necrosis of bone) from intraarticular glucocorticoids. The risk of this complication is reported to range from less than 0.1 to 3 percent of injected joints [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, experience suggests that the former figure is closer to the mark, and severity of the underlying joint disease may contribute more to this risk than the injection itself.",
"   </p>",
"   <p>",
"    Bone metabolism markers suggest that bone metabolism recovers completely in one to two weeks after the injection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Glucocorticoid-induced osteoporosis is probably not a major concern for the majority of patients who have reasonably long intervals between their injections.",
"   </p>",
"   <p>",
"    Instead, the major practical feature of glucocorticoid toxicity from joint injection is impaired blood glucose control in diabetic patients for several days after the injection, particularly if multiple injections are used. However, on average, diabetic patients suffer no decrement in blood glucose control from a single soft tissue injection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/7\">",
"     7",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adverse effects of hyaluronate injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a canine model of osteoarthritis, there was a significant decrease in the concentration of cartilage proteoglycan following injections of hyaluronate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/8\">",
"     8",
"    </a>",
"    ]. This finding has raised concern that a similar effect may occur with repeated injections in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=see_link\">",
"     \"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several short-term adverse effects of intraarticular hyaluronate injection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Each intraarticular injection carries a small risk of iatrogenic infection; this is perhaps as small as 1 in 10,000 injections as reported in some textbooks, but we have observed an incidence of approximately 1 in 2500.",
"     </li>",
"     <li>",
"      Acute flares, termed pseudoseptic reactions, may occur in 11 percent of injections [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. These reactions generally occur within one week of injection and after a follow-up injection rather than after the first injection, involve an effusion from 10 to 70 mL in volume, have nucleated cell counts of 3500 to over 100,000, and show a differential of approximately 50 to 90 percent of polymorphonuclear leukocytes. In addition, the fluids are culture negative and, with a few exceptions, show no crystals. Nonbirefringent intracellular material in Wright stained leukocytes in synovial fluid was seen in six of eight patients in one observational study [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With the hylan GF-20 preparation (Synvisc), some cases of crystal-proven pseudogout have occurred two or three days after hyaluronate injection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IATROGENIC SEPTIC ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of a septic joint is the most feared complication of joint aspiration (arthrocentesis), with or without glucocorticoid injection. The frequency of this complication is estimated to lie between 1 in 2000 and 1 in 15,000 procedures. The former number is the combined experience of one author of this topic review and a community-based practice of rheumatology; the latter estimate is the experience of the other author and the accepted textbook frequency.",
"   </p>",
"   <p>",
"    A septic joint must be distinguished from the more common postinjection flare. Infection should be suspected if the flare lasts longer than or begins later than 48 hours after injection. The usual postinjection flare lasts hours rather than days. Other findings suggestive of an iatrogenic septic joint include a crescendo pattern of pain, redness or drainage around the injection site, and fever or malaise.",
"   </p>",
"   <p>",
"    The principles of management of iatrogenic septic joints due to arthrocentesis and of management of spontaneous septic joints are identical, while the principles of primary prevention differ radically [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28564/abstract/12\">",
"     12",
"    </a>",
"    ]. The major determinant of outcome in almost all clinical studies is the length of delay between the first symptom and initial drainage (the diagnostic arthrocentesis) plus antibiotic treatment. In spontaneous septic joints, the patient alone controls the length of this delay. In contrast, the clinician has the chance to educate the patient at the time of arthrocentesis and, therefore, can potentially control the delay in iatrogenic sepsis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=see_link&amp;anchor=H2#H2\">",
"     \"Joint aspiration or injection in adults: Technique and indications\", section on 'Patient education'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of nongonococcal septic joints is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link&amp;anchor=H17#H17\">",
"     \"Septic arthritis in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2951889\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications of glucocorticoid injections are uncommon. Two major types of adverse effects include atrophy of articular or periarticular tissues and iatrogenic infection (",
"      <a class=\"graphic graphic_table graphicRef74660 \" href=\"UTD.htm?14/25/14747\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noninfectious complications include tendon rupture, due to injection of glucocorticoids into a tendon or of undiluted glucocorticoids in very close proximity to the tendon; nerve atrophy or necrosis, when glucocorticoids enter the nerve sheath directly; and loss of pigmentation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atrophy of the skin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Noninfectious complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intraarticular glucocorticoid injections do not appear to have measurable effects upon the rate of progression of osteoarthritis. However, side effects related to systemic absorption of glucocorticoids may occur, including increases in blood glucose for up to several days in diabetics. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Glucocorticoid toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adverse effects of hyaluronate injection include pseudoseptic flares of acute arthritis, rare cases of calcium pyrophosphate crystalline arthritis, and iatrogenic infection (risk between 1 in 2500 and 1 in 10,000). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Adverse effects of hyaluronate injection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of iatrogenic septic arthritis following joint aspiration or injection is estimated between 1 in 2000 and 1 in 15,000 procedures. Infection, rather than the more common postinjection flare, should be suspected if the flare lasts longer than or begins later than 48 hours after injection. The usual postinjection flare lasts hours rather than days. The principles of management of iatrogenic septic joints due to arthrocentesis and of management of spontaneous septic joints are identical. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Iatrogenic septic arthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/1\">",
"      Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/2\">",
"      Mader R, Lavi I, Luboshitzky R. Evaluation of the pituitary-adrenal axis function following single intraarticular injection of methylprednisolone. Arthritis Rheum 2005; 52:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/3\">",
"      Black DM, Filak AT. Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection. J Fam Pract 1989; 28:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/4\">",
"      Sparling M, Malleson P, Wood B, Petty R. Radiographic followup of joints injected with triamcinolone hexacetonide for the management of childhood arthritis. Arthritis Rheum 1990; 33:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/5\">",
"      Neidel J, Boehnke M, K&uuml;ster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum 2002; 46:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/6\">",
"      Emkey RD, Lindsay R, Lyssy J, et al. The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/7\">",
"      Slotkoff, et al. Effects of soft-tissue corticosteroid injection on glucose control in diabetics (abstract). Arthritis Rheum 1994; 37:S347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/8\">",
"      Smith GN Jr, Myers SL, Brandt KD, Mickler EA. Effect of intraarticular hyaluronan injection in experimental canine osteoarthritis. Arthritis Rheum 1998; 41:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/9\">",
"      Puttick MP, Wade JP, Chalmers A, et al. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J Rheumatol 1995; 22:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/10\">",
"      Pullman-Mooar S, Mooar P, Sieck M, et al. Are there distinctive inflammatory flares after hylan g-f 20 intraarticular injections? J Rheumatol 2002; 29:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/11\">",
"      Kroesen S, Schmid W, Theiler R. Induction of an acute attack of calcium pyrophosphate dihydrate arthritis by intra-articular injection of hylan G-F 20 (Synvisc). Clin Rheumatol 2000; 19:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28564/abstract/12\">",
"      Schmid FR. New developments in bacterial arthritis. Bull Rheum Dis 1992; 41:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7977 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28564=[""].join("\n");
var outline_f27_57_28564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2951889\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONINFECTIOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Glucocorticoid toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adverse effects of hyaluronate injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IATROGENIC SEPTIC ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2951889\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7977|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/61/29663\" title=\"figure 1\">",
"      Aspiration shoulder effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7977|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/13/8402\" title=\"picture 1\">",
"      Steroid injection skin hypopigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/25/14747\" title=\"table 1\">",
"      Intraarticular steroid toxicity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30951?source=related_link\">",
"      Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23368?source=related_link\">",
"      Joint aspiration or injection in adults: Technique and indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_57_28565="Synovectomy for inflammatory arthritis of the knee";
var content_f27_57_28565=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Synovectomy for inflammatory arthritis of the knee",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28565/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28565/contributors\">",
"     R John Wright, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28565/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28565/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28565/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28565/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/57/28565/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synovectomy refers to the destruction or surgical removal of the membrane (synovium) that lines a joint. As the largest articulation and the one most frequently affected by chronic inflammation, the knee is the joint most often selected for synovectomy. Open surgical, chemical, radiation, and arthroscopic synovectomies are all options for removing potentially damaging synovium from the knee.",
"   </p>",
"   <p>",
"    There are various disorders that are indications for synovectomy. Among them are chronic inflammatory arthritides (eg, rheumatoid arthritis, psoriatic arthritis, Lyme arthritis), benign neoplastic disorders (eg, osteochondromatosis, pigmented villonodular synovitis), recurrent hemarthrosis (eg, hemophilia). (See appropriate topics.)",
"   </p>",
"   <p>",
"    Surgical debridement of synovial tissue, either open or arthroscopic, is also indicated for the treatment of some joint infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of synovectomy in the diagnosis and management of inflammatory arthritis of the knee is reviewed here. Synovectomy has a limited role in treatment of osteoarthritis of the knee, and the use of arthroscopy in that setting is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=see_link\">",
"     \"Surgical therapy of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chronic inflammatory arthritis of the knee, microbiologic and histopathologic examination of synovium may be useful in diagnostic and prognostic studies. Arthroscopically guided synovial biopsy is an attractive alternative to closed needle biopsy techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Synovial biopsy and joint examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopic synovial biopsy, as well as articular and synovial examination, may provide useful prognostic information concerning disease progression among patients with inflammatory arthritis. Establishing the stage in the progression of changes from effusion and synovial proliferation with hyperemia through pannus formation with cartilaginous erosions to bony erosions allows some prediction of the efficacy of treatments, such as arthroscopic debridement or synovectomy, and of the likelihood of the need for eventual joint replacement. As an example, one study of 26 knees in patients with rheumatoid arthritis (five knees), juvenile idiopathic arthritis (18 knees), or psoriatic arthritis (three knees) used arthroscopy and clinical examination to assess the efficacy of open synovectomy in the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/1\">",
"     1",
"    </a>",
"    ]. Arthroscopy included synovial biopsy for immunohistologic evaluation. The absence or low incidence of immunoglobulin A (IgA)-positive plasma cells in biopsies of knee synovium, as well as the amount of fibrin in the superficial layer 12 months after the synovectomy, suggested a less aggressive disease process and predicted a more reliable outcome after synovectomy. However, preoperative biopsies and those done six months after synovectomy were not predictive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYNOVECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Open synovectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The beneficial role of open synovectomy of the knee has been clearly demonstrated for inflammatory arthritis, hemophilic synovitis, pigmented villonodular synovitis, and synovial chondromatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. By ablating the synovial joint lining, this operative technique reduces inflammation, thereby reducing pain, swelling, and loss of joint motion. Synovectomy should be considered when medical management for a minimum of six months fails to control synovitis and pain. However, open synovectomy of the knee may result in significant morbidity; it is also associated with prolonged hospitalization and rehabilitation and may cause significant blood loss.",
"   </p>",
"   <p>",
"    The long-term results of multiple studies of open synovectomy indicate that the procedure, although effective in temporarily relieving pain, is primarily palliative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/1-3,5\">",
"     1-3,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report evaluated the efficacy of synovectomy in 78 knees among 55 patients with rheumatoid arthritis followed for a minimum of 10 years after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/2\">",
"       2",
"      </a>",
"      ]. Seventy-five of the knees had moderate or severe pain preoperatively. Surgery resulted in significant pain relief, as only 24 of the 75 knees continued to have moderate or severe pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/2\">",
"       2",
"      </a>",
"      ]. Symptom relief was more reliable in patients who underwent surgery prior to the development of significant radiographic evidence of degenerative change. However, surgery failed to halt disease progression; no significant difference in joint space narrowing was observed between the two knees of patients in whom surgery was performed on only one knee.",
"     </li>",
"     <li>",
"      The failure to delay the deterioration of secondary degenerative changes leads to knee replacement in many patients within a few years after synovectomy. In one study of 83 cases of knee synovectomy for rheumatoid arthritis, over 50 percent had undergone an osteotomy or total knee replacement at five years after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective five-year clinical follow-up study of open synovectomy in chronic inflammatory joint disease employed arthroscopic examination of the joint before, six months after, and 12 months after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/1\">",
"       1",
"      </a>",
"      ]. Patients were found to have decreased pain and swelling for up to six months after the procedure. The amount of wear on visual examination of the articular cartilage was the best predictor of good outcome, and those with recurrent synovitis at 12 months did worse at five-year follow-up. Patients with absent or low numbers of IgA-positive plasma cells on histologic examination of the synovium had better clinical scores at five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In light of the temporary nature of the procedure and of the high cost and complication rate of the open synovectomy technique, additional techniques have been introduced to avoid the open procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Arthroscopic synovectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopic synovectomy, in the hands of a skilled arthroscopist, produces results comparable to open synovectomy, but with decreased morbidity and with considerably decreased cost. The procedure is associated with a decreased rate of infection, causes little if any loss of motion of the knee as long as early range of motion is encouraged, and can usually be performed in the outpatient setting, unless medical conditions require inpatient observation postoperatively.",
"   </p>",
"   <p>",
"    Arthroscopic synovectomy is performed under general or spinal anesthesia, and a tourniquet is used. The knee is distended using a pressure irrigation system. The procedure requires considerable patience and a systematic approach to ensure that as much synovium as possible is removed. A specialized suction shaver and use of multiple portals, including posterior portals, facilitate a more complete excision. The posterior portals have significant associated risks of neurovascular damage, particularly to the saphenous vein and nerve. Care must be exercised to ensure that the excision is not too deep since this may promote scarring and subsequent loss of motion.",
"   </p>",
"   <p>",
"    Because the excision, particularly posteriorly, may be incomplete, an open synovectomy using anterior and posterior incisions is recommended in the treatment of pigmented villonodular synovitis when there is a significant bulk of abnormal tissue. Otherwise, recurrence will lead to an early resumption of symptoms.",
"   </p>",
"   <p>",
"    The efficacy of arthroscopic synovectomy was evaluated in one study of 96 patients with a variety of inflammatory arthritic disorders who underwent arthroscopic synovectomy because of at least six months of persistent synovitis and effusion of the knee that did not respond to medical management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/8\">",
"     8",
"    </a>",
"    ]. Preoperatively, 56 percent had knee pain. At four years after the procedure, only 21 percent had pain, and 24 percent had a synovitis.",
"   </p>",
"   <p>",
"    This study group was subsequently enlarged to 211 synovectomies and was followed over a period of 2 to 10 years after arthroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/9\">",
"     9",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 112 rheumatoid knees responded better (80 percent characterized as good or excellent) than the 32 knees with other inflammatory arthritides, such as psoriatic arthritis or ankylosing spondylitis (60 percent characterized as good or excellent).",
"     </li>",
"     <li>",
"      Recurrence occurred in only 2 of 19 cases of pigmented villonodular synovitis.",
"     </li>",
"     <li>",
"      There were no recurrences in 17 patients with synovial chondromatosis.",
"     </li>",
"     <li>",
"      The 31 knees with nonspecific or posttraumatic synovitis showed decreased synovitis, but only one-half had reduced pain and improved function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arthroscopic synovectomy of the knee in patients with rheumatoid arthritis is, therefore, indicated after failure of an adequate trial of medical management for six months in a patient with persisting synovitis, with little or no degenerative changes on radiographs, and with functional class of I or II according to the American College of Rheumatology criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients with a greater functional impairment are usually candidates for more extensive surgery.",
"   </p>",
"   <p>",
"    Arthroscopic or open synovectomy can also play a role in the management of the arthritic complications of hemophilia. One study of synovectomy in 13 knees in 11 patients (eight open and five arthroscopic) showed a reduction in recurrent hemarthroses at an average follow-up of two and eight years for the arthroscopic and open groups, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/6\">",
"     6",
"    </a>",
"    ]. In most cases, arthroscopic synovectomy increased the range of motion, and open synovectomy reduced or did not affect the range of motion. The roentgenographic progression of disease decreased but did not stop after synovectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link\">",
"     \"Treatment of hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=see_link\">",
"     \"Hemarthrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laser synovial ablation may prove to be a useful modality in this setting. The effectiveness of a holmium:yttrium-aluminum-garnet (holmium:YAG) laser system was assessed in 17 patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/10\">",
"     10",
"    </a>",
"    ]. Symptomatic improvement was more likely in those with less severe joint space narrowing (Larsen grade I or II). The proper role for this technique requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19430830\">",
"    <span class=\"h2\">",
"     Open versus arthroscopic synovectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopic synovectomy may be associated with a greater risk of disease recurrence and of radiologic progression than open synovectomy, although they appear to result in a comparable degree of pain relief. These techniques have not been compared in randomized trials, but they were compared indirectly in a 2011 meta-analysis of 58 studies involving 2589 patients (with mean follow-up of 6.1 years) who underwent open or arthroscopic synovectomy for rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/11\">",
"     11",
"    </a>",
"    ]. Those undergoing arthroscopic synovectomy in the knees had a statistically significant lower risk of progression to total joint arthroplasty compared with those undergoing open synovectomy (11 versus 19 percent). Radiographic progression was statistically significantly less frequent in the elbow and knees in patients who underwent the arthroscopic procedures (66 versus 28 percent and 75 versus 55 percent, respectively). However, the proportion of patients reporting less pain was similar for the two groups in each of the joints studied (mean of 75 percent). Limitations of the analysis included the performance of the majority of the studies prior to the availability of biologic disease-modifying antirheumatic drugs and the tendency of the arthroscopic studies to have been performed more recently than many of the open synovectomy studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81273043\">",
"    <span class=\"h2\">",
"     Chemical synovectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical synovectomy utilizing intraarticular injection of osmium tetroxide (osmic acid) or alkylating agents has been used to perform a &ldquo;medical synovectomy&rdquo; in patients with synovial inflammation due to various disorders, including rheumatoid arthritis, psoriatic arthritis, pigmented villonodular synovitis, and ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/12\">",
"     12",
"    </a>",
"    ]. However, concerns about potential mutagenicity of alkylating agents have limited enthusiasm for their use.",
"   </p>",
"   <p>",
"    The possible value of osmium tetroxide synovectomy was illustrated in an uncontrolled consecutive series of 65 patients with various diseases causing persistent knee inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/13\">",
"     13",
"    </a>",
"    ]. Aspiration of the symptomatic knee, with removal of as much fluid as possible, was followed by the injection of local anesthetic (10 mL of 1 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ). After the local anesthetic had taken effect, 10 mL of an aqueous solution of osmium tetroxide (100",
"    <span class=\"nowrap\">",
"     mg/10",
"    </span>",
"    mL) was instilled. Then, 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide were injected, and the needle was removed. Knee immobilization and bed rest for 24 hours were employed to reduce the risk of leakage. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Responses to the injections were good to excellent in 86 percent of patients when assessed six weeks following the injection. However, recurrence of synovitis occurred gradually, and 80 percent of injected knees were again inflamed three years following the initial injection.",
"     </li>",
"     <li>",
"      Adverse effects of osmium tetroxide chemical synovectomy included immediate postinjection pain in 12 percent of injections, skin burns at the site of needle insertion in 3 percent, and early &ldquo;reactive&rdquo; effusion that required aspiration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While chemical synovectomy with osmium tetroxide appears to be a generally safe technique for controlling synovitis of the knee that has not responded to other medical therapy, it is performed at only a few tertiary centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81273086\">",
"    <span class=\"h2\">",
"     Radiation synovectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation synovectomy with the use of short-acting dysprosium-165-ferric hydroxide macro aggregates is an effective alternative to open synovectomy. One study, for example, found that 39 of 59 patients with rheumatoid arthritis at two-year follow-up had complete or almost complete relief of pain, a small or no effusion, and improved or no loss of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, despite initial suggestions of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/15\">",
"     15",
"    </a>",
"    ], radiation synovectomy utilizing another radioisotope (yttrium-90) combined with intraarticular glucocorticoid injection appears to be no more effective than intraarticular glucocorticoids alone. This was illustrated in a study that randomly assigned the knees of 97 patients with chronic sterile synovitis to yttrium plus glucocorticoid (20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    hexacetonide or 40 mg of triamcinolone acetonide) and assessed a composite measure of clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28565/abstract/16\">",
"     16",
"    </a>",
"    ]. Yttrium plus glucocorticoids did not produce a greater response than intraarticular glucocorticoids alone (48 percent responded in each group), nor were the responses more durable.",
"   </p>",
"   <p>",
"    Limited geographic availability and the experimental nature of this procedure in many locales limit the consideration of radiation synovectomy as a general solution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81272601\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Synovectomy refers to the destruction or surgical removal of the membrane (synovium) that lines a joint. Open surgical, chemical, radiation, and arthroscopic synovectomies are all options for removing potentially damaging synovium. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In chronic inflammatory arthritis of the knee, microbiologic and histopathologic examination of synovium may be useful in diagnostic and prognostic studies. Arthroscopically guided synovial biopsy is an attractive alternative to closed needle biopsy techniques. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Synovial biopsy and joint examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of open synovectomy of the knee has been demonstrated for inflammatory arthritis, hemophilic synovitis, pigmented villonodular synovitis, and synovial chondromatosis. By ablating the synovial joint lining, signs and symptoms of inflammation are reduced. Synovectomy should be considered when medical management for a minimum of six months fails to control synovitis and pain. However, open synovectomy of the knee may result in significant morbidity, and, although it can be effective in temporarily relieving pain, the procedure is primarily palliative. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Open synovectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arthroscopic synovectomy can produce results comparable to open synovectomy, but with decreased morbidity and cost. It can usually be performed in the outpatient setting, unless medical conditions require inpatient observation postoperatively, and it is performed under general or spinal anesthesia. It has shown benefit in patients with rheumatoid arthritis, pigmented villonodular synovitis, synovial chondromatosis, and hemophilic arthritis and in some patients with nonspecific or posttraumatic synovitis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Arthroscopic synovectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemical synovectomy and radiation synovectomy may reduce synovial inflammation, but their availability is limited to experimental use in a limited number of tertiary care centers. (See",
"      <a class=\"local\" href=\"#H81273043\">",
"       'Chemical synovectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H81273086\">",
"       'Radiation synovectomy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/1\">",
"      Paus AC, F&oslash;rre O, Pahle JA, et al. A prospective clinical five year follow up study after open synovectomy of the knee joint in patients with chronic inflammatory joint disease. The prognostic power of clinical, arthroscopic, histologic and immunohistologic variables. Scand J Rheumatol 1992; 21:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/2\">",
"      Ishikawa H, Ohno O, Hirohata K. Long-term results of synovectomy in rheumatoid patients. J Bone Joint Surg Am 1986; 68:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/3\">",
"      McEwen C. Multicenter evaluation of synovectomy in the treatment of rheumatoid arthritis. Report of results at the end of five years. J Rheumatol 1988; 15:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/4\">",
"      Montane I, McCollough NC 3rd, Lian EC. Synovectomy of the knee for hemophilic arthropathy. J Bone Joint Surg Am 1986; 68:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/5\">",
"      Rydholm U, Elborgh R, Ranstam J, et al. Synovectomy of the knee in juvenile chronic arthritis. A retrospective, consecutive follow-up study. J Bone Joint Surg Br 1986; 68:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/6\">",
"      Triantafyllou SJ, Hanks GA, Handal JA, Greer RB 3rd. Open and arthroscopic synovectomy in hemophilic arthropathy of the knee. Clin Orthop Relat Res 1992; :196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/7\">",
"      Doets HC, Bierman BT, von Soesbergen RM. Synovectomy of the rheumatoid knee does not prevent deterioration. 7-year follow-up of 83 cases. Acta Orthop Scand 1989; 60:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/8\">",
"      Ogilvie-Harris DJ, Basinski A. Arthroscopic synovectomy of the knee for rheumatoid arthritis. Arthroscopy 1991; 7:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/9\">",
"      Ogilvie-Harris DJ, Weisleder L. Arthroscopic synovectomy of the knee: is it helpful? Arthroscopy 1995; 11:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/10\">",
"      Takagi T, Koshino T, Okamoto R. Arthroscopic synovectomy for rheumatoid arthritis using a holmium:YAG laser. J Rheumatol 2001; 28:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/11\">",
"      Chalmers PN, Sherman SL, Raphael BS, Su EP. Rheumatoid synovectomy: does the surgical approach matter? Clin Orthop Relat Res 2011; 469:2062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/12\">",
"      Cruz-Esteban C, Wilke WS. Innovative treatment approaches for rheumatoid arthritis. Non-surgical synovectomy. Baillieres Clin Rheumatol 1995; 9:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/13\">",
"      Bessant R, Steuer A, Rigby S, Gumpel M. Osmic acid revisited: factors that predict a favourable response. Rheumatology (Oxford) 2003; 42:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/14\">",
"      Sledge CB, Zuckerman JD, Shortkroff S, et al. Synovectomy of the rheumatoid knee using intra-articular injection of dysprosium-165-ferric hydroxide macroaggregates. J Bone Joint Surg Am 1987; 69:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/15\">",
"      Jacob R, Smith T, Prakasha B, Joannides T. Yttrium90 synovectomy in the management of chronic knee arthritis: a single institution experience. Rheumatol Int 2003; 23:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28565/abstract/16\">",
"      Jahangier ZN, Jacobs JW, Lafeber FP, et al. Is radiation synovectomy for arthritis of the knee more effective than intraarticular treatment with glucocorticoids? Results of an eighteen-month, randomized, double-blind, placebo-controlled, crossover trial. Arthritis Rheum 2005; 52:3391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7969 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-C1C910ED83-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28565=[""].join("\n");
var outline_f27_57_28565=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H81272601\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Synovial biopsy and joint examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYNOVECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Open synovectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Arthroscopic synovectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19430830\">",
"      Open versus arthroscopic synovectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81273043\">",
"      Chemical synovectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H81273086\">",
"      Radiation synovectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81272601\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/42/5800?source=related_link\">",
"      Hemarthrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/9/12440?source=related_link\">",
"      Surgical therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_57_28566="Acetazolamide: Pediatric drug information";
var content_f27_57_28566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetazolamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"    see \"Acetazolamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6549?source=see_link\">",
"    see \"Acetazolamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diamox&reg; Sequels&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acetazolam;",
"     </li>",
"     <li>",
"      Diamox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Carbonic Anhydrase Inhibitor",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Diuretic, Carbonic Anhydrase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"      see \"Acetazolamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glaucoma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 8-30 mg/kg/day or 300-900 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 20-40 mg/kg/day divided every 6 hours, not to exceed 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edema: Oral, I.V.: 5 mg/kg/dose or 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epilepsy: Oral: 4-16 mg/kg/day in 1-4 divided doses, not to exceed 30 mg/kg/day or 1 g/day;",
"     <b>",
"      extended release capsule is not recommended for treatment of epilepsy",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Glaucoma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chronic simple (open-angle): Oral: 250 mg 1-4 times/day or 500 mg once followed by 125-250 mg every 4 hours, or 500 mg sustained release capsule twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Secondary, acute (closed-angle): I.V.: 250-500 mg, may repeat in 2-4 hours to a maximum of 1 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Edema: Oral, I.V.: 250-375 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Epilepsy: Oral: 4-16 mg/kg/day in 1-4 divided doses, not to exceed 30 mg/kg/day or 1 g/day;",
"     <b>",
"      extended release capsule is not recommended for treatment of epilepsy",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altitude sickness: Oral: 500-1000 mg daily in divided doses such as 250 mg every 8-12 hours or 500 mg extended release capsules every 12-24 hours; therapy should begin 24-48 hours before and continued during ascent and for at least 48 hours after arrival at the high altitude",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Urine alkalinization: Oral: 5 mg/kg/dose repeated 2-3 times over 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-50 mL/minute: Administer every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sustained release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diamox&reg; Sequels&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 125 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food to decrease GI upset; tablet may be crushed and suspended in cherry or chocolate syrup to disguise the bitter taste of the drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Reconstitute with at least 5 mL SWI to provide a solution containing not more than 100 mg/mL; maximum concentration: 100 mg/mL; maximum rate of I.V. infusion: 500 mg/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Not generally recommended as the drug's alkaline pH makes it very painful",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F129848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, R, SL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration:",
"     </b>",
"     <b>",
"      Compatible:",
"     </b>",
"     Pantoprazole.",
"     <b>",
"      Incompatible:",
"     </b>",
"     TrophAmine&reg;.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Diltiazem.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Pantoprazole",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1056198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets and capsules at room temperature; after reconstitution, acetazolamide injection is stable for 12 hours at room temperature and for 1 week when refrigerated; physically incompatible with parenteral multivitamins",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce elevated intraocular pressure in glaucoma; diuretic; adjunct to the treatment of refractory seizures; prevent acute altitude sickness; treatment of centrencephalic epilepsies; reduce CSF production in hydrocephalus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Diamox [Canada and multiple international markets] may be confused with Diabinese brand name for chlorpropamide [Multiple international markets]; Dobutrex brand name for dobutamine [Multiple international markets]; Trimox brand name for amoxicillin [Brazil]; Zimox brand name for amoxicillin [Italy] and carbidopa/levodopa [Greece]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F129847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Ataxia, confusion, convulsions, depression, dizziness, drowsiness, excitement, fatigue, fever, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic skin reactions, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte imbalance, growth retardation (children), hyperglycemia, hypoglycemia, hypokalemia, hyponatremia, metabolic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite decreased, diarrhea, melena, nausea, taste alteration, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Crystalluria, glycosuria, hematuria, polyuria, renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, leukopenia, thrombocytopenia, thrombocytopenic purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Abnormal liver function tests, cholestatic jaundice, fulminant hepatic necrosis, hepatic insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Flaccid paralysis, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Myopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing disturbance, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetazolamide, any component, or other sulfonamides; patients with hepatic disease or insufficiency; decreased serum sodium and/or potassium; adrenocortical insufficiency; hyperchloremic acidosis; or severe renal disease; long-term administration in patients with chronic noncongestive angle-closure glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1056193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with respiratory acidosis, COPD, diabetes mellitus, and gout; reduce dosage in patients with renal impairment; growth retardation has been reported in children receiving chronic therapy (possibly due to chronic acidosis)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1056192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities associated with sulfonamides, although rare, have occurred due to severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; discontinue use at first sign of rash or any sign of adverse reaction. Anorexia, tachypnea, lethargy, metabolic acidosis, and death have been reported in patients receiving acetazolamide and high-dose aspirin concomitantly. Tolerance to antiepileptic effects may require dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Carbonic Anhydrase Inhibitors may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Carbonic Anhydrase Inhibitors may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Barbiturate): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Anticonvulsants (Hydantoin). Specifically, osteomalacia and rickets.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Carbonic Anhydrase Inhibitors may increase the serum concentration of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): AcetaZOLAMIDE may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Carbonic Anhydrase Inhibitors may increase the serum concentration of Flecainide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Carbonic Anhydrase Inhibitors may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Carbonic Anhydrase Inhibitors may decrease the excretion of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Carbonic Anhydrase Inhibitors may diminish the therapeutic effect of Methenamine.  Management: Consider avoiding this combination. Monitor for decreased therapeutic effects of methenamine if used concomitant with a carbonic anhydrase inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Carbonic Anhydrase Inhibitors may enhance the adverse/toxic effect of Primidone. Specifically, osteomalacia and rickets. Carbonic Anhydrase Inhibitors may decrease the serum concentration of Primidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Carbonic Anhydrase Inhibitors may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Bicarbonate: AcetaZOLAMIDE may enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Carbonic Anhydrase Inhibitor Diuretics may decrease the serum concentration of Trientine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1056214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F129783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1056201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum electrolytes, CBC and platelet counts",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive, reversible inhibition of the enzyme carbonic anhydrase resulting in increased renal excretion of sodium, potassium, bicarbonate, and water and decreased formation of aqueous humor; also inhibits carbonic anhydrase in CNS to retard abnormal and excessive discharge from CNS neurons",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1056209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule, extended release: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule, extended release: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule, extended release: 18-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 4-5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1056210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Appears to be dose dependent; erratic with daily doses &gt;10 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Into erythrocytes, kidneys, and breast milk (breast milk to plasma ratio of 0.25 has been reported); crosses the blood-brain barrier and the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2.4-5.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Tablet: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 70% to 100% of an I.V. or tablet dose and 47% of an extended release capsule excreted unchanged in urine within 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: 20% to 50% removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1056200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6549?source=see_link\">",
"      see \"Acetazolamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush or chew long-acting capsule; may cause dry mouth. May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1056212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 500 mg injection: 2.049 mEq",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Extended release capsules are indicated only for use for the adjunctive treatment of open-angle or secondary glaucoma and the prevention of high altitude sickness; avoid using extended release capsules for anticonvulsant or diuretic therapy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Acetazolamide has been used with questionable efficacy to slow the progression of hydrocephalus in neonates and infants who may not be good candidates for surgery. I.V. or oral doses of 5 mg/kg/dose every 6 hours increased by 25 mg/kg/day to a maximum of 100 mg/kg/day, if tolerated, have been used. Furosemide was used in combination with acetazolamide (Libenson, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F129778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 25 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;. Crush twelve 250 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;refrigerate&rdquo;. Stable for 60 days (Allen, 1996). When diluted in 120 mL solution of cherry syrup concentrate diluted 1:4 with simple syrup, NF, it is stable 60 days refrigerated (preferred) or at room temperature (Nahata, 2004).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr and Erickson MA 3rd, \"Stability of Acetazolamide, Allopurinol, Azathioprine, Clonazepam, and Flucytosine in Extemporaneously Compounded Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(16):1944-9.",
"     <span class=\"pubmed-id\">",
"      8862208",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Libenson MH, Kaye EM, Rosman NP, et al, &ldquo;Acetazolamide and Furosemide for Posthemorrhagic Hydrocephalus of the Newborn,&rdquo;",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1999, 20(3):185-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/57/28566/abstract-text/10207925/pubmed\" id=\"10207925\" target=\"_blank\">",
"        10207925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reiss WG and Oles KS, &ldquo;Acetazolamide in the Treatment of Seizures,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(5):514-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/57/28566/abstract-text/8740334 /pubmed\" id=\"8740334 \" target=\"_blank\">",
"        8740334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shinnar S, Gammon K, Bergman EW Jr, et al, &ldquo;Management of Hydrocephalus in Infancy: Use of Acetazolamide and Furosemide to Avoid Cerebrospinal Fluid Shunts,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 107(1):31-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/57/28566/abstract-text/4009338/pubmed\" id=\"4009338\" target=\"_blank\">",
"        4009338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13213 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28566=[""].join("\n");
var outline_f27_57_28566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129795\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129796\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056202\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056194\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129772\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129756\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056206\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129848\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056198\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056205\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129850\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129847\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056211\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056193\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056192\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129837\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129765\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056214\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129768\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129783\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056201\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056191\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056209\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056210\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056200\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056212\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129778\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13213\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13213|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=related_link\">",
"      Acetazolamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/25/6549?source=related_link\">",
"      Acetazolamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_57_28567="Insulin resistance: Definition and clinical spectrum";
var content_f27_57_28567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Insulin resistance: Definition and clinical spectrum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28567/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28567/contributors\">",
"     Christos Mantzoros, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28567/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28567/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28567/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/57/28567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance can be broadly defined as a subnormal biological response to normal insulin concentrations. By this definition, it may pertain to many biological actions of insulin in many tissues of the body. Typically, however, in clinical practice, insulin resistance refers to a state in which a given concentration of insulin is associated with a subnormal glucose response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/1\">",
"     1",
"    </a>",
"    ]. The term first came into use several years after the introduction of insulin therapy in 1922 to describe occasional diabetic patients who required increasingly large doses of insulin to control hyperglycemia. Most of these patients developed insulin resistance secondary to antibodies directed against the therapeutic insulin, which at that time was both impure and derived from non-human species [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/2\">",
"     2",
"    </a>",
"    ]. Antiinsulin antibodies are rare in patients treated with recombinant human insulin, and the spectrum of clinical disorders in which insulin resistance plays a major role has changed markedly. Insulin resistance, rather than being a rare complication of the treatment of diabetes, is now recognized as a component of several disorders, including the following (",
"    <a class=\"graphic graphic_table graphicRef75383 \" href=\"UTD.htm?42/37/43611\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extreme insulin-resistance syndromes, such as the type B syndrome with autoantibodies against the insulin receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/3\">",
"       3",
"      </a>",
"      ], and rare inherited disorders, such as Leprechaunism with insulin-receptor mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/4\">",
"       4",
"      </a>",
"      ] and the lipodystrophic states [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Impaired glucose tolerance and type 2 diabetes mellitus.",
"     </li>",
"     <li>",
"      Obesity, stress, infection, uremia, acromegaly, glucocorticoid excess, and pregnancy, which cause secondary insulin resistance.",
"     </li>",
"     <li>",
"      Common disorders such as the metabolic syndrome, hypertension, hyperlipidemia, coronary artery disease, the polycystic ovary syndrome, and ovarian hyperthecosis, in which the mechanism of the associated hyperinsulinemia is unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"       \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=see_link\">",
"       \"Ovarian hyperthecosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Possible mechanisms for the development of insulin resistance are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND QUANTIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance may be defined as a subnormal glucose response to both endogenous and exogenous insulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Resistance to endogenous insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to endogenous insulin is identified by high serum insulin concentrations in association with blood glucose concentrations that are normal or high. In practice, we measure serum insulin only when evaluating patients with clinical features of extreme insulin resistance (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Clinical spectrum'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    To confirm the diagnosis, it is also necessary to determine that the structure and biological activity of the patient's insulin are normal. There are rare cases of mutations in the insulin gene resulting in the production of insulin that has subnormal bioactivity but normal immunoactivity. These insulins circulate at high concentrations, simulating insulin resistance, but the response to exogenous insulin is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Resistance to exogenous insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A reduced response to exogenous insulin is readily evident in insulin-treated diabetic patients who require higher doses to prevent hyperglycemia, even though the insulin dose in a given patient is an imperfect means for quantitating the degree of insulin resistance. However, most patients with insulin resistance (such as those with obesity) are not treated with insulin. In them, resistance to exogenous insulin can be assessed and quantified by techniques such as the intravenous glucose tolerance test, the insulin suppression test, or the euglycemic insulin clamp technique. With the latter, insulin-induced glucose uptake is measured while blood glucose concentration is maintained at a steady concentration (via exogenous dextrose infusion) to avoid the confounding effects of counterregulatory hormones such as epinephrine and glucagon&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef69265 \" href=\"UTD.htm?7/30/7662\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Biochemical markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a clinical setting, it would be useful to identify obese patients who are insulin resistant, as they are at highest risk for the development of type 2 diabetes mellitus, cardiovascular disease, and certain malignancies associated with obesity and insulin resistance (eg, colon, breast, and endometrial cancers). However, there is currently no validated test for measuring insulin resistance in a clinical setting.",
"   </p>",
"   <p>",
"    In a research setting, the euglycemic insulin clamp technique has been considered to be the gold standard, and intravenous glucose tolerance test (IVGTT)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the insulin tolerance test",
"    <span class=\"nowrap\">",
"     (ITT)/insulin",
"    </span>",
"    suppression test are the tests most frequently used [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, these techniques are impractical for routine clinical use.",
"   </p>",
"   <p>",
"    In nondiabetic, normotensive overweight individuals, serum triglyceride concentration, the ratio of triglyceride to high density lipoprotein (HDL)-cholesterol concentrations, and fasting insulin concentration are useful markers for identifying those who may be insulin resistant (as measured by an insulin suppression test). Optimal cut-points were identified as 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.47",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    3.0 (1.8 SI units), and 109",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    for triglycerides, triglyceride-to HDL ratio, and insulin, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/10\">",
"     10",
"    </a>",
"    ]. Sensitivity and specificity for the cut-points were 67, 64, and 57 percent, respectively, and 71, 68, and 85 percent, respectively.",
"   </p>",
"   <p>",
"    In large population epidemiology studies, simple ratios derived from fasting insulin and glucose (eg, glucose to insulin ratios, homeostasis model assessment of insulin resistance [HOMA-IR or HOMA]) have been extensively used. There are limitations to their use, including changes in beta-cell function over time, lack of a standardized universal insulin assay, and lack of data demonstrating that markers of insulin resistance predict response to treatment. As a result, although indexes such as HOMA, QUICKI (quantitative insulin sensitivity check index), etc, have been proposed and cut-points identified [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/11\">",
"     11",
"    </a>",
"    ], none are recommended for routine assessment of insulin resistance in the clinic.",
"   </p>",
"   <p>",
"    The co-segregation of overall obesity (increased body mass index, BMI)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abdominal obesity (increased waist circumference), increased blood pressure, increased fasting glucose and triglyceride levels, and low HDL suggests the existence of the metabolic syndrome, which is very closely related with insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link&amp;anchor=H2#H2\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL SPECTRUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin resistance can present in a variety of ways. Hyperglycemia despite large doses of insulin is the classical presentation, but many patients with extreme resistance to insulin do not have overt hyperglycemia. However, nearly all such patients have one or more clinical features suggesting the presence of severe insulin resistance (",
"    <a class=\"graphic graphic_table graphicRef73294 \" href=\"UTD.htm?41/5/42075\">",
"     table 2",
"    </a>",
"    ). These features include acanthosis nigricans (",
"    <a class=\"graphic graphic_picture graphicRef53776 \" href=\"UTD.htm?3/7/3198\">",
"     picture 1",
"    </a>",
"    ), ovarian hyperandrogenism (polycystic ovary syndrome), lipodystrophy, accelerated or impaired linear growth, autoimmunity, and muscle cramps. The presence of severe features should lead to measurement of serum insulin. A finding of hyperinsulinemia should prompt further studies to evaluate the presence of circulating anti-insulin receptor antibodies and the other disorders listed in the table (",
"    <a class=\"graphic graphic_table graphicRef75383 \" href=\"UTD.htm?42/37/43611\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In most cases, the precise basis for the link between insulin resistance and these clinical findings is not yet identified. It is likely that high serum insulin concentrations over-stimulate specific insulin-responsive pathways that are less impaired than those affecting glucose transport. This may occur via activation of insulin-like growth factor-1 (IGF-1) receptors or hybrid receptors formed by covalent linkage of subunits of the homologous receptors for insulin and IGF&ndash;1 (",
"    <a class=\"graphic graphic_figure graphicRef61896 \" href=\"UTD.htm?38/60/39886\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Abnormal glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose homeostasis varies from extremely abnormal (either diabetes or hypoglycemia) to normal. At one end of the spectrum are insulin-treated diabetic patients who require large doses of insulin to control serum glycemia. Insulin resistance in these patients may be induced by the production of antiinsulin antibodies or autoantibodies directed against the insulin receptor. Next in the spectrum are patients with overt diabetes who are not receiving insulin, such as most patients with type 2 diabetes in whom there is also a component of impaired pancreatic beta-cell function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, many patients with insulin resistance have normal or only slightly high blood glucose concentrations. Included in this group are most patients with obesity, many patients with hypertension and hyperandrogenism, and those with inherited syndromes of severe insulin resistance such as the Type A syndrome. Some patients with insulin resistance due to autoantibodies against the insulin receptor actually have hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cutaneous abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthosis nigricans and skin tags are commonly associated with primary insulin resistance, regardless of its molecular cause. Acanthosis nigricans is a skin lesion characterized by brown, velvety, hyperkeratotic plaques. The lesions are usually found on the back of the neck, the axilla (",
"    <a class=\"graphic graphic_picture graphicRef53776 \" href=\"UTD.htm?3/7/3198\">",
"     picture 1",
"    </a>",
"    ), the groin, and over the elbows, but they may cover the entire surface of the skin, sparing only the palms and soles. The lesions may be papillomatous. Histological hallmarks are hyperkeratosis, epidermal papillomatosis, and increased numbers of melanocytes.",
"   </p>",
"   <p>",
"    The common denominator in all cases of acanthosis nigricans, with the possible exception of tumor-induced lesions, is insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/14\">",
"     14",
"    </a>",
"    ]. It may vary in severity and may be inherited or acquired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27897?source=see_link\">",
"     \"Acanthosis nigricans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hyperandrogenism and reproductive abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with insulin resistance are not known to have disorders of the reproductive system. In contrast, women with insulin resistance commonly present with reproductive abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, most women with severe tissue resistance to insulin, regardless of cause, have marked hyperandrogenism. This association has been described in women with the Type B syndrome (caused by insulin-receptor autoantibodies) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/16\">",
"     16",
"    </a>",
"    ] or the Type A syndrome (caused by genetic defects in the insulin-signaling system, such as mutations in the insulin-receptor gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/3,17,18\">",
"     3,17,18",
"    </a>",
"    ]. Affected women can present with overt virilization or hirsutism, amenorrhea, and infertility. The ovary shows the histologic changes of hyperthecosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most women with ovarian hyperandrogenism have tissue resistance to insulin that is identified by fasting hyperinsulinemia or subnormal insulin-mediated glucose uptake (from euglycemic clamp studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/20\">",
"     20",
"    </a>",
"    ]. The molecular basis for the tissue resistance to insulin in these women is not known. Studies in cultured skin fibroblasts suggest that approximately 50 percent of them have a defect in phosphorylation of the insulin receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The basis for the association between insulin resistance and ovarian hyperandrogenism is not known, and there is no clear correlation between the severity of the two disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/21\">",
"     21",
"    </a>",
"    ]. While androgen excess can cause a modest reduction of insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/22\">",
"     22",
"    </a>",
"    ], the primary abnormality is probably insulin resistance, which in some way causes the ovarian abnormality. Insulin receptors, and the closely related receptors for IGF&ndash;1, are present on ovarian cells and stimulation of these receptors increases androgen production [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reducing insulin resistance by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or a thiazolidinedione lowers serum free testosterone concentrations and reduces cytochrome P450c17 (17-hydroxylase) activity in the ovaries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Linear and acral growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Linear growth is normal in most patients with insulin resistance. There are, however, two pediatric disorders with severe insulin resistance, Leprechaunism and the Rabson-Mendenhall syndrome, in which growth is impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Leprechaunism is due to a complete or nearly complete absence of insulin-receptor function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/28\">",
"     28",
"    </a>",
"    ] and is associated with markedly delayed linear growth and failure to thrive.",
"   </p>",
"   <p>",
"    Pseudoacromegaly, in contrast, is a syndrome in which severe insulin resistance is associated with accelerated linear growth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/29\">",
"     29",
"    </a>",
"    ]. In these patients, hyperinsulinemia probably promotes linear growth by activating skeletal IGF-1 receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Musculoskeletal changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with severe tissue resistance to insulin have muscle cramps unrelated to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/30\">",
"     30",
"    </a>",
"    ]. The severity of cramping can sometimes be reduced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Adipose tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount and distribution of adipose tissue is normal in many patients with insulin resistance, but an increasing number of subjects in Western societies have obesity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    only abdominal obesity. High serum free fatty acid concentrations in the circulation, either derived from enlarged adipose cells (the storage capacity of which has been exceeded) or because there is not enough storage space in the adipose tissue of lipodystrophic subjects, have been implicated in the pathogenesis of obesity-related metabolic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Increased release of adipocytokines, such as tumor necrosis factor (TNF-alpha), or decreased production of protective adipocytokines, such as adiponectin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/35\">",
"     35",
"    </a>",
"    ], are thought to mediate the effects of obesity in the pathogenesis of insulin resistance, and subsequently, the metabolic syndrome and type 2 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Role of diet, obesity, and inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lipodystrophy syndromes are a clinically diverse group of disorders characterized by an unusual amount and distribution of adipose tissue. The patients often have severe tissue resistance to insulin and may have some of the other clinical features of insulin resistance, such as acanthosis nigricans. The syndromes can be congenital or acquired, and atrophy of adipose tissue can be total or partial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=see_link\">",
"     \"Lipodystrophic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In leptin-deficient subjects with lipodystrophy, decreased production of leptin by adipose tissue may also be implicated in the pathogenesis of insulin resistance. Administration of leptin to these subjects, in the context of clinical trials, improves several of their metabolic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=see_link\">",
"     \"Lipodystrophic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, subjects with lipodystrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    insulin resistance may also have low levels of adiponectin, another adipocyte-secreted hormone that functions as an endogenous insulin sensitizer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/38\">",
"     38",
"    </a>",
"    ]. Adiponectin levels are decreased with intraabdominal fat accumulation, and increased with healthy dietary patterns and exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Peroxisome proliferator-activated receptor gamma activators, including thiazolidinediones, increase adiponectin levels in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H22#H22\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Adiponectin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H2#H2\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A syndrome of acquired lipodystrophy is associated with highly active antiretrovirals (HAART), including protease-inhibitor therapy in patients with HIV infection. These patients have insulin resistance and develop hyperglycemia and hyperlipidemia sooner and more often than patients with HIV infection who are treated with other regimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few patients have severe insulin resistance as a consequence of autoantibodies directed against the insulin receptor (type B syndrome of insulin resistance) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/3\">",
"     3",
"    </a>",
"    ]. These patients may have insulin-resistant diabetes or hypoglycemia, depending upon the properties of the antireceptor antibodies. Many also have other autoimmune disorders, including systemic lupus or scleroderma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28567/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an apparent association between abdominal obesity, insulin resistance, and a variety of abnormalities that impact upon the cardiovascular system, such as type 2 diabetes, hypertension, an atherogenic lipid profile that includes hypertriglyceridemia and low serum HDL-cholesterol concentrations, and coronary disease. This constellation of these disorders is called the metabolic syndrome (or insulin resistance syndrome or syndrome X). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2101924\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insulin resistance is a state in which a given concentration of insulin is associated with a subnormal glucose response. Important long-term consequences of insulin resistance include the development of type 2 diabetes, cardiovascular disease, and certain malignancies associated with obesity and insulin resistance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and quantification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In research settings, the euglycemic insulin clamp technique has been considered to be the gold standard, and intravenous glucose tolerance test (IVGTT)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the insulin tolerance test",
"      <span class=\"nowrap\">",
"       (ITT)/insulin",
"      </span>",
"      suppression test are the tests most frequently used to identify patients who are insulin resistant. However, these techniques are impractical for routine clinical use. There currently is no validated test for measuring insulin resistance in a clinical setting. As a result, we do not routinely measure insulin resistance. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Biochemical markers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin resistance can have a variety of clinical presentations (",
"      <a class=\"graphic graphic_table graphicRef73294 \" href=\"UTD.htm?41/5/42075\">",
"       table 2",
"      </a>",
"      ). Some of these features include acanthosis nigricans, ovarian hyperandrogenism (polycystic ovary syndrome), lipodystrophy, accelerated or impaired linear growth, autoimmunity, and muscle cramps. In patients with severe phenotypes suggesting an inherited state of target cell resistance (ie, Leprechaunism) or with lipodystrophy phenotypes, fasting insulin should be measured. The finding of hyperinsulinemia should prompt further studies to evaluate the presence of insulin receptor mutations, circulating anti-insulin receptor antibodies, and other disorders (",
"      <a class=\"graphic graphic_table graphicRef75383 \" href=\"UTD.htm?42/37/43611\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical spectrum'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=see_link\">",
"       \"Lipodystrophic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/1\">",
"      Moller DE, Flier JS. Insulin resistance--mechanisms, syndromes, and implications. N Engl J Med 1991; 325:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/2\">",
"      Kahn CR, Rosenthal AS. Immunologic reactions to insulin: insulin allergy, insulin resistance, and the autoimmune insulin syndrome. Diabetes Care 1979; 2:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/3\">",
"      Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976; 294:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/4\">",
"      Musso C, Cochran E, Moran SA, et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 2004; 83:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/5\">",
"      Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/6\">",
"      Steiner DF, Tager HS, Chan SJ, et al. Lessons learned from molecular biology of insulin-gene mutations. Diabetes Care 1990; 13:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/7\">",
"      Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/8\">",
"      Buchanan TA, Watanabe RM, Xiang AH. Limitations in surrogate measures of insulin resistance. J Clin Endocrinol Metab 2010; 95:4874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/9\">",
"      Tritos NA, Mantzoros CS. Clinical review 97: Syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998; 83:3025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/10\">",
"      McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/11\">",
"      Ascaso JF, Pardo S, Real JT, et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26:3320.",
"     </a>",
"    </li>",
"    <li>",
"     Barb, D, Mantzoros, C. Diagnosing obesity, diabetes mellitus and the insulin resistance syndrome. In: Obesity and Diabetes, Mantzoros, C. (Eds), Humana Press, Inc., Totowa, NJ 2006. p.129.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/13\">",
"      Taylor SI, Grunberger G, Marcus-Samuels B, et al. Hypoglycemia associated with antibodies to the insulin receptor. N Engl J Med 1982; 307:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/14\">",
"      Rogers DL. Acanthosis nigricans. Semin Dermatol 1991; 10:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/15\">",
"      Poretsky L, Piper B. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol 1994; 84:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/16\">",
"      Taylor SI, Dons RF, Hernandez E, et al. Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann Intern Med 1982; 97:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/17\">",
"      Taylor SI, Cama A, Accili D, et al. Mutations in the insulin receptor gene. Endocr Rev 1992; 13:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/18\">",
"      Moller DE, Cohen O, Yamaguchi Y, et al. Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistance. Diabetes 1994; 43:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/19\">",
"      Dunaif A, Hoffman AR, Scully RE, et al. Clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans and masculinization. Obstet Gynecol 1985; 66:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/20\">",
"      Dunaif A, Segal KR, Shelley DR, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/21\">",
"      Dunaif A, Xia J, Book CB, et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995; 96:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/22\">",
"      Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987; 64:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/23\">",
"      Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril 1988; 50:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/24\">",
"      Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/25\">",
"      Dunaif A, Scott D, Finegood D, et al. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/26\">",
"      Elders MJ, Schedewie HK, Olefsky J, et al. Endocrine-metabolic relationships in patients with leprechaunism. J Natl Med Assoc 1982; 74:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/27\">",
"      RABSON SM, MENDENHALL EN. Familial hypertrophy of pineal body, hyperplasia of adrenal cortex and diabetes mellitus; report of 3 cases. Am J Clin Pathol 1956; 26:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/28\">",
"      Taylor SI. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/29\">",
"      Flier JS, Moller DE, Moses AC, et al. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993; 76:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/30\">",
"      Flier JS, Young JB, Landsberg L. Familial insulin resistance with acanthosis nigricans, acral hypertrophy, and muscle cramps. N Engl J Med 1980; 303:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/31\">",
"      Minaker KL, Flier JS, Landsberg L, et al. Phenytoin-induced improvement in muscle cramping and insulin action in three patients with the syndrome of insulin resistance, acanthosis nigricans, and acral hypertrophy. Arch Neurol 1989; 46:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/32\">",
"      Fiorenza CG, Chou SH, Mantzoros CS. Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 2011; 7:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/33\">",
"      Bj&ouml;rntorp P. \"Portal\" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990; 10:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/34\">",
"      Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/35\">",
"      Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010; 91:258S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/36\">",
"      Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/37\">",
"      Mantzoros CS. Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome? J Clin Endocrinol Metab 2009; 94:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/38\">",
"      Brennan AM, Mantzoros CS. Leptin and adiponectin: their role in diabetes. Curr Diab Rep 2007; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/39\">",
"      Gavrila A, Chan JL, Yiannakouris N, et al. Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab 2003; 88:4823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/40\">",
"      Fargnoli JL, Fung TT, Olenczuk DM, et al. Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am J Clin Nutr 2008; 88:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/41\">",
"      Bl&uuml;her M, Williams CJ, Kl&ouml;ting N, et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 2007; 30:3110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/42\">",
"      Magkos F, Mantzoros CS. Body fat redistribution and metabolic abnormalities in HIV-infected patients on highly active antiretroviral therapy: novel insights into pathophysiology and emerging opportunities for treatment. Metabolism 2011; 60:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28567/abstract/43\">",
"      Tsokos GC, Gorden P, Antonovych T, et al. Lupus nephritis and other autoimmune features in patients with diabetes mellitus due to autoantibody to insulin receptors. Ann Intern Med 1985; 102:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1762 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-DCF38A056D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28567=[""].join("\n");
var outline_f27_57_28567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2101924\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND QUANTIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Resistance to endogenous insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Resistance to exogenous insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Biochemical markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL SPECTRUM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Abnormal glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cutaneous abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hyperandrogenism and reproductive abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Linear and acral growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Musculoskeletal changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adipose tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2101924\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1762\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1762|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/30/7662\" title=\"figure 1\">",
"      Euglycemic insulin clamp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/60/39886\" title=\"figure 2\">",
"      IGF receptors in insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1762|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/7/3198\" title=\"picture 1\">",
"      Acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1762|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/37/43611\" title=\"table 1\">",
"      Causes of insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/5/42075\" title=\"table 2\">",
"      Manifestations of insulin resis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27897?source=related_link\">",
"      Acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/43/26298?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=related_link\">",
"      Lipodystrophic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38662?source=related_link\">",
"      Ovarian hyperthecosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_57_28568="Bullectomy for giant bullae in COPD";
var content_f27_57_28568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bullectomy for giant bullae in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28568/contributors\">",
"     Fernando J Martinez, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28568/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28568/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/57/28568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bulla is defined as an air space in the lung measuring more than one centimeter in diameter in the distended state; the term giant bulla is used for bullae that occupy at least 30 percent of a hemithorax [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. A single giant bulla may be surrounded by normal lung tissue or may be accompanied by a number of smaller adjacent bullae. Bullectomy involves the surgical removal of one or more giant bullae to improve symptoms and respiratory function in patients with bullous emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications and contraindications for bullectomy, as well as the perioperative management and operative technique of bullectomy will be reviewed here. The evaluation and medical management of giant bullae in patients with chronic obstructive pulmonary disease (COPD) and the roles of lung volume reduction surgery and lung transplantation in the management of advanced COPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=see_link\">",
"     \"Evaluation and medical management of giant bullae in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"     \"Lung volume reduction surgery in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Giant bullae adversely affect respiratory physiology in several ways. They occupy a large volume of the chest cavity and compress adjacent, more normal lung tissue. The compressed areas have reduced aeration and reduced elastic recoil. In addition, giant bullae can exert pressure on the diaphragm, leading to a flatter and less efficient shape. During exercise, bullae that communicate with the tracheobronchial tree increase in size due to dynamic hyperinflation and further impair respiratory function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36454?source=see_link&amp;anchor=H2#H2\">",
"     \"Dynamic hyperinflation in patients with COPD\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The proposed mechanisms by which excising a giant bulla and relieving lung compression improve lung function include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reducing the size mismatching between the hyperinflated lungs and the chest cavity, which restores the outward circumferential pull on the bronchioles (ie, increases elastic recoil).",
"     </li>",
"     <li>",
"      With improved elastic recoil, airway resistance is decreased and expiratory airflow improved, thus reducing air trapping.",
"     </li>",
"     <li>",
"      Removing the space occupying effect of the bulla and reducing air trapping help to restore the diaphragm to a more domed shape, which is more efficient.",
"     </li>",
"     <li>",
"      Reinflation of compressed areas decreases the physiologic dead space that was caused by compression of normal lung by the inflated bulla and improves matching of ventilation and perfusion.",
"     </li>",
"     <li>",
"      Reducing airway resistance, air trapping, and physiologic dead space decreases the work of breathing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rationale of lung volume reduction surgery in diffuse bullous emphysema is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link&amp;anchor=H2#H2\">",
"     \"Lung volume reduction surgery in COPD\", section on 'Rationale of LVRS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POTENTIAL BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials of giant bullectomy have not been performed; however, the potential benefits of elective giant bullectomy have been described in a number of case series and a systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2,4,5,8,9\">",
"     2,4,5,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an observational cohort study of 41 patients, significant improvements were noted in dyspnea, lung volumes, forced expiratory volume in one second (FEV1), and the",
"    <span class=\"nowrap\">",
"     FEV1/forced",
"    </span>",
"    vital capacity (FVC) ratio over baseline and persisted for two years following bullectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2\">",
"     2",
"    </a>",
"    ]. At five years following surgery, these parameters remained improved compared to prebullectomy values, although the degree of improvement had declined. Patients with diffuse emphysema deteriorated faster than patients without diffuse emphysema.",
"   </p>",
"   <p>",
"    A systematic review of bullectomy of giant bullae noted that hypoxemia was more likely to improve compared with spirometric parameters or diffusing capacity (DLCO) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with radiographic evidence of compressed lung were most to likely experience improved oxygenation, whereas patients with radiographically diffuse emphysema, a low DLCO, or hypercapnia were less likely to improve, although the exact degree of improvement was not described.",
"   </p>",
"   <p>",
"    The degree of improvement in PaO2 reported in a separate series of 41 patients was modest (approximately 8 mmHg) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the proportion of patients requiring supplemental oxygen decreased from 42 percent before to 7 percent one year after bullectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ]. Over the next three years, there was a gradual increase in the percent requiring continuous oxygen up to 21 percent.",
"   </p>",
"   <p>",
"    Improvements in exercise tolerance following giant bullectomy were noted in other case series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. In a series of 12 patients, improvements were noted in aerobic exercise capacity and dynamic inspiratory capacity (ie, a decrease in dynamic hyperinflation) relative to baseline values [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/3\">",
"     3",
"    </a>",
"    ]. A modest reduction in the partial arterial pressure of carbon dioxide (mean of 43 to 40 mmHg) was noted in one series, although the improvement was no longer present at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36454?source=see_link\">",
"     \"Dynamic hyperinflation in patients with COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for bullectomy are severe dyspnea due to a giant bulla (ie, occupying 30 percent of more of the hemithorax) and spontaneous secondary pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2,3,10\">",
"     2,3,10",
"    </a>",
"    ]. Mediastinal shift",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    herniation due to a giant bulla have been mentioned as additional clinical indications, although outcomes data are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important challenge for the clinician is to select the patient for bullectomy who can benefit the most with the lowest morbidity and mortality. One factor that suggests that bullectomy may be particularly beneficial is a bulla that occupies greater than 50 percent of the hemithorax [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ]. Radiographic evidence that the bulla is compressing adjacent normal (rather than emphysematous) pulmonary parenchyma (ie, radiographic signs of atelectasis or adjacent vascular crowding) is also a favorable factor [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/5\">",
"     5",
"    </a>",
"    ]. Other specific characteristics in favor of bullectomy are described in the table (",
"    <a class=\"graphic graphic_table graphicRef68646 \" href=\"UTD.htm?28/38/29292\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Limited information is available regarding the use of pulmonary function test (PFT) parameters to guide the decision to perform bullectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/12\">",
"     12",
"    </a>",
"    ]. The majority of patients who undergo bullectomy have a forced expiratory volume in one second (FEV1) that is below 80 percent predicted, but greater than or equal to 40 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2\">",
"     2",
"    </a>",
"    ]. In a series of 18 patients, a better clinical response to bullectomy was noted in those with an FEV1 greater than 40 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/13\">",
"     13",
"    </a>",
"    ]. In contrast, the mean FEV1 in a series of 43 patients who benefited from bullectomy was 34 percent predicted, suggesting that this criterion is not absolute in otherwise carefully selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, patients who will benefit from bullectomy have PFT evidence of air trapping (eg, total lung capacity [TLC] &gt; 100 percent predicted, residual volume [RV] &gt; 150 percent predicted) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The difference in lung volume measurements obtained by the body plethysmography and helium dilution techniques can be compared to estimate the volume of nonventilated lung. A larger nonventilated volume suggests that the patient is likely to derive greater benefit from bullectomy. Chest computed tomography (CT) scanning provides a direct visual assessment of the extent to which normal lung is compressed by bullae and complements the physiologic measures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Lung volumes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications for bullectomy include ongoing cigarette smoking, significant co-morbid disease, poorly defined bullae on chest imaging, and pulmonary hypertension. Additional contraindications are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef68646 \" href=\"UTD.htm?28/38/29292\">",
"     table 1",
"    </a>",
"    ). As no randomized trials of bullectomy have been performed, most of the contraindications derive from case series and experience with lung volume reduction surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"     \"Lung volume reduction surgery in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Age over 50 has been associated with increased morbidity and mortality in some older studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. However, in a series of 41 patients undergoing bullectomy, patients up to age 77 were included [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2\">",
"     2",
"    </a>",
"    ]. No increase in risk was associated with older age, although results were not stratified based on age. In a separate series of 43 patients, the mean age was 56, and age was not a risk factor for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, we now view age over 60 as a less favorable feature, but not a contraindication.",
"   </p>",
"   <p>",
"    A markedly reduced forced expiratory volume in one second (FEV1) (eg, less than 500 mL or less than 40 percent of predicted) is also associated with an increased risk for perioperative morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/6,7,15\">",
"     6,7,15",
"    </a>",
"    ]. Hypercapnia and cor pulmonale are also associated with markedly increased risk and are considered contraindications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/5,6,11,15\">",
"     5,6,11,15",
"    </a>",
"    ]. As an example, significant cor pulmonale was associated with 33 percent mortality in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A diffusing capacity for carbon monoxide (DLCO) less than 40 percent predicted is considered a contraindication to bullectomy, as it suggests a greater degree of diffuse underlying emphysema and is associated with a greater likelihood of postoperative air leaks and a poor outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and medical management of giant bullae in COPD\", section on 'Pulmonary function tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the systematic review of giant bullectomy, patients with chronic sputum production or frequent lung infections were less likely to improve than those without these clinical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the preoperative evaluation for bullectomy (eg, arterial blood gases, pulmonary function tests, radiographic imaging) is performed while determining whether the patient fits the indications and contraindications for bullectomy. The details of this evaluation are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and medical management of giant bullae in COPD\", section on 'Pulmonary function tests'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation and medical management of giant bullae in COPD\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Underlying COPD should be treated aggressively with an appropriate combination of inhaled glucocorticoids, anticholinergic agents, and long-acting beta-agonist to achieve their best possible baseline level of function. Inhaled agents are normally administered the morning of surgery. Inhaled bronchodilator agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) can be delivered through the circuit of the ventilator during surgery, as needed. For the rare patient using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , this medication is discontinued the evening before surgery as it interacts with many of the drugs used perioperatively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H5#H5\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Chronic obstructive lung disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=see_link&amp;anchor=H12#H12\">",
"     \"Perioperative medication management\", section on 'Pulmonary agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the radiographic evaluation that identified the giant bulla(e) was performed more than six months previously, a repeat CT scan is usually obtained to exclude any new pulmonary pathology (eg, pulmonary nodules, pleural disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation and medical management of giant bullae in COPD\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preoperative assessment for coronary heart disease is appropriate given the increased risk among patients with COPD. Uncontrolled coronary heart disease would be a contraindication to bullectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional testing typically includes an echocardiogram to assess pulmonary artery pressures and left ventricular function. Right-sided cardiac catheterization is usually performed in patients with elevated pulmonary artery pressures by echocardiogram or clinical evidence of cor pulmonale.",
"   </p>",
"   <p>",
"    Routine preoperative laboratory testing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANESTHETIC MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with giant bullae who are referred for bullectomy typically have a baseline degree of respiratory insufficiency and are at increased risk for perioperative complications. Anesthetic considerations include antimicrobial prophylaxis, route and choice of anesthetic and analgesic medications, intubation, and management of single lung ventilation in a patient with obstructive airways disease.",
"   </p>",
"   <p>",
"    Antimicrobial prophylaxis is administered within 60 minutes prior to the skin incision, following guidelines for noncardiac thoracic surgery. The choice of antimicrobial therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Noncardiac thoracic surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standard monitoring during the procedure includes blood pressure, pulse oximetry, capnography, core temperature, and continuous electrocardiography. Arterial and central venous pressure monitoring are frequent, but not universal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bullectomy is typically performed under general anesthesia; short-acting anesthetic agents are preferred over longer-acting agents to enable early extubation. Intravenous agents are typically used for induction of anesthesia, as severe bullous disease may make the uptake and distribution of inhalational agents unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/17\">",
"     17",
"    </a>",
"    ]. A thoracic epidural catheter is usually placed for administration of epidural anesthetic agents during",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of preoperative pulmonary risk\", section on 'Type of anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After induction of anesthesia, appropriate positioning, and sterile draping, a double-lumen endotracheal tube (or other endotracheal tube that will allow isolation of ventilation to one lung) is placed to administer single lung ventilation to the nonoperative lung and to enable deflation of the operative lung [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/17\">",
"     17",
"    </a>",
"    ]. The technique of single lung ventilation for lung resectional surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link&amp;anchor=H16#H16\">",
"     \"Lung volume reduction surgery in COPD\", section on 'Anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediately postoperatively, patients are assessed for anemia due to excessive intraoperative blood loss, cardiac ischemia, electrolyte abnormalities, hypercapnia, hypoxemia, and inadequate lung reexpansion (eg, due to massive air leak associated with suboptimal function of chest tubes). If these factors are all acceptable, the patient is extubated. The majority of patients are extubated in the operating room to minimize the duration of positive pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OPERATIVE APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of advances in video-assisted thoracoscopic surgery (VATS), the majority of surgeons prefer an open approach for bullectomy, rather than a thoracoscopic approach. However, a growing number of surgeons use VATS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9,19,20\">",
"     9,19,20",
"    </a>",
"    ]. When an open thoracotomy is performed, the posterolateral approach is generally used for unilateral bullous disease, while median sternotomy is often performed for resection of bilateral bullae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data in support of using VATS for bullectomy comes from case series of elective resection of giant bullae and resection of a giant bulla in the management of a secondary spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/20-25\">",
"     20-25",
"    </a>",
"    ]. Some series have included patients with very limited lung function who have traditionally been considered at high risk for thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/24\">",
"     24",
"    </a>",
"    ]. VATS is a less invasive procedure than open thoracotomy and has been used in conjunction with staplers, electric cautery, laser, and combinations of these techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/20-25\">",
"     20-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental approaches using flexible fiberoptic bronchoscopy have been used in a few patients with giant bullae who were not considered candidates for surgery. One technique involves the placement of one-way endobronchial valves via flexible fiberoptic bronchoscopy. This investigative approach to lung volume reduction surgery has also been used to treat a few patients with giant bullae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Transbronchoscopic aspiration and deflation of a giant bulla using a transbronchial aspiration needle followed by instillation of autologous blood to prevent air leakage is another investigative technique [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OPERATIVE TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the giant bulla has been accessed by thoracotomy or thoracoscopy, the next several steps include deciding how much of the lung adjacent to the bulla to remove, whether to use an automatic stapler or other method of resection, and how to reduce or prevent air leaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Extent of resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A key decision for the surgeon is determining the amount of lung to resect in addition to the main bulla, as patients frequently have adjacent smaller bullae. This decision involves balancing removal of diseased tissue to optimize reexpansion of compressed tissue, avoiding resection of healthy lung tissue, and achieving a suture line that is least likely to have prolonged air leakage.",
"   </p>",
"   <p>",
"    The specific characteristics of the bulla influence the decision regarding the amount of lung tissue adjacent to the giant bulla to be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. For the rare single bulla that is well-demarcated and has a clear, narrow pedicle, a simple stapled excision is typically performed. When the bulla is broad based or when numerous bullae are in close proximity and merge indistinctly, a broad stapled wedge resection is usually necessary.",
"   </p>",
"   <p>",
"    Lobectomy and segmentectomy (resection of an anatomic lung segment) are used less commonly, as they generally involve resection of a greater amount of lung tissue and are associated with less favorable outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/3,5,9,14\">",
"     3,5,9,14",
"    </a>",
"    ]. However, when a lobe is nearly completely replaced by bullous disease and the lobar fissures are well-formed, a lobectomy may be performed rather than a simple bullectomy to reduce the likelihood and severity of postoperative air leakage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Resection technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ablation or excision of giant bulla(e) can be achieved by a variety of surgical methods, including plication, laser ablation, and the more common stapler excision. Plication involves sewing tucks or folds into the bulla to obliterate the air space and is occasionally used for bullae that are on a narrow pedicle of lung tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laser ablation via video-assisted thoracoscopic surgery (VATS) is rarely used due to several important disadvantages. The duration of anesthesia is often more than four hours, and the mean duration of one-lung ventilation in a representative study was approximately three hours [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/25\">",
"     25",
"    </a>",
"    ]. Hypoxemia, prolonged mechanical ventilation, and air leaks were frequent, possibly due to the very limited lung function in these patients. In addition, increased mortality (eg, 7 to 16 percent) has been noted with laster ablation, compared with stapler resection, although the studies were small and nonrandomized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/21-25\">",
"     21-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common method of excision uses an automatic stapler. The initial step is to compress the lung along the line of the proposed incision, using an Endo-Duval grasper or similar instrument [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/18\">",
"     18",
"    </a>",
"    ]. After compression of the lung, an automatic stapler is advanced and applied. Once the staple line is complete, the bulla is excised along the staple line.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Reducing postoperative air leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques have been developed to reduce postoperative air leakage, a common complication of bullectomy that leads to a longer duration of chest tube drainage, a greater likelihood of associated infection, and a longer hospital stay. These techniques include using exogenous materials to buttress staple sutures, application of fibrin sealant (also known as fibrin \"glue\") to areas of air leak intraoperatively, and creation of a \"pleural tent\".",
"   </p>",
"   <p>",
"    When stapler excision of a bulla is performed, the staple line is frequently buttressed with bovine pericardial strips",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other materials (eg, polytetrafluoroethylene strips) to reduce the incidence of postoperative air leaks. Buttressing is particularly important when the underlying lung is fragile and emphysematous.",
"   </p>",
"   <p>",
"    For patients with visible air leakage after resection of a giant bulla, application of fibrin sealant to the staple line may reduce the severity of the air leak, although data assessing this technique are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A pleural tent is a surgical technique designed to reduce the size of the pleural cavity and enable apposition between the sutured surface of the lung and the chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ]. The shape of the upper lobe after partial resection or lobectomy does not facilitate apposition between the stapled raw surface and the parietal pleura and it is thought that the residual air space increases the likelihood of air leakage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/31\">",
"     31",
"    </a>",
"    ]. Creation of a pleural tent facilitates apposition and supports the fragile lung tissue. In a case series, this technique decreased the duration of postoperative air leakage and reduced the number of hospital days after upper lobectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/31\">",
"     31",
"    </a>",
"    ]. However, additional study is needed to fully assess the outcomes of this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to create a pleural tent, the parietal pleura is dissected free from the chest wall, starting at the upper border of the thoracotomy incision and extending up into the apex and to the mediastinum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/32\">",
"     32",
"    </a>",
"    ]. The freed parietal pleura is tailored to make a tent (or cap) for the residual lung. When the pleural tent is created thoracoscopically, the upper part of the parietal pleura incision is closed with clips from the inside. Two chest tubes are inserted through the lower thoracotomy ports into the chest cavity (inside the intrapleural space). The upper part of the pleural incision is secured to the chest wall and the extrapleural space is closed, leaving a tunnel inferiorly for the chest tubes. Blood generally fills the extrapleural space and coagulates, closing any small remaining holes in the pleura.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Final examination and closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;After resection of the bulla, the operated lung is inspected for air leaks and bleeding. The clamp or bronchial blocker is removed from that side of the endotracheal tube, and mechanical ventilation is resumed to the deflated lung. A gradual reinflation is preferred to aggressive efforts at reinflation. Two chest tubes are placed in the pleural cavity, one apical and one basal and the pleural and chest wall are closed in standard fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rarely used techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modified Monaldi procedure, or the Brompton technique, consists of a limited thoracotomy to visualize the bulla, insufflation of the bulla with iodized talc, and drainage of the bulla for several days with a Foley catheter under water seal to collapse the bulla [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/7,33,34\">",
"     7,33,34",
"    </a>",
"    ]. Talc is also instilled into the pleural cavity to achieve pleurodesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative management entails careful attention to respiratory status and pain control, treatment of bronchoconstriction, monitoring for development or worsening of a pneumothorax, and prevention of deep venous thrombosis and pulmonary embolism. A discussion of general postoperative management issues is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H17#H17\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Postoperative strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nebulized bronchodilator therapy is administered every four to six hours, but may be increased to every one to two hours for patients with increased cough, wheeze, or dyspnea. Nebulizer treatments are continued for 24 to 48 hours and then transitioned back to the patient's usual regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=see_link&amp;anchor=H665782#H665782\">",
"     \"Overview of the management of postoperative pulmonary complications\", section on 'Bronchospasm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the high proportion of patients with air leaks, careful attention to the proper function of the chest tubes is key to prevent development of a pneumothorax and consequent respiratory insufficiency. Brief kinking or blockage of a chest tube can lead to rapid accumulation of a pneumothorax and cardiopulmonary decompensation. A chest radiograph is obtained daily to confirm full lung re-expansion. Chest tubes are generally left in place until the lung is fully reexpanded and there is no evidence of air leak. However, some patients with slow air leaks may be transitioned to a minichest tube with a unidirectional flutter valve (ie, Heimlich valve) to enable discharge prior to complete resolution of the air leak. The procedure for chest tube removal is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of postoperative pain usually involves a combination of regional and systemic agents to enable early mobilization of the patient and effective cough [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H17#H17\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Postoperative strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postextubation respiratory insufficiency can result from bronchoconstriction from the underlying COPD, atelectasis, pneumothorax, pneumonia, or hypoventilation due to postoperative pain or analgesic medication. For awake patients with a rising PaCO2 despite prompt attention to these factors, noninvasive positive pressure ventilation may be used to avoid re-intubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of deep venous thrombosis and pulmonary embolism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolonged air leakage is the most common complication following bullectomy, although the reported incidence varies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ]. In one series of 43 patients, air leakage for longer than seven days occurred in 53 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ]. In another series, prolonged air leak occurred in 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2\">",
"     2",
"    </a>",
"    ]. The mean forced expiratory volume in one second (FEV1) values for patients in the two series were 32 and 64 percent predicted, respectively, suggesting a greater degree of underlying diffuse emphysema in the first study. This may explain the difference in postoperative air leakage.",
"   </p>",
"   <p>",
"    Other complications include atrial fibrillation (12 percent), postoperative mechanical ventilation (9 percent), pneumonia (5 percent), and postoperative incisional pain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series and uncontrolled observational studies suggest that resection of giant bullae in carefully selected patients is associated with symptomatic and functional improvement lasting for five or more years in 60 to 90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/3,5,7,9,11,35-37\">",
"     3,5,7,9,11,35-37",
"    </a>",
"    ]. The potential clinical and physiologic benefits of bullectomy are described separately. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Potential benefits'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The perioperative mortality reported in case series of bullectomy for giant bulla(e) ranges from 0 to 7 percent for bullectomy via open thoracotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2,3,9\">",
"     2,3,9",
"    </a>",
"    ]. In these series, patients with diffuse emphysema had a higher mortality rate than those with relatively normal lung parenchyma aside from the giant bulla(e). As an example, in a series of 41 patients undergoing bullectomy, the first year mortality rate of 7 percent was entirely attributable to patients with diffuse emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Causes of death include postoperative pneumonia, acute and chronic respiratory failure, pulmonary embolism, and myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28568/abstract/5,9,21-23,25\">",
"     5,9,21-23,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A bulla is defined as an air space in the lung measuring more than one centimeter in diameter in the distended state; the term giant bulla is used for bullae that occupy at least 30 percent of a hemithorax. A single giant bulla may be present, or a giant bulla may be accompanied by a number of smaller adjacent bullae. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For selected patients with a giant bulla and persistent dyspnea despite optimal medical therapy and pulmonary rehabilitation, we suggest bullectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Clinical and laboratory features that guide patient selection are presented in the table (",
"      <a class=\"graphic graphic_table graphicRef68646 \" href=\"UTD.htm?28/38/29292\">",
"       table 1",
"      </a>",
"      ). The patient's values and preferences should be used to guide the decision. Patients who highly value a potential reduction in dyspnea and are willing to accept the risk of perioperative mortality may choose bullectomy over medical management, whereas others may not wish to accept the risk of perioperative mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with a giant bulla and a secondary spontaneous pneumothorax, we recommend video-assisted thoracoscopic surgery (VATS) with pleurodesis, due to the high risk of recurrent pneumothorax (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with minimal surrounding diffuse emphysema, a bullectomy is typically performed at the time of pleurodesis. However, for patients with diffuse bullous emphysema, pleurodesis may be performed without bullectomy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link&amp;anchor=H9#H9\">",
"       \"Secondary spontaneous pneumothorax in adults\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contraindications for bullectomy include a bulla smaller than 30 percent of the hemithorax, cigarette smoking within the previous six months, advanced emphysema in the non-bullous adjacent lung, and significant comorbidities. Patient with diffuse upper lobe emphysema may be considered for lung volume reduction surgery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"       \"Lung volume reduction surgery in COPD\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both thoracotomy and video-assisted thoracoscopic surgery (VATS) approaches have been used in the resection or ablation of giant bullae. The choice between these approaches usually depends on the expertise and preference of the operating team. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Operative approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequently used operative technique for bullectomy is a broad stapled wedge resection along the border of the giant bulla, resecting as little normal or near normal adjacent tissue as possible. The staple line is frequently buttressed with bovine pericardial strips",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other materials (eg, polytetrafluoroethylene strips) to reduce the incidence of postoperative air leaks. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Operative technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative management entails careful attention to respiratory status and pain control, treatment of bronchoconstriction, monitoring for development or worsening of a pneumothorax, and prevention of deep venous thrombosis and pulmonary embolism. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Postoperative care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative complications include prolonged air leak, atrial fibrillation, postoperative mechanical ventilation, pneumonia, and postoperative incisional pain. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reported operative mortality ranges from 0 to 7 percent. Causes of death include postoperative pneumonia, acute and chronic respiratory failure, pulmonary embolism, and myocardial infarction. Persistent air leak is the most common complication. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/1\">",
"      Thurlbeck WM. Pathophysiology of chronic obstructive pulmonary disease. Clin Chest Med 1990; 11:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/2\">",
"      Palla A, Desideri M, Rossi G, et al. Elective surgery for giant bullous emphysema: a 5-year clinical and functional follow-up. Chest 2005; 128:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/3\">",
"      Neviere R, Catto M, Bautin N, et al. Longitudinal changes in hyperinflation parameters and exercise capacity after giant bullous emphysema surgery. J Thorac Cardiovasc Surg 2006; 132:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/4\">",
"      Laros CD, Gelissen HJ, Bergstein PG, et al. Bullectomy for giant bullae in emphysema. J Thorac Cardiovasc Surg 1986; 91:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/5\">",
"      Snider GL. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. Chest 1996; 109:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/6\">",
"      Kinnear WJ, Tattersfield AE. Emphysematous bullae. BMJ 1990; 300:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/7\">",
"      Shah SS, Goldstraw P. Surgical treatment of bullous emphysema: experience with the Brompton technique. Ann Thorac Surg 1994; 58:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/8\">",
"      Gaensler EA, Jederlinic PJ, FitzGerald MX. Patient work-up for bullectomy. J Thorac Imaging 1986; 1:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/9\">",
"      Schipper PH, Meyers BF, Battafarano RJ, et al. Outcomes after resection of giant emphysematous bullae. Ann Thorac Surg 2004; 78:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/10\">",
"      Meyers BF, Patterson GA. Chronic obstructive pulmonary disease. 10: Bullectomy, lung volume reduction surgery, and transplantation for patients with chronic obstructive pulmonary disease. Thorax 2003; 58:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/11\">",
"      Nickoladze GD. Functional results of surgery for bullous emphysema. Chest 1992; 101:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/12\">",
"      Ohta M, Nakahara K, Yasumitsu T, et al. Prediction of postoperative performance status in patients with giant bulla. Chest 1992; 101:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/13\">",
"      Nakahara K, Nakaoka K, Ohno K, et al. Functional indications for bullectomy of giant bulla. Ann Thorac Surg 1983; 35:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/14\">",
"      FitzGerald MX, Keelan PJ, Cugell DW, Gaensler EA. Long-term results of surgery for bullous emphysema. J Thorac Cardiovasc Surg 1974; 68:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/15\">",
"      Gunstensen J, McCormack RJ. The surgical management of bullous emphysema. J Thorac Cardiovasc Surg 1973; 65:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/16\">",
"      Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/17\">",
"      Brister NW, Barnette RE, Kim V, Keresztury M. Anesthetic considerations in candidates for lung volume reduction surgery. Proc Am Thorac Soc 2008; 5:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/18\">",
"      Boasquevisque CH, Yildirim E, Waddel TK, Keshavjee S. Surgical techniques: lung transplant and lung volume reduction. Proc Am Thorac Soc 2009; 6:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/19\">",
"      Greenberg JA, Singhal S, Kaiser LR. Giant bullous lung disease: evaluation, selection, techniques, and outcomes. Chest Surg Clin N Am 2003; 13:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/20\">",
"      Tsuchida M, Nakayama K, Shinonaga M, et al. Video-assisted thoracic surgery for thorascopic resection of giant bulla. Surg Today 1996; 26:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/21\">",
"      Lewis RJ, Caccavale RJ, Sisler GE. VATS-Argon Beam Coagulator treatment of diffuse end-stage bilateral bullous disease of the lung. Ann Thorac Surg 1993; 55:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/22\">",
"      Wakabayashi A, Brenner M, Kayaleh RA, et al. Thoracoscopic carbon dioxide laser treatment of bullous emphysema. Lancet 1991; 337:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/23\">",
"      Brenner M, Kayaleh RA, Milne EN, et al. Thoracoscopic laser ablation of pulmonary bullae. Radiographic selection and treatment response. J Thorac Cardiovasc Surg 1994; 107:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/24\">",
"      Wakabayashi A. Thoracoscopic technique for management of giant bullous lung disease. Ann Thorac Surg 1993; 56:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/25\">",
"      Barker SJ, Clarke C, Trivedi N, et al. Anesthesia for thoracoscopic laser ablation of bullous emphysema. Anesthesiology 1993; 78:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/26\">",
"      Noppen M, Tellings JC, Dekeukeleire T, et al. Successful treatment of a giant emphysematous bulla by bronchoscopic placement of endobronchial valves. Chest 2006; 130:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/27\">",
"      Santini M, Fiorello A, Di Crescenzo VG, et al. Use of unidirectional endobronchial valves for the treatment of giant emphysematous bulla. J Thorac Cardiovasc Surg 2010; 139:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/28\">",
"      Bhattacharyya P, Sarkar D, Nag S, et al. Transbronchial decompression of emphysematous bullae: a new therapeutic approach. Eur Respir J 2007; 29:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/29\">",
"      Cho S, Huh DM, Kim BH, et al. Staple line covering procedure after thoracoscopic bullectomy for the management of primary spontaneous pneumothorax. Thorac Cardiovasc Surg 2008; 56:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/30\">",
"      Moser C, Opitz I, Zhai W, et al. Autologous fibrin sealant reduces the incidence of prolonged air leak and duration of chest tube drainage after lung volume reduction surgery: a prospective randomized blinded study. J Thorac Cardiovasc Surg 2008; 136:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/31\">",
"      Brunelli A, Al Refai M, Muti M, et al. Pleural tent after upper lobectomy: a prospective randomized study. Ann Thorac Surg 2000; 69:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/32\">",
"      Venuta F, De Giacomo T, Rendina EA, et al. Thoracoscopic pleural tent. Ann Thorac Surg 1998; 66:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/33\">",
"      Chandra D, Soubra SH, Musher DM. A 57-year-old man with a fluid-containing lung cavity: infection of an emphysematous bulla with methicillin-resistant Staphylococcus aureus. Chest 2006; 130:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/34\">",
"      Goldstraw P, Petrou M. The surgical treatment of emphysema. The Brompton approach. Chest Surg Clin N Am 1995; 5:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/35\">",
"      Boushy SF, Kohen R, Billig DM, Heiman MJ. Bullous emphysema: clinical, roentgenologic and physiologic study of 49 patients. Dis Chest 1968; 54:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/36\">",
"      Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28568/abstract/37\">",
"      Wesley JR, Macleod WM, Mullard KS. Evaluation and surgery of bullous emphysema. J Thorac Cardiovasc Surg 1972; 63:945.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1441 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28568=[""].join("\n");
var outline_f27_57_28568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POTENTIAL BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANESTHETIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OPERATIVE APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OPERATIVE TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Extent of resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Resection technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Reducing postoperative air leakage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Final examination and closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rarely used techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1441\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1441|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/38/29292\" title=\"table 1\">",
"      Selection for bullectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36454?source=related_link\">",
"      Dynamic hyperinflation in patients with COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=related_link\">",
"      Evaluation and medical management of giant bullae in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=related_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_57_28569="Heart failure in diabetes mellitus";
var content_f27_57_28569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heart failure in diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28569/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28569/contributors\">",
"     Richard W Nesto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28569/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28569/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28569/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28569/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28569/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28569/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/57/28569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus (DM) increases the risk of heart failure (HF) independent of coronary heart disease and hypertension and may cause a cardiomyopathy. The term diabetic cardiomyopathy was initially introduced based upon postmortem findings in four diabetic adults who had HF in the absence of coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetic cardiomyopathy has been defined as ventricular dysfunction that occurs in diabetic patients independent of a recognized cause (eg, coronary heart disease, hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the frequency with which this occurs is not well defined and there is some evidence that diabetic cardiomyopathy is uncommon in patients with type 1 diabetes in the era of intensive insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to heart failure in diabetic patients will be reviewed here. The prevalence of and risk factors for coronary heart disease among patients with diabetes mellitus and the evaluation and treatment of heart failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a well established association between diabetes and HF that is partly but not entirely linked to coronary heart disease and hypertension. Associations have also been reported between absolute blood glucose levels, glycemic control, and HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diabetes and HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Framingham Study firmly established the epidemiologic link between diabetes and HF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/5\">",
"     5",
"    </a>",
"    ]. The risk of HF was increased 2.4-fold in men and fivefold in women. Diabetes predicted heart failure independent of coexisting hypertension or coronary disease. When patients with prior coronary or rheumatic heart disease were excluded, the relative risk of HF remained elevated at 3.8 in diabetic men and 5.5 in diabetic women.",
"   </p>",
"   <p>",
"    Similar findings have since been noted in a number of other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. As an example, in a report of 9591 subjects with type 2 diabetes and matched controls, HF was more frequent at baseline in diabetics (11.8 versus 4.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/6\">",
"     6",
"    </a>",
"    ]. Among those free of HF at baseline, HF developed more often in diabetics during a 30 month follow-up (7.7 versus 3.4 percent).",
"   </p>",
"   <p>",
"    The frequency of HF in diabetic patients is even higher among elderly adults. This was demonstrated in a national sample of Medicare claims from 1994 to 1999 for over 150,000 beneficiaries with diabetes who were &ge;65 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/7\">",
"     7",
"    </a>",
"    ]. The prevalence of HF was 22.3 percent in 1994, with a subsequent incidence of newly diagnosed HF of 12.6 percent per year.",
"   </p>",
"   <p>",
"    Factors associated with HF in adult diabetic patients are [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/6-8,11,12\">",
"     6-8,11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age",
"     </li>",
"     <li>",
"      Duration of diabetes",
"     </li>",
"     <li>",
"      Insulin use",
"     </li>",
"     <li>",
"      Ischemic heart disease",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"     <li>",
"      Elevated serum creatinine",
"     </li>",
"     <li>",
"      Poor glycemic control",
"     </li>",
"     <li>",
"      Microalbuminuria",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of HF after revascularization with angioplasty or bypass surgery is also greater in diabetic patients; in one study of 3 patients followed for 13 years after revascularization, the cumulative incidence of hospitalizations for heart failure was higher in diabetics (25 versus 11 percent for nondiabetics), with a rapidly increasing incidence after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the increased risk of HF in patients with diabetes, there is also a high rate of diabetes among patients with HF. In the OPTIMIZE-HF registry of 48,612 patients hospitalized with HF, 42 percent had diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Glycemic control and blood glucose levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with diabetes, the risk of development of heart failure is associated with hyperglycemia as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A report from Kaiser Permanente of 48,858 adults (mean age 58 years) with DM (predominantly type 2) and no HF who were followed for a mean of 2.2 years. The risk of HF was associated with the HbA1c and varied from 4.5 to 9.2 per 1000 patient-years. After adjustment for covariates, each 1 percent increase in hemoglobin (Hb) A1c was associated with an 8 percent increased relative risk of HF [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/8\">",
"       8",
"      </a>",
"      ]. An HbA1c &ge;10 increased the risk of HF by 1.56 fold compared to an HbA1c &lt;7. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"       \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A relationship was found between blood glucose levels and hospitalization for HF in patients with or without type 2 DM in a cohort of 31,546 adults (mean age 67 years) at high cardiovascular risk from two clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/15\">",
"       15",
"      </a>",
"      ]. At a mean follow-up of 2.4 years, each 18",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      increase in baseline fasting plasma glucose was associated with a modest but statistically significant increase in the risk of HF hospitalization (adjusted hazard ratio 1.05, CI 1.02-1.08).",
"     </li>",
"     <li>",
"      A similar relationship was found in cohort of 20,985 adults with type 1 DM (mean age 39 years) followed for a median of nine years [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/16\">",
"       16",
"      </a>",
"      ]. The incidence of HF ranged from 1.42 per 1000 patient-years for HbA1c &lt;6.5 percent to 5.20 per 1000 for &ge;10.5 percent. After adjustment for covariates, each 1 percent increase in HbA1c was associated with a 30 percent increased relative risk of HF during follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the available data have not shown a causal relationship, ie, improved glucose control has not been shown to reduce incident HF in patients with type 2 DM. A meta-analysis including 27,049 patients with type 2 DM found that more intensive glucose control, compared to less intensive control, did not decrease incident HF or mortality, although major cardiovascular events (primarily myocardial infarction) were decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with type 1 DM, data are lacking on the effect of intensive glucose control on risk of incident HF.",
"   </p>",
"   <p>",
"    A potential role of diastolic dysfunction as a mediator of the relationship between glycemic control and functional status and HF is discussed below. (See",
"    <a class=\"local\" href=\"#H5468747\">",
"     'Functional abnormalities'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5468747\">",
"    <span class=\"h2\">",
"     Functional abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular dysfunction due to diabetic cardiomyopathy is manifested by systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The following observations illustrate the spectrum of functional changes that can occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the Strong Heart Study, diabetic patients had higher left ventricular mass, wall thickness, and arterial stiffness and reduced systolic function compared to individuals without diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/22\">",
"       22",
"      </a>",
"      ]. These abnormalities were independent of body mass index and blood pressure.",
"     </li>",
"     <li>",
"      Noninvasive evaluation of cardiac performance in diabetic patients without overt heart failure has demonstrated a prolonged preejection period and a shortened ejection time, both of which correlate with reduced resting left ventricular ejection fraction (LVEF) and diminished systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/2\">",
"       2",
"      </a>",
"      ]. Diabetic patients also have a lower LVEF in response to exercise, suggesting a reduction in cardiac reserve [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diastolic dysfunction is common in diabetic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/25,26\">",
"       25,26",
"      </a>",
"      ], which may be due in part to increased left ventricular mass [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. For example, an",
"      <span class=\"nowrap\">",
"       E/e&rsquo;",
"      </span>",
"      ratio &gt;15 (a marker of elevated left ventricular diastolic pressure) was observed in 23 percent of 1760 diabetic patients studied in Olmsted County [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"       \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Greater diastolic dysfunction is observed in those with worse glycemic control and in those who are also hypertensive [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Further evidence for diastolic dysfunction as a mediator of the relationship between glycemic control and functional status comes from an observational study of 1085 individuals with glucose metabolism ranging from normal to insulin treated type 2 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/25\">",
"       25",
"      </a>",
"      ]. On multivariate analysis, HbA1c level correlated with",
"      <span class=\"nowrap\">",
"       E/e&rsquo;",
"      </span>",
"      ratio as well as reduced six minute walk distance.",
"     </li>",
"     <li>",
"      The prognostic significance of diastolic dysfunction in diabetics is discussed below. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prognosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5468754\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pathologic changes in the myocardium have been described in diabetic patients that may account for observed functional changes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], although they may occur in the absence of functional abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/4\">",
"     4",
"    </a>",
"    ]. These include fibrosis, infiltration of the interstitium with periodic acid-Schiff (PAS)-positive material, and alterations in the myocardial capillary basement membrane, including the formation of microaneurysms.",
"   </p>",
"   <p>",
"    Myocardial fibrosis, advanced glycation end product deposition and cardiomyocyte resting tension were compared in diabetic and nondiabetic HF patients without coronary disease with normal LVEF (28 patients, 16 diabetic) or reduced LVEF (36 patients, 10 diabetic) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/32\">",
"     32",
"    </a>",
"    ]. Diabetic HF patients had higher diastolic LV stiffness irrespective of LVEF. Significantly increased myocardial collagen volume fraction and increased myocardial AGE deposition was observed only among diabetic patients with reduced LVEF; on the other hand, increased cardiomyocyte resting tension was observed only in diabetic patients with normal LVEF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic cardiomyopathy has been defined as ventricular dysfunction that occurs in diabetic patients independent of a recognized cause (eg, coronary heart disease, hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A variety of derangements may contribute to ventricular dysfunction in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/3,33,34\">",
"     3,33,34",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autonomic neuropathy may play a role in the development of left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/2\">",
"       2",
"      </a>",
"      ]. Sympathetic stimulation improves left ventricular contraction and increases left ventricular relaxation rates, perhaps by facilitating calcium uptake by the sarcoplasmic reticulum. Autopsy studies have found that myocardial catecholamine stores are depleted in diabetic patients which could impair both systolic and diastolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/35\">",
"       35",
"      </a>",
"      ]. These changes may be associated with functional impairment in cardiac sympathetic nerve fibers [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The capacity of the vascular bed to meet metabolic demands may be impaired by abnormal epicardial vessel tone and microvascular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/21,37\">",
"       21,37",
"      </a>",
"      ]. Diabetics have impaired endothelium-dependent relaxation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/38\">",
"       38",
"      </a>",
"      ], a defect that may be related to inactivation of nitric oxide by advanced glycation end products and increased generation of free radicals [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/39\">",
"       39",
"      </a>",
"      ]. The abnormal vasodilator response in diabetes extends to the coronary microcirculation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/40\">",
"       40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Microcirculatory dysfunction in diabetics may be due in part to downregulation of the expression of vascular endothelial growth factor (VEGF). In an animal model, local replenishment of VEGF via DNA gene therapy was associated with increased capillary density and a significant improvement in cardiac function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Advanced glycation end product deposition may increase LV diastolic stiffness directly by cross-linking collagen, or indirectly by enhancing collagen formation or reducing nitric oxide bioavailability [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/32,42,43\">",
"       32,42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased insulin availability or responsiveness can impair energy-independent transport of glucose across the cell membrane. Since ischemic myocardium depends upon anaerobic metabolism of glucose, increased glucose uptake and metabolism are necessary for maintenance of myocardial function [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. Diminished insulin activity limits glucose availability, resulting in a shift toward fatty acid metabolism. These changes increase myocardial oxygen utilization and can reduce the compensatory capacity of noninfarcted myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other factors that may contribute include myocardial accumulation of lipid and other toxic products of fatty acid metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/47-49\">",
"     47-49",
"    </a>",
"    ], impaired calcium handling [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/3,50,51\">",
"     3,50,51",
"    </a>",
"    ], upregulation of the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/3,52\">",
"     3,52",
"    </a>",
"    ], increased reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/3,53\">",
"     3,53",
"    </a>",
"    ], and mitochondrial defects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/3,33\">",
"     3,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While clinical and laboratory evidence support the above proposed mechanisms by which diabetes and insulin resistance may cause HF, a reciprocal causal relation has been postulated in which HF promotes insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/34\">",
"     34",
"    </a>",
"    ]. Neurohumoral activation in HF causes increased free fatty acid metabolism, which may cause systemic and myocardial insulin resistance. These metabolic alterations may impair myocardial energetics so that a vicious cycle is produced of HF leading to altered metabolism leading to HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with HF, those with diabetes have higher mortality rates (",
"    <a class=\"graphic graphic_figure graphicRef80473 \" href=\"UTD.htm?34/27/35261\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. This relationship was demonstrated in a report from Studies of Left Ventricular Dysfunction (SOLVD) which enrolled 6791 patients, including 1310 with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/54\">",
"     54",
"    </a>",
"    ]. Compared to nondiabetics, diabetic patients were significantly more likely to be admitted for heart failure (risk ratio 1.6) and had higher rates at one year of all-cause mortality (32 versus 22 percent), cardiovascular mortality (28 versus 19 percent) and mortality related to pump failure (11 versus 6 percent).",
"   </p>",
"   <p>",
"    The increase in all-cause mortality associated with diabetes in SOLVD was limited to patients with an ischemic cardiomyopathy (adjusted relative risk 1.37 compared to 0.98 in patients with nonischemic cardiomyopathy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/55\">",
"     55",
"    </a>",
"    ]. In the presence of coronary disease, diabetes was independent of other risk factors for predicting worsening of heart failure and it was third in order of importance, after age and LVEF. Previous surgical revascularization may identify diabetic patients with heart failure who have improved survival (91 versus 86 percent without revascularization). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with diabetes, those who develop HF have markedly poorer survival than in those who do not. In the national sample of Medicare claims, the mortality rates were 32.7 and 3.7 percent per year, respectively (hazard ratio [HR] 10.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/7\">",
"     7",
"    </a>",
"    ]. This risk was only slightly attenuated by adjustment for age, sex, and race (HR 9.5). The five-year survival rate for diabetics with HF was 12.5 percent.",
"   </p>",
"   <p>",
"    The prognostic significance of pre-clinical diastolic dysfunction was demonstrated in a study of 1760 patients with diabetes in Olmsted County [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/26\">",
"     26",
"    </a>",
"    ]. The presence of an",
"    <span class=\"nowrap\">",
"     E/e&rsquo;",
"    </span>",
"    ratio &gt;15 was an independent predictor of HF (HR 1.6, 95% CI 1.2 to 2.2) and increased mortality (HR 2.0, 95% CI 1.3 5o 3.1) at five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIABETES DRUGS TO USE WITH CAUTION IN HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thiazolidinediones and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , two classes of oral hypoglycemic drugs, have toxicities that have made them relatively or absolutely contraindicated in patients with HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thiazolidinediones can cause fluid retention. As a result, they are not recommended in patients with symptomatic heart failure and are contraindicated in NYHA class III or IV HF (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       Metformin",
"      </a>",
"      is contraindicated in HF requiring pharmacologic therapy because of the risk of lactic acidosis. However, the risk for lactic acidosis in the setting of metformin is extremely low and whether heart failure increases this risk is arguable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones (TZDs) act by increasing insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/57\">",
"     57",
"    </a>",
"    ]. The TZDs bind to and activate peroxisome proliferator-activated receptor-gamma (PPAR-gamma). The following section will focus upon the risks of HF related to TZD use. A detailed discussion of the overall cardiovascular effects of TZDs is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H8#H8\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Cardiovascular Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is strong evidence that TZDs contribute to fluid retention and increase the risk of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/58-64\">",
"     58-64",
"    </a>",
"    ]. In meta-analyses of randomized trials of thiazolidinediones for the treatment or prevention of type 2 diabetes, the estimated relative risk of heart failure in patients randomly assigned to TZDs compared with placebo ranged from 1.7 to 2.1 (95% CIs 1.2-2.4 and 1.1-4.1, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The incidence of heart failure was not limited to the elderly and occurred at high and low doses after a median treatment duration of 24 weeks.",
"   </p>",
"   <p>",
"    Similar findings were noted in a later randomized trial (RECORD) that evaluated the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or sulfonylurea therapy compared to combination metformin and sulfonylurea therapy; there was a 2.1 fold (95% CI 1.35-3.27) increased risk of HF resulting in hospitalization or death with the addition of rosiglitazone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/64\">",
"     64",
"    </a>",
"    ]. There was no difference in the primary endpoint of cardiovascular hospitalization or cardiovascular death.",
"   </p>",
"   <p>",
"    One mechanism by which TZDs increase heart failure risk is renal sodium retention. Peripheral edema occurs in 4 to 6 percent of patients treated with TZDs (compared to 1 to 2 percent with placebo) and in a higher percentage of patients with a history of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/57\">",
"     57",
"    </a>",
"    ]. In both randomized and observational studies, TZD use has been associated with worsening HF and pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Weight gain and fluid retention are more common with concomitant insulin therapy. Fluid retention induced by TZDs appears to be relatively resistant to loop diuretics but responds promptly to withdrawal of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/66,69\">",
"     66,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fluid retention with TZDs appears to result at least in part from PPAR-gamma stimulation of sodium reabsorption by sodium channels (called the epithelial sodium channel) in the luminal membrane of the collecting tubule cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/70\">",
"     70",
"    </a>",
"    ]. This effect is mediated by increased expression of the epithelial sodium channel gene mRNA.",
"   </p>",
"   <p>",
"    Sodium retention by aldosterone is also mediated by this channel. However, aldosterone excess is not associated with edema, due to the phenomenon of aldosterone escape in which sodium reabsorption is reduced at other sites in the nephron to minimize fluid retention. Escape does not appear to occur with the thiazolidinediones perhaps due to a concurrent fall in blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/69,71\">",
"     69,71",
"    </a>",
"    ], in contrast to the increase in blood pressure in primary aldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features of primary aldosteronism\", section on 'Lack of edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To the degree that increased activity of the collecting tubule sodium channel is involved, blockade of this channel may be effective. Administration of a mineralocorticoid receptor antagonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , is part of the standard medical regimen of many patients with HF and, in a study of diabetic patients without heart failure who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , spironolactone produced more fluid removal than a loop diuretic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/69\">",
"     69",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     Amiloride",
"    </a>",
"    , which blocks this channel, may also be effective. Hyperkalemia is a potential problem with any of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Major society and FDA guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In May 2011, the US Food and Drug Administration (FDA) announced restrictions on access to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    which were placed based on data suggesting increased risk of myocardial infarction in patients treated with the drug (see",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     \"Rosiglitazone: Drug information\"",
"    </a>",
"    ). Under this program, access to rosiglitazone is now limited to patients already successfully treated with it or patients whose blood sugar cannot be controlled with other diabetes drugs and who decide not to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    after consulting with the healthcare provider. Use of rosiglitazone had already declined sharply prior to this announcement and is now severely restricted.",
"   </p>",
"   <p>",
"    In December 2003, a consensus statement on this issue was published by the American Heart Association and the American Diabetes Association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/72\">",
"     72",
"    </a>",
"    ]. Given the restrictions on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    use, this statement now applies chiefly to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    . The following approach was recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without established heart disease,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      should be prescribed according to the package insert guidelines. Weight gain and edema will occur more often with concomitant insulin therapy.",
"     </li>",
"     <li>",
"      In patients with one or more risk factors for HF with TZD therapy (",
"      <a class=\"graphic graphic_table graphicRef69087 \" href=\"UTD.htm?30/32/31243\">",
"       table 2",
"      </a>",
"      ), in patients with a decreased LVEF but no signs or symptoms of HF, and in patients with NYHA class I or II HF, the initial dose of the TZD should be low (eg, 2 to 4 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      daily or 15 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      daily). Patients should be observed for weight gain or edema. Dose escalation should be performed gradually while reassessing the patient for signs of HF.",
"     </li>",
"     <li>",
"      In patients with NYHA class III or IV HF, TZDs should not be used.",
"     </li>",
"     <li>",
"      If weight gain and edema develop in a patient taking a TZD, a careful assessment for evidence of HF should be made. This may include review of symptoms of HF, physical examination, electrocardiogram, echocardiogram, and serum brain natriuretic peptide concentration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If there is no evidence of HF, other possible causes of edema should be investigated, including other drugs, venous insufficiency, and renal dysfunction. Diuretics may be prescribed, although the efficacy of such therapy in TZD-induced edema is variable. Dosage change or discontinuation of the TZD are options.",
"     </li>",
"     <li>",
"      If there is evidence of HF, the use of the TZD should be reconsidered. Dosage change and temporary or permanent discontinuation are options; the drug should be discontinued in patients who also have known left ventricular dysfunction. Therapy for HF should be initiated as necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) has issued a boxed warning for TZDs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/73\">",
"     73",
"    </a>",
"    ]. The FDA recommends that patients who are initiating or currently taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    be observed for signs and symptoms of heart failure, and the TZD should be stopped \"if any deterioration in cardiac status occurs.\" The FDA also concluded that drugs in this class are not recommended in patients with symptomatic heart failure and are contraindicated in patients with New York Heart Association class III or IV heart failure (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Health Canada usage restrictions for TZDs include contraindicating these agents with any stage (class I-IV) of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The European Society of Cardiology (ESC) HF guidelines note that TZDs are contraindicated in patients with NYHA class III-IV HF but that they may be considered in patients with NYHA functional class I-II HF with careful monitoring for fluid retention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/75\">",
"     75",
"    </a>",
"    ]. The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    HF guidelines with 2009 update note that TZDs are contraindicated in patients with class III-IV HF, that risk of fluid retention is low in patients with class I-II HF, and that TZDs should be used with caution in patients with reduced cardiac reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     TZD summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, strong evidence indicates that TZDs cause fluid retention which can precipitate HF. Thus, TZDs are not generally recommended in patients with symptomatic HF and are contraindicated in patients with NYHA class III-IV HF. TZDs may be considered as part of diabetes management in selected patients with class I-II HF with careful monitoring for fluid retention. Current evidence does not support the preferential use of TZDs for the purpose of improving cardiovascular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF who take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are at increased risk of potentially lethal lactic acidosis, especially in the presence hemodynamic instability or of other concurrent medical conditions such as renal insufficiency, liver disease, or severe infection with decreased tissue perfusion. Labeling required by the FDA includes a boxed warning concerning the increased risk of metformin associated lactic acidosis among patients with heart failure requiring pharmacologic management, in particular those with unstable or acute heart failure at risk of hypoperfusion and hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link&amp;anchor=H7#H7\">",
"     \"Metformin in the treatment of diabetes mellitus\", section on 'Lactic acidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is an effective and useful agent in the management of diabetes mellitus, and the general safety of and possible survival benefit from metformin in this setting has been suggested by observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/58,78\">",
"     58,78",
"    </a>",
"    ]. The risk of lactic acidosis is probably small in patients with stable, well-compensated heart failure who have a serum creatinine concentration below 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    In the ESC HF guidelines, metformin is suggested as a first-line agent in overweight patients with type 2 diabetes without significant renal dysfunction (GFR &gt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/75\">",
"     75",
"    </a>",
"    ]. Metformin use is not discussed in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    HF guidelines (with 2009 focused update).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic patients with heart failure are treated in the same fashion as nondiabetics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .) Data supporting this approach are available for both beta blockers and ACE inhibitors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a meta-analysis of beta blocker trials in HF that included 1883 diabetics and 7042 nondiabetics, the survival benefit with beta blocker therapy was significant for both those with diabetes and for those without (relative risk 0.77 and 0.65, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/79\">",
"       79",
"      </a>",
"      ]. The difference in risk reduction between diabetics and nondiabetics was not significant.",
"     </li>",
"     <li>",
"      Both the SOLVD and SAVE trials showed that diabetics benefit from angiotensin converting enzyme (ACE) inhibitors to the same degree as nondiabetics [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/54,80\">",
"       54,80",
"      </a>",
"      ]. In a meta-analysis of ACE inhibitor trials in HF that included 2398 diabetics and 10,188 nondiabetics, the survival benefit with ACE inhibitor therapy was the same for those with diabetes as for those without (relative risk 0.84 and 0.85, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Role of glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, tighter glycemic control is associated with lower risk of HF. However, a causal relationship between glycemic control and heart failure has not been established. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Glycemic control and blood glucose levels'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The impact of diabetes therapies on cardiac function has not been defined. Although thiazolidinedione (TZD) use is associated with increased HF risk as discussed above, some studies suggest a beneficial impact on myocardial metabolism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. In the PIRAMID trial, 78 men with type 2 diabetes were randomly assigned to TZD (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    for 24 weeks. TZD treatment improved some measures of left ventricular diastolic function but did not change myocardial high-energy phosphate metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/81\">",
"     81",
"    </a>",
"    ]. The clinical significance of this observation is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Heart transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus, even without evidence of significant end-organ damage (neuropathy, retinopathy, or nephropathy), is a relative contraindication to heart transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. However, the outcome in properly selected patients is comparable to that in nondiabetics. This was illustrated in an analysis of 345 consecutive heart transplant recipients, 101 with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/84\">",
"     84",
"    </a>",
"    ]. Diabetics, compared to nondiabetics, had a nonsignificant trend toward decreased survival at one year (85 versus 91 percent) but comparable survival at five years (82 percent). Rates of infection severe enough to require hospitalization were higher among diabetics at 90 days (14 versus 3 percent) and four years (29 versus 15 percent). There were no differences in the incidence of rejection, transplant coronary disease, or renal dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Possible prevention with angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) reduce disease progression and mortality in patients with overt HF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible preventive effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    in diabetic patients with type 2 diabetes was evaluated in subset analysis of two large randomized trials: RENAAL for renal protection and LIFE for hypertension with left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28569/abstract/12\">",
"     12",
"    </a>",
"    ]. Compared to placebo, losartan significantly reduced the incidence first hospitalization for HF: 39 versus 54 percent in RENAAL (adjusted hazard ratio 0.69); and 11 versus 19 percent in LIFE (adjusted hazard ratio 0.50).",
"   </p>",
"   <p>",
"    These findings are consistent with the use of ACE inhibitors or ARBs for the treatment of hypertension and renal disease in patients with diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=see_link\">",
"     \"Treatment of hypertension in patients with diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=see_link\">",
"     \"Treatment of diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3042978\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATION",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Independent of CAD and HTN, diabetes is a cause of systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic ventricular dysfunction which has been termed diabetic cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the relationship of glycemia to the risk of developing HF, there is no evidence that tight glycemic control affects the natural history of HF. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Role of glycemic control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diabetes is associated with a variety of derangements which may reduce LV compliance and contribute to the risk of diastolic dysfunction and HF. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TZDs cause fluid retention which can precipitate HF. Thus, TZDs are not generally recommended in patients with symptomatic HF and are contraindicated in patients with NYHA class III-IV HF. TZDs may be considered as part of diabetes management in selected patients with class I-II HF with careful monitoring for fluid retention. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Thiazolidinediones'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/1\">",
"      Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/2\">",
"      Zarich SW, Nesto RW. Diabetic cardiomyopathy. Am Heart J 1989; 118:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/3\">",
"      Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115:3213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/4\">",
"      Konduracka E, Gackowski A, Rostoff P, et al. Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 2007; 28:2465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/5\">",
"      Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/6\">",
"      Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/7\">",
"      Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/8\">",
"      Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/9\">",
"      Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 2003; 26:2791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/10\">",
"      Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004; 27:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/11\">",
"      Barzilay JI, Kronmal RA, Gottdiener JS, et al. The association of fasting glucose levels with congestive heart failure in diabetic adults &gt; or =65 years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/12\">",
"      Carr AA, Kowey PR, Devereux RB, et al. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. Am J Cardiol 2005; 96:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/13\">",
"      Halon DA, Merdler A, Flugelman MY, et al. Late-onset heart failure as a mechanism for adverse long-term outcome in diabetic patients undergoing revascularization (a 13-year report from the Lady Davis Carmel Medical Center registry). Am J Cardiol 2000; 85:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/14\">",
"      Greenberg BH, Abraham WT, Albert NM, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007; 154:277.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/15\">",
"      Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007; 115:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/16\">",
"      Lind M, Bounias I, Olsson M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet 2011; 378:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/17\">",
"      Control Group, Turnbull FM, Abraira C, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/18\">",
"      Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol 1989; 14:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/19\">",
"      Vered A, Battler A, Segal P, et al. Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). Am J Cardiol 1984; 54:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/20\">",
"      Arvan S, Singal K, Knapp R, Vagnucci A. Subclinical left ventricular abnormalities in young diabetics. Chest 1988; 93:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/21\">",
"      Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 2006; 48:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/22\">",
"      Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000; 101:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/23\">",
"      Mildenberger RR, Bar-Shlomo B, Druck MN, et al. Clinically unrecognized ventricular dysfunction in young diabetic patients. J Am Coll Cardiol 1984; 4:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/24\">",
"      Mustonen JN, Uusitupa MI, Laakso M, et al. Left ventricular systolic function in middle-aged patients with diabetes mellitus. Am J Cardiol 1994; 73:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/25\">",
"      Stahrenberg R, Edelmann F, Mende M, et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 2010; 53:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/26\">",
"      From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010; 55:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/27\">",
"      Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991; 68:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/28\">",
"      Liu JE, Palmieri V, Roman MJ, et al. The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. J Am Coll Cardiol 2001; 37:1943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/29\">",
"      Fischer VW, Barner HB, Leskiw ML. Capillary basal laminar thichness in diabetic human myocardium. Diabetes 1979; 28:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/30\">",
"      Factor SM, Okun EM, Minase T. Capillary microaneurysms in the human diabetic heart. N Engl J Med 1980; 302:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/31\">",
"      van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/32\">",
"      van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/33\">",
"      An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006; 291:H1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/34\">",
"      Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007; 116:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/35\">",
"      Neubauer B, Christensen NJ. Norepinephrine, epinephrine, and dopamine contents of the cardiovascular system in long-term diabetics. Diabetes 1976; 25:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/36\">",
"      Scognamiglio R, Avogaro A, Casara D, et al. Myocardial dysfunction and adrenergic cardiac innervation in patients with insulin-dependent diabetes mellitus. J Am Coll Cardiol 1998; 31:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/37\">",
"      Rossen JD. Abnormal microvascular function in diabetes: relationship to diabetic cardiomyopathy. Coron Artery Dis 1996; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/38\">",
"      Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation 1993; 88:2510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/39\">",
"      Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/40\">",
"      Sebbag L, Forrat R, Canet E, et al. Effect of experimental non-insulin requiring diabetes on myocardial microcirculation during ischaemia in dogs. Eur J Clin Invest 1994; 24:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/41\">",
"      Yoon YS, Uchida S, Masuo O, et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005; 111:2073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/42\">",
"      Heymes C, Vanderheyden M, Bronzwaer JG, et al. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 1999; 99:3009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/43\">",
"      Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 47:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/44\">",
"      Wheeler TJ. Translocation of glucose transporters in response to anoxia in heart. J Biol Chem 1988; 263:19447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/45\">",
"      Sun D, Nguyen N, DeGrado TR, et al. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes. Circulation 1994; 89:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/46\">",
"      Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 1995; 27:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/47\">",
"      McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007; 116:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/48\">",
"      Ruberg FL. Myocardial lipid accumulation in the diabetic heart. Circulation 2007; 116:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/49\">",
"      Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 2008; 52:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/50\">",
"      Cesario DA, Brar R, Shivkumar K. Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006; 35:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/51\">",
"      Jweied EE, McKinney RD, Walker LA, et al. Depressed cardiac myofilament function in human diabetes mellitus. Am J Physiol Heart Circ Physiol 2005; 289:H2478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/52\">",
"      Frustaci A, Kajstura J, Chimenti C, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/53\">",
"      Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 48:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/54\">",
"      Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/55\">",
"      Dries DL, Sweitzer NK, Drazner MH, et al. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/56\">",
"      Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004; 43:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/57\">",
"      Yki-J&auml;rvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/58\">",
"      Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/59\">",
"      Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007; 49:1696.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/SAFETY/2002/summary-actos-avandia.PDF (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/61\">",
"      Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/62\">",
"      Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007; 30:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/63\">",
"      Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/64\">",
"      Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/65\">",
"      Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/66\">",
"      Wang CH, Weisel RD, Liu PP, et al. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003; 107:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/67\">",
"      Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001; 35:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/68\">",
"      Hirsch IB, Kelly J, Cooper S. Pulmonary edema associated with troglitazone therapy. Arch Intern Med 1999; 159:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/69\">",
"      Karalliedde J, Buckingham R, Starkie M, et al. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006; 17:3482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/70\">",
"      Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/71\">",
"      Song J, Knepper MA, Hu X, et al. Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats. J Pharmacol Exp Ther 2004; 308:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/72\">",
"      Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108:2941.",
"     </a>",
"    </li>",
"    <li>",
"     Available from the US Food and Drug Administration website at www.fda.gov/bbs/topics/NEWS/2007/NEW01683.html (Accessed 8/15/07).",
"    </li>",
"    <li>",
"     file://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2007/avandia_hpc-cps_5-eng.php.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/75\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/76\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     Product information Glucophage (metformin hydrochloride) Bristol-Myers Squibb. at file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8463 Accessed March 25, 2009 .",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/78\">",
"      Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/79\">",
"      Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/80\">",
"      Moy&eacute; LA, Pfeffer MA, Wun CC, et al. Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study. Eur Heart J 1994; 15 Suppl B:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/81\">",
"      van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009; 119:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/82\">",
"      Horio T, Suzuki M, Suzuki K, et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005; 18:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/83\">",
"      Lautam&auml;ki R, Airaksinen KE, Sepp&auml;nen M, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes 2005; 54:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/84\">",
"      Marelli D, Laks H, Patel B, et al. Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant 2003; 22:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/85\">",
"      Rhenman MJ, Rhenman B, Icenogle T, et al. Diabetes and heart transplantation. J Heart Transplant 1988; 7:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28569/abstract/86\">",
"      Ladowski JS, Kormos RL, Uretsky BF, et al. Heart transplantation in diabetic recipients. Transplantation 1990; 49:303.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3458 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28569=[""].join("\n");
var outline_f27_57_28569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diabetes and HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Glycemic control and blood glucose levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5468747\">",
"      Functional abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5468754\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIABETES DRUGS TO USE WITH CAUTION IN HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Major society and FDA guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - TZD summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Metformin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Role of glycemic control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Heart transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Possible prevention with angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3042978\">",
"      SUMMARY AND RECOMMENDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3458\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3458|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/27/35261\" title=\"figure 1\">",
"      Mortality diabetes in HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3458|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/32/31243\" title=\"table 2\">",
"      Risks heart failure TZDs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/22/43368?source=related_link\">",
"      Clinical manifestations and diagnosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=related_link\">",
"      Rosiglitazone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40714?source=related_link\">",
"      Treatment of diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21210?source=related_link\">",
"      Treatment of hypertension in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_57_28570="Determinants and management of cardiovascular risk in women";
var content_f27_57_28570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Determinants and management of cardiovascular risk in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28570/contributors\">",
"     Pamela S Douglas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28570/contributors\">",
"     Athena Poppas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28570/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/57/28570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/57/28570/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/57/28570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease (CVD) is the leading cause of death in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The incidence of myocardial infarction (MI) in women, although lower than in men, increases dramatically after the menopause. The increase is at least in part due to increasing age, since men also have a progressive increase in MI with age (",
"    <a class=\"graphic graphic_figure graphicRef57061 \" href=\"UTD.htm?32/28/33229\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/4\">",
"     4",
"    </a>",
"    ]. The role of menopause itself is not so clear. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Menopause'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Coronary heart disease (CHD) mortality is higher in women compared to men, an effect that is largely due to comorbidities, such as older age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/5\">",
"     5",
"    </a>",
"    ]. Risk factors such as smoking and dyslipidemia may be particularly important [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factor reduction may have contributed to the decline in CHD in women that has occurred in recent years. The magnitude of change was illustrated in a report from the Nurses' Health Study of 85,941 women who were followed for 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/7\">",
"     7",
"    </a>",
"    ]. There was a 31 percent reduction in the incidence of CHD in 1992 to 1994 compared to 1980 to 1982. The overall risk and the magnitude of reduction were greatest in women &ge;65 years of age.",
"   </p>",
"   <p>",
"    During this time period, the number of subjects who smoked decreased by 41 percent, the use of hormone replacement therapy (HRT) increased by 175 percent, and the number who were overweight increased by 38 percent. It was concluded that the reduction in smoking accounted for a 13 percent decline in CHD and an improvement in diet explained a 16 percent decline, while the increase in weight accounted for an 8 percent increase in CHD. It was thought that HRT was beneficial but this no longer seems to be correct. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Menopause'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The determinants and general management of cardiovascular risk in women will be reviewed here. The management of women with coronary disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11258?source=see_link\">",
"     \"Management of coronary heart disease in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a diagnostic category, cardiovascular disease (CVD) includes four major areas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary heart disease (CHD) manifested by myocardial infarction (MI), angina pectoris, heart failure (HF), and coronary death",
"     </li>",
"     <li>",
"      Cerebrovascular disease manifested by stroke and transient ischemic attack",
"     </li>",
"     <li>",
"      Peripheral artery disease manifested by intermittent claudication",
"     </li>",
"     <li>",
"      Aortic atherosclerosis and thoracic or abdominal aortic aneurysm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of vascular disease in one of these territories significantly increases the likelihood of disease in other vascular distributions. For example, patients with a low ankle-brachial index (a noninvasive test for peripheral artery disease) have a significantly increased risk of fatal MI, transient ischemic attack, or stroke, and stroke patients have an increased incidence of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In the 2002 National Cholesterol Education Program report, the presence of noncoronary atherosclerotic vascular disease was considered to carry the same risk for future cardiac events as the presence of CHD, thus classifying it as a CHD risk equivalent&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR RISK FACTORS IN WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the guidelines of the National Cholesterol Education Program (NCEP) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/11\">",
"     11",
"    </a>",
"    ] and scientific statements from the American Heart Association (AHA) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/3\">",
"     3",
"    </a>",
"    ], the following are the primary cardiovascular risk factors or CAD equivalents in women, and their assessment should be an important component of periodic health examinations (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Personal history of CHD",
"     </li>",
"     <li>",
"      Age over 55",
"     </li>",
"     <li>",
"      Dyslipidemia: high LDL",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low HDL",
"     </li>",
"     <li>",
"      Family history of premature CHD (first degree male relative under age 55 or a female under age 65)",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Personal history of peripheral artery disease (peripheral arterial, cerebrovascular, and aortic disease). Noncoronary vascular diseases are CHD risk equivalents as they carry the same risk for future cardiac events",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated triglycerides, obesity, and a sedentary lifestyle, while not considered primary risk factors in the NCEP guidelines, are also highly associated with coronary risk, and assessment is recommended by society guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/3\">",
"     3",
"    </a>",
"    ]. These cardiovascular risk factors are more frequent among ethnic minority women than among white women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/12\">",
"     12",
"    </a>",
"    ]. Central obesity and elevated triglycerides, along with hypertension, glucose intolerance and a low HDL, are diagnostic elements of the metabolic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar set of risk factors predicts subsequent MI or death from CHD among women who are already known to have CHD. In the HERS trial of 2763 postmenopausal women with CHD, 361 had an MI or CHD death at 4.1 years of follow-up, an average annual rate of 3.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/13\">",
"     13",
"    </a>",
"    ]. The annual rate of MI or death from CHD was significantly lower for women with no risk factors than for women with five or more risk factors (1.3 versus 8.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lipoprotein risk factors for CHD are somewhat different in women compared to men.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low HDL, rather than high LDL cholesterol, is more predictive of coronary risk in women [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lipoprotein(a) is a determinant of CHD (manifested as angina or MI) in premenopausal women and postmenopausal women under age 66 (odds ratio 5.1 and 2.4, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The total cholesterol concentration appears to be associated with CHD only in premenopausal women or at very high levels (&gt;265",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [6.9",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Triglycerides appear to uniquely influence coronary risk in older women [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/14,15,18\">",
"       14,15,18",
"      </a>",
"      ], especially at levels above 400",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.5",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relative predictive value of the different lipid parameters was evaluated in a prospective analysis from the Women's Health Study of over 15,600 initially healthy women &ge;45 years of age who were followed over a 10-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/19\">",
"     19",
"    </a>",
"    ]. The total cholesterol to HDL-C ratio was most highly predictive of cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/19\">",
"     19",
"    </a>",
"    ]. Comparing women in the highest and lowest quintiles for each test, the different lipid parameters were associated with the following hazard ratios (HR) for future cardiovascular events after adjusting for age, smoking status, blood pressure, diabetes, and body mass index:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol to HDL-C ratio &mdash; HR 3.81",
"     </li>",
"     <li>",
"      Apolipoprotein B100 to HDL-C &mdash; HR 3.56",
"     </li>",
"     <li>",
"      LDL-C to HDL-C &mdash; HR 3.18",
"     </li>",
"     <li>",
"      Apolipoprotein B100 to apolipoprotein A-I &mdash; HR 3.01",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal quintile values for risk were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol to HDL-C ratio &mdash; less than 3.2 (median 2.8)",
"     </li>",
"     <li>",
"      Apolipoprotein B100 to HDL-C &mdash; less than 1.4 (median 1.1)",
"     </li>",
"     <li>",
"      LDL-C to HDL-C &mdash; less than 1.8 (median 1.5)",
"     </li>",
"     <li>",
"      Apolipoprotein B100 to apolipoprotein A-I &mdash; less than 0.54 (median 0.46)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is therefore recommended that every woman over age 20 should have a fasting lipid profile measured [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/11\">",
"     11",
"    </a>",
"    ]. Lipoprotein(a) and apolipoprotein B and A-I levels should be measured if the standard profile is normal in women with premature CHD (less than 60 years of age). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data from prospective primary prevention studies are lacking in women, current practice is to treat high-risk women in the same fashion as men. Meta-analysis of the clinical studies which have included women have shown that lipid-altering medications have similar effects in women and men on both the lipid profiles and the reduction in CHD events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Secondary intervention trials aimed at regression of CHD have shown that, compared to men, women may have increased regression of coronary lesions and a similar improvement in survival with intensive lipid-lowering [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Scandinavian",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       Simvastatin",
"      </a>",
"      Survival Study included 827 women with MI or angina (19 percent of the total cohort) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. Women who received simvastatin had equivalent reductions to men in serum total and LDL cholesterol (30 percent), major coronary events (34 percent), and the need for revascularization (49 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/23\">",
"       23",
"      </a>",
"      ]. There was a nonsignificant trend toward reduction in CHD mortality in women.",
"     </li>",
"     <li>",
"      In the CARE trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      in survivors of myocardial infarction without high cholesterol, women showed a significantly greater reduction in major cardiovascular events when compared with men (46 versus 20 percent) (",
"      <a class=\"graphic graphic_figure graphicRef72888 \" href=\"UTD.htm?10/54/11118\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the REVERSAL trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       pravastatin",
"      </a>",
"      in patients with angiographic coronary disease, 28 percent (140) of the study subjects were women [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/25\">",
"       25",
"      </a>",
"      ]. In a prespecified analysis, the progression of atheroma volume seen with pravastatin, and the regression of atheroma volume seen with atorvastatin, were more pronounced among women than among men. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'REVERSAL trial'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A family history of premature CHD is an independent predictor of coronary risk in women. It is also found more commonly in women than in men with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes mellitus is an important predictor of CHD risk and prognosis in women and men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/14,26-30\">",
"     14,26-30",
"    </a>",
"    ]. In a study from Finland, patients with type 2 diabetes without a prior infarction were at the same risk for myocardial infarction (20 and 19 percent, respectively) and coronary mortality (15 versus 16 percent) as nondiabetic patients with a prior MI (",
"    <a class=\"graphic graphic_figure graphicRef80251 \" href=\"UTD.htm?34/1/34845\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/31\">",
"     31",
"    </a>",
"    ]. The risk of infarction was greatest in diabetics with a prior MI and lowest in nondiabetic patients without a prior MI (45 and 4 percent, respectively). These findings were independent of other risk factors such as total cholesterol, hypertension, and smoking.",
"   </p>",
"   <p>",
"    Based upon such observations, diabetes was considered a CHD risk equivalent for both men and women in the 2002 National Cholesterol Education Program report, thereby elevating it to the highest risk category [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H6#H6\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Myocardial infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in CHD risk in patients with diabetes is greater in women than in men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/27,29,30\">",
"     27,29,30",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a meta-analysis of 37 studies of almost 450,000 patients with type 2 diabetes: the summary relative risk for fatal CHD in patients with diabetes was 3.5 in women and 2.1 in men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/29\">",
"     29",
"    </a>",
"    ]. The excess risk is at least in part due to diabetes being more commonly accompanied by other cardiovascular risk factors in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes appears to confer greater prognostic information in women than any of the other traditional cardiac risk factors. In a study of women presenting with chest pain, for example, diabetes was the only risk factor that distinguished between those with and those without angiographic CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Impaired glucose tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the risk associated with overt diabetes, there appears to be a graded rise in cardiovascular risk with increasing degrees of glucose intolerance below the definition of overt diabetes, as well as with increasing levels of hemoglobin A1c (HbA1c) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to these observations for new onset cardiovascular disease, impaired glucose tolerance may not be a risk factor for adverse cardiovascular outcomes in postmenopausal women with known CHD. This was illustrated in a report from the HERS trial of 2763 such women who were followed for 6.8 years; outcomes were assessed according to the presence or absence of impaired fasting glucose (IFG) at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/28\">",
"     28",
"    </a>",
"    ]. Using the 2003 definition (IFG 100 to 125",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.6 to 6.0",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    IFG was not predictive of risk of CHD, stroke, transient ischemic attack, and heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of diabetes mellitus\", section on 'ADA criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Smoking has been associated with one-half of all coronary events in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Furthermore, coronary risk is elevated even in women with minimal use (relative risk 2.4 for 1.4",
"    <span class=\"nowrap\">",
"     cigarettes/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/14,36\">",
"     14,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cessation of smoking in women is associated with a rapid reduction in the risk of MI. In a case control study of 910 patients with a first episode of myocardial infarction, for example, the relative risk was 3.6 among current smokers versus 1.2 in ex-smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/37\">",
"     37",
"    </a>",
"    ]. Most of the increased risk induced by smoking dissipates within two to three years of cessation of smoking. The relative risk in women who had not smoked for three or more years was indistinguishable from that in women who had never smoked. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"     \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of hypertension reaches 70 to 80 percent in women above age 70 (",
"    <a class=\"graphic graphic_figure graphicRef58221 \" href=\"UTD.htm?18/46/19182\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/38\">",
"     38",
"    </a>",
"    ]. Although the incidence of hypertensive complications is generally lower in women than in men, hypertension is still a strong predictor of cardiovascular risk. Among older adults, for example, hypertension in women (compared to men) is both a stronger predictor of coronary risk and is more commonly seen in those with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/14,26\">",
"     14,26",
"    </a>",
"    ]. This increase in risk is also seen in premenopausal women in whom the presence of hypertension is associated with up to a 10 fold increase in coronary mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Hypertension also increases the risk of cardiovascular events in women who have known CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial therapy in hypertensive women is similar to that in men and should begin with lifestyle modification followed, if necessary, by the administration of antihypertensive drugs. Initial first-line therapy consists or a low-dose thiazide diuretic, an angiotensin converting enzyme inhibitor (ACE inhibitor) or angiotensin II receptor blocker (ARB), or a long-acting calcium channel blocker (most often a long-acting dihydropyridine) added if further therapy is needed. Some patients, however, have specific indications or contraindications to the use of particular drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of obesity as a coronary risk factor was demonstrated in the prospective cohort Nurses' Health Study of over 115,000 middle-aged women followed for eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Body weight and mortality were directly related with a relative risk of death from CHD of 4.1 and from all causes of 2.2 in women with a body mass index (BMI) &ge;32",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    compared to lean women with a body mass index below 20",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/43\">",
"     43",
"    </a>",
"    ]. The increase in risk associated with obesity was independent of diabetes, although the two disorders may be closely linked in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/14\">",
"     14",
"    </a>",
"    ]. Abdominal or central obesity (waist-hip ratio of above 0.9) is more predictive than simple body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/14,44,45\">",
"     14,44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=see_link\">",
"     \"Obesity and weight reduction in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increase in risk is also seen with increasing weight within the \"normal\" range, but is most pronounced with obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/43,45,46\">",
"     43,45,46",
"    </a>",
"    ]. Using a BMI less than 21",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    as a reference in the Nurses' Health Study, the adjusted relative risk for CHD was 1.19 at a BMI of 21 to 22.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    1.46 at 23 to 24.9",
"    <span class=\"nowrap\">",
"     kg/m2,",
"    </span>",
"    2.06 at 25 to 28.9",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    (considered overweight but not obese), and 3.56 at a BMI &ge;29",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/43\">",
"     43",
"    </a>",
"    ]. The effect of weight gain is independent of the risk associated with physical inactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight gain after age 18 is also a graded risk factor, even if the BMI is less than 25",
"    <span class=\"nowrap\">",
"     kg/m2.",
"    </span>",
"    A similar graded relationship was noted in a report of 8373 Finnish women followed for 15 years (aged 30 to 59 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/46\">",
"     46",
"    </a>",
"    ]. For each increase in body weight of approximately 1 kg the risk of coronary mortality increased by 1 to 1.5 percent. A substantial part of this risk was mediated through the link between body weight and blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=see_link\">",
"     \"Obesity and weight reduction in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No controlled clinical trial has demonstrated that voluntary weight loss alone has any effect upon long-term outcomes in women, such as total mortality or CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/47\">",
"     47",
"    </a>",
"    ]. Nevertheless, recommendations from the AHA suggest a target BMI of less than 25",
"    <span class=\"nowrap\">",
"     kg/m2",
"    </span>",
"    (less than 110 percent of desirable body weight) and a waist circumference less than 35 inches [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although obesity is associated with an increased cardiac mortality and weight loss is beneficial, weight cycling (repeated weight loss and weight gain) increases the risk of CHD death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. As an example, one study of 33,760 women found that the six-year coronary mortality was highest in women with the greatest amount of weight change compared to those without weight cycling (relative risk 1.67) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/49\">",
"     49",
"    </a>",
"    ]. The mechanism for the increase in mortality may be related, in part, to a significant reduction in HDL cholesterol concentration with each cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Metabolic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral or abdominal obesity is associated with insulin resistance and an array of metabolic and hemodynamic disorders, including hyperinsulinemia, atherogenic blood lipid changes, hypertension, and type 2 diabetes. This constellation of findings has been called the metabolic syndrome, insulin resistance syndrome, or syndrome X. Guidelines from the 2001 National Cholesterol Education Program (Adult Treatment Panel [ATP] III) suggest that the clinical identification of the metabolic syndrome should be based upon the presence of any",
"    <strong>",
"     three",
"    </strong>",
"    of the following traits [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Central obesity as measured by waist circumference (men &mdash; greater than 40 inches [102 cm]; women &mdash; greater than 35 inches [89 cm])",
"     </li>",
"     <li>",
"      Fasting blood triglycerides greater than or equal to 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Low blood HDL cholesterol (men &mdash; less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.04",
"      <span class=\"nowrap\">",
"       mmol/L];",
"      </span>",
"      women &mdash; less than 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.30",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Blood pressure greater than or equal to",
"      <span class=\"nowrap\">",
"       130/85",
"      </span>",
"      mmHg",
"     </li>",
"     <li>",
"      Fasting glucose greater than or equal to 110",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The metabolic syndrome is associated with a significant increase in the subsequent risk of cardiovascular events in both men and women. The largest analysis of this association was performed on data from NHANES III [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/52\">",
"     52",
"    </a>",
"    ]. Of 15,922 participants, 1098 (6.9 percent) had a history of MI or stroke. After adjusting for race, age, and history of cigarette smoking, there was a significant association between the metabolic syndrome and MI or stroke (odds ratio [OR] 2.1), which was comparable for both men (OR 1.9) and women (OR 2.2).",
"   </p>",
"   <p>",
"    An analysis of the cardiovascular risk of the metabolic syndrome in women was also performed using data from the Women's Ischemia Syndrome Evaluation (WISE) study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/53\">",
"     53",
"    </a>",
"    ]. Among 755 women referred for coronary angiography, 25 percent had the metabolic syndrome at study entry. At four years of follow-up, women with the metabolic syndrome had a significantly lower rate of survival (94 versus 98 percent) and freedom from major adverse cardiovascular events (88 versus 94 percent). In another analysis from the WISE study, the metabolic syndrome, but not BMI alone, was significantly associated with the subsequent three-year risk of death or major adverse cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dietary fat intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it has been recommended that a low-fat, high carbohydrate diet or a low-fat, vegetarian diet is a way to reduce the risk for CHD by reducing serum concentrations of LDL, such a diet also reduces the concentration of HDL and raises that of triglycerides [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/55\">",
"     55",
"    </a>",
"    ]. It is likely that specific types of fat may be of importance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link\">",
"     \"Dietary fat\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Nurses' Health Study prospectively evaluated 80,082 women age 34 to 59 who were free of CVD and hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The following findings were noted with respect to fat intake:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of CHD was increased by 17 percent by each 5 percent increase in energy intake from saturated fat and by 93 percent by each 2 percent increment in energy intake from trans-unsaturated fat",
"     </li>",
"     <li>",
"      The risk of CHD was reduced by 19 percent by each 5 percent increment of energy from monounsaturated fat and by 38 percent by each 5 percent increment in polyunsaturated fat",
"     </li>",
"     <li>",
"      Women with a higher intake of fruits, vegetables, legumes, fish, poultry, and whole grains (prudent diet, median fiber intake 26",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      and lower intake of red and processed meats, sweets, fried foods, and refined grains had a significantly lower risk of CHD compared to those with the opposite dietary intake (median fiber intake 13",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      (adjusted relative risk for total CVD and myocardial infarction 0.79 and 0.68) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/57,58\">",
"       57,58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=see_link\">",
"       \"Healthy diet in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It was estimated that the risk of CHD would be reduced by 42 percent if 5 percent of energy from saturated fat were replaced with energy from unsaturated fats and by 53 percent if 2 percent of energy from trans fat was replaced by energy from unhydrogenated, unsaturated fat.",
"   </p>",
"   <p>",
"    Although a low intake of saturated fat appears to reduce CHD risk, such a diet may be associated with an increased risk of intraparenchymal hemorrhagic stroke, primarily in hypertensive women (relative risk 3.66 compared to those with higher saturated fat intake in the Nurses' Health Study); there was no relationship with other stroke subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link\">",
"     \"Clinical diagnosis of stroke subtypes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sedentary lifestyle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although women tend to be less physically active than men, higher fitness and activity levels in women as in men are predictive of freedom from all causes of mortality, CHD, and stroke. In addition, healthy women also benefit from light to moderate exercise. The data supporting these conclusions are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link&amp;anchor=H6#H6\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\", section on 'Relation to exercise'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\", section on 'Relation to fitness'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased coronary risk in patients with end-stage renal disease has been well described, but there is also evidence that mild to moderate renal dysfunction is associated with an increase in CHD risk. Practice guidelines from the National Kidney Foundation and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association task force have recommended that chronic kidney disease be considered a CHD risk equivalent in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of this effect was illustrated in the Atherosclerosis Risk in Communities (ARIC) study of over 15,000 randomly chosen subjects, 55 percent of whom were women. A minor degree of renal dysfunction, as assessed by the Modified Diet in Renal Disease formula, was noted in nearly 50 percent of participants, with 3 percent exhibiting severe dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/62\">",
"     62",
"    </a>",
"    ]. When decreasing renal function was assessed as a continuous variable, each 10",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 decrease in the glomerular filtration rate (GFR) correlated independently with a five percent higher cardiovascular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;CHD is unusual in premenopausal women, particularly in the absence of other risk factors (",
"    <a class=\"graphic graphic_figure graphicRef57061 \" href=\"UTD.htm?32/28/33229\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/4\">",
"     4",
"    </a>",
"    ]. In comparison, the NCEP recognizes the postmenopausal state as a risk factor for CHD, assigning it the same weight as male sex [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/17\">",
"     17",
"    </a>",
"    ]. Hormonal status may also influence CHD risk in males; men with a common variant in the estrogen receptor alpha gene have an increased risk of MI compared to those without the variant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early natural menopause (&le;44 years of age) has been associated with an increase in the risk of cardiovascular disease in two large epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. In one, this effect was limited to current smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/64\">",
"     64",
"    </a>",
"    ], while the second study only included women who never smoked [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are conflicting on whether the type of menopause (surgical or natural) affects cardiovascular risk. In a 1987 report from the Nurses' Health Study, bilateral oophorectomy, but not natural menopause, was associated with an excess risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/66\">",
"     66",
"    </a>",
"    ]. However, adjustments were only made for age and smoking, not for other major cardiovascular risk factors. Furthermore, a later study of healthy, postmenopausal women (age 46 to 81) who were not on hormone therapy found that carotid artery intima-media thickness, a marker of subclinical atherosclerosis, was positively associated with years since menopause, but not with the type of menopause (natural versus oophorectomy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations do not prove that menopause itself is a risk factor for CHD. Although the incidence rises dramatically over time after menopause, there is also a marked increase in men with age (",
"    <a class=\"graphic graphic_figure graphicRef57061 \" href=\"UTD.htm?32/28/33229\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/4\">",
"     4",
"    </a>",
"    ]. An important contributing factor is that postmenopausal women who develop CHD have an increased burden of cardiovascular risk factors compared to those who do not [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with this hypothesis is the observation that postmenopausal endogenous hormone concentrations may not be a significant risk factor after adjustment for other variables. This was suggested by an analysis from the Women's Health Study in which 200 postmenopausal women who had CHD were matched with controls who remained free of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/69\">",
"     69",
"    </a>",
"    ]. Among women who were not taking hormone replacement therapy (HRT), those with a low serum sex hormone binding globulin concentration or a high free androgen index were at increased risk of cardiac events. However, this correlation was not significant after adjustment for body mass index and other cardiovascular risk factors.",
"   </p>",
"   <p>",
"    A second finding consistent with menopause not being directly responsible for the increase in CHD risk after menopause is the lack of benefit from HRT in the Women's Health Initiative (WHI), mostly of primary prevention, and in the HERS trials of secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. Estrogen-progestin replacement had no cardioprotective effect and may have produced harm (",
"    <a class=\"graphic graphic_figure graphicRef76930 graphicRef62591 \" href=\"UTD.htm?5/30/5615\">",
"     figure 5A-B",
"    </a>",
"    ). As a result, HRT cannot be recommended to reduce CHD risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of hysterectomy as a predictor of cardiovascular risk was assessed in a report from the Women's Health Initiative Observational Study of almost 90,000 postmenopausal women, approximately 40 percent of whom had undergone hysterectomy with or without oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/68\">",
"     68",
"    </a>",
"    ]. The women with hysterectomy, regardless of oophorectomy status, had a significant increase in total mortality and fatal and nonfatal cardiovascular disease. However, these women, compared to those without hysterectomy, also were significantly more likely to have hypertension, diabetes, hypercholesterolemia, obesity, and less education and were significantly less likely to exercise.",
"   </p>",
"   <p>",
"    After adjustment for these and other variables, the effect of hysterectomy with or without oophorectomy was reduced and no longer significant. This observation is consistent with the findings in the previous section suggesting that menopause itself may not be an independent risk factor for CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Oral contraceptives",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that low-dose oral contraceptive (OC) use increases the risk of CVD in women under age 30 or in nonsmoking women without other risk factors. The cardiovascular effects of OCs are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence correlating the number of pregnancies with the risk of CHD. In an analysis of data from the Framingham Heart Study and the NHEFS study, the rates of CHD were higher for multigravid women than for women who had never been pregnant, although this finding was statistically significant only for women with six or more pregnancies (20 versus 32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/73\">",
"     73",
"    </a>",
"    ]. Most, although perhaps not all, of this effect may be accounted for by lifestyle risk factors found to be associated with child-rearing, including smoking, physical inactivity, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In primigravid women, development of early-onset preeclampsia may predict remote cardiovascular events (eg, hypertension, ischemic heart disease, stroke). In contrast,",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    occurring late in gestation in primigravid women does not appear to be associated with remote cardiovascular risk. Review of all of a woman's pregnancies is necessary to define her long-term risk accurately. Those with early onset severe preeclampsia, recurrent preeclampsia, gestational hypertension, or preeclampsia with onset as a multipara appear to be at increased risk of cardiovascular disease later in life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Excess alcohol intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol intake above two drinks per day is associated with an increase in the incidence of hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link&amp;anchor=H8#H8\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\", section on 'Hypertension'",
"    </a>",
"    .) In comparison, mild to moderate alcohol intake may have a cardioprotective effect in men. However, the issue is complicated in women by a potential increase in the risk for breast cancer.",
"   </p>",
"   <p>",
"    In an attempt to estimate the overall effect of alcohol in women, a prospective study was conducted among 85,709 middle-aged women (34 to 59 years) without a history of CVD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/75\">",
"     75",
"    </a>",
"    ]. Over a 12-year follow-up period, the relative risk of death in drinkers compared with nondrinkers was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0.83 with one to three drinks per week",
"     </li>",
"     <li>",
"      0.88 with three to 18 drinks per week",
"     </li>",
"     <li>",
"      1.19 with greater than 18 drinks per week",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Light to moderate drinking was associated with a decreased risk of death from CVD; heavier drinking was associated with an increased mortality from other causes, particularly breast cancer and cirrhosis. The benefit associated with light to moderate drinking was most apparent among women with risk factors for CHD and those 50 years of age or older. In a Nurses' Health Study report, the benefit of moderate drinking was most pronounced in women who also had a high intake of folate (",
"    <a class=\"graphic graphic_figure graphicRef51335 \" href=\"UTD.htm?5/7/5247\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Markers of inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Women's Health Study found that serum C-reactive protein (CRP) was a strong independent risk factor for CVD that added to the predictive value of other factors, such as serum total cholesterol, and that may have greater predictive value than serum LDL-cholesterol (",
"    <a class=\"graphic graphic_figure graphicRef62229 \" href=\"UTD.htm?17/41/18064\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"     \"C-reactive protein in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=see_link\">",
"     \"Screening for cardiovascular risk with C-reactive protein\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The baseline white blood cell count is also a predictor of cardiovascular events as illustrated in a report of postmenopausal women from the Women's Health Initiative Observational Study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/80\">",
"     80",
"    </a>",
"    ]. Women in the top quartile (WBC count 6700 to",
"    <span class=\"nowrap\">",
"     15,000/&micro;L)",
"    </span>",
"    compared to those in the lowest quartile had, after adjustment, a two-fold increase in risk of coronary mortality and 40 to 50 percent increases in nonfatal MI and stroke. In multivariable models, the WBC count was an independent predictor of risk that was comparable in magnitude to serum CRP.",
"   </p>",
"   <p>",
"    Other markers of inflammation, such as serum amyloid A and interleukin-6, also were significantly associated with an increased risk for a cardiovascular event (death, nonfatal myocardial infarction, stroke, or the need for revascularization) in the Women's Health Study [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/78,81\">",
"     78,81",
"    </a>",
"    ]. Measurement of these markers increased the predictive values of models based only upon standard lipid screening, since one-half of all cardiovascular events occurred in women without hyperlipidemia. However, evaluating the strength of these relationships is difficult, and the quantitation of these predictors in estimating a woman's CHD risk is of unknown usefulness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Microalbuminuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microalbuminuria reflects vascular damage and may be a marker of early arterial disease. In a population-based cohort study of 12,239 postmenopausal women, for example, cardiovascular mortality was increased in those in the highest quintile of urinary albumin levels compared to those without detectable urinary albumin (13.2 versus 2.6 per 1000 years, age-adjusted rate ratio 4.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/82\">",
"     82",
"    </a>",
"    ]. This relationship was independent of diabetes and hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=see_link\">",
"     \"High albuminuria (microalbuminuria) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Hemostatic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevated plasma fibrinogen concentration increases the risk of developing CHD in women. In a study of 4860 women in the Scottish Heart Health Study followed for eight years, there were 35 CHD deaths and 148 nonfatal coronary events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/83\">",
"     83",
"    </a>",
"    ]. The mean plasma fibrinogen was significantly higher among women who experienced a fatal or nonfatal CHD event than among those who did not (2.6 versus 2.3",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    Women without coronary disease at baseline with a plasma fibrinogen in the top fifth of the study group (&gt;2.82",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    when compared to those in the bottom fifth (&le;1.90",
"    <span class=\"nowrap\">",
"     g/L),",
"    </span>",
"    had a trend toward increased risk of a fatal or nonfatal CHD event (adjusted hazard ratio 2.54). No such trend was seen among women with prior CHD (adjusted hazard ratio 1.20).",
"   </p>",
"   <p>",
"    The procoagulant state associated with factor V Leiden also may increase cardiovascular risk. Among young women with an acute myocardial infarction, the increase in risk may be limited to smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"     \"Activated protein C resistance and factor V Leiden\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Low bone density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low bone density at menopause may be an additional risk factor for CHD mortality. In one study, for example, each decrease of one standard deviation in bone mineral density measured soon after the menopause was associated with a 43 percent increase in mortality, primarily cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This relationship could be explained at least in part by cumulative exposure to estrogen. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Menopause'",
"    </a>",
"    above.) Women with the least estrogen exposure would be expected to have both lower bone mass and a higher risk of CHD. Nevertheless, it is too soon to begin recommending measurements of bone mass to estimate cardiovascular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Hyperhomocysteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum concentrations of homocysteine have been associated with an increased risk for CHD. This association has been demonstrated for women as well as men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One cause of hyperhomocysteinemia is low intake of folate and vitamin B6, which are cofactors for homocysteine metabolism. The Nurses' Health Study found a graded inverse association between higher intakes of folate and vitamin B6 and CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/76\">",
"     76",
"    </a>",
"    ]. The lowest risk was seen in women with an intake of folate above 400",
"    <span class=\"nowrap\">",
"     microg/day",
"    </span>",
"    and an intake of vitamin B6 above 3",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    which are well above the current recommended daily allowances (180 microg and 1.6",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Psychosocial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial and behavioral factors are associated with an increased risk and a worse prognosis of CHD in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/89\">",
"     89",
"    </a>",
"    ]. Lower socioeconomic status in men and particularly in women has consistently been associated with increased cardiovascular morbidity and mortality, but most of the increased risk appears to be due to psychosocial stress and lifestyle factors and, to a lesser extent, traditional risk factors of hypertension and hyperlipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H1267687#H1267687\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Socioeconomic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other risk factors which may impact a woman's health, such as endothelial dysfunction, collagen vascular disease, and asymmetrical dimethylarginine are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H10122097#H10122097\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     RISK ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessing the risk of CHD requires the synthesis of multiple risk factors into a multivariable profile. Three validated models are available for use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Framingham risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The model most frequently used is that developed by the Framingham Heart Study, which allows the sex-specific calculation of the risk of a coronary event within 10 years (",
"    <a class=\"graphic graphic_table graphicRef76742 \" href=\"UTD.htm?8/17/8478\">",
"     table 1",
"    </a>",
"    ). This model includes hypertension, age, smoking and hyperlipidemia, but not diabetes. A validation study found that the Framingham CHD predictor performed well for prediction of CHD events in white men and women and black men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/91\">",
"     91",
"    </a>",
"    ]. However, the Framingham score may both underestimate and overestimate risk among some other populations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Reynolds risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Reynolds risk score was developed and validated using data available in nearly 25,000 healthy women followed prospectively for incident CHD and stroke during a median of 10.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/92\">",
"     92",
"    </a>",
"    ]. This model included age, HbA1c with diabetes, current smoking, parental history of MI &lt;age 60 years, hypertension, hs-CRP and total and HDL cholesterol and reclassified into either higher or lower risk categories 40 to 50 percent of women thought to be at intermediate risk using the Framingham risk model.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     SCORE risk system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple models have been developed in an attempt to provide better predictive accuracy for European patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/73-77,93,94\">",
"     73-77,93,94",
"    </a>",
"    ]. SCORE, which is recommended in the 2007 European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice, included data on more than 200,000 patients pooled from cohort studies in 12 European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/57/28570/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Variables incorporated into the model included age, gender, systolic blood pressure, total cholesterol, HDL cholesterol, and cigarette smoking. The mean follow-up was 13 years, with the end-point being cardiovascular death. A unique aspect of SCORE is that separate risk scores were calculated for high-risk and low-risk regions of Europe. The predictive value of SCORE was high in each component study cohort.",
"   </p>",
"   <p>",
"    SCORE differs from the Framingham risk model (and others) in two important ways: it estimates the ten-year risk of any first fatal atherosclerotic event (eg, stroke or ruptured abdominal aneurysm), not just coronary heart disease-related deaths, and it estimates only cardiovascular disease mortality, not all cardiovascular events.",
"   </p>",
"   <p>",
"    The role of further risk assessment of women at intermediate risk using either coronary artery calcium scoring or measurement of carotid intimal-media thickness is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H10122097#H10122097\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=see_link\">",
"       \"Patient information: Coronary heart disease in women (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    Established cardiac risk factors in women are (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Cardiovascular risk factors in women'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Personal history of coronary heart disease (CHD)",
"     </li>",
"     <li>",
"      Age over 55",
"     </li>",
"     <li>",
"      Dyslipidemia: high low density lipoprotein",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low high density lipoprotein cholesterol",
"     </li>",
"     <li>",
"      Family history of premature CHD (first degree male relative under age 55 or a female under age 65)",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Peripheral artery disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some risk factors are more potent in women than in men:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Smoking has been associated with one-half of all coronary events in women.",
"     </li>",
"     <li>",
"      Diabetes appears to confer greater prognostic information in women than any of the other traditional cardiac risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assessment of risk is best accomplished using a synthesis of multiple risk factors into a multivariable profile using one of three validated models: Framingham risk score, Reynolds risk score or SCORE risk system. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Risk assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We make the following lifestyle recommendations for women, which are generally in accord with the 2007 American Heart Association guideline update on cardiovascular disease prevention in women:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552797\">",
"    <span class=\"h2\">",
"     For all women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate intensity physical activity for at least 30 minutes and for 60 to 90 minutes for weight management on most days of the week.",
"     </li>",
"     <li>",
"      Avoidance and cessation of cigarette smoking and avoidance of environmental cigarette smoke.",
"     </li>",
"     <li>",
"      Referral to a comprehensive",
"      <span class=\"nowrap\">",
"       risk-reduction/rehabilitation",
"      </span>",
"      program after recent acute coronary syndrome, coronary intervention, cerebrovascular event, or diagnosis of angina or peripheral artery disease. Women with chronic coronary or peripheral artery disease or heart failure with an LVEF below 40 percent are also candidates.",
"     </li>",
"     <li>",
"      Weight",
"      <span class=\"nowrap\">",
"       maintenance/reduction",
"      </span>",
"      to achieve a BMI of &lt;25",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      and a waist circumference &le;35 inches.",
"     </li>",
"     <li>",
"      Maintenance of a heart healthy diet. The addition of omega-3 fatty acids may be considered in women with established CHD or in women with high triglyceride levels.",
"     </li>",
"     <li>",
"      Treatment of hypercholesterolemia to primary prevention targets. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of hypertension. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of diabetes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link\">",
"       \"Overview of medical care in adults with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoidance of oral contraceptives in women who smoke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      81 mg daily can be considered in women &ge;65 years of age if blood pressure is controlled and the benefits of the prevention of ischemic stroke and MI outweigh the risk of gastrointestinal bleeding and in women &lt;65 years of age when the benefits of the prevention of ischemic stroke outweigh the risks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of primary prevention of coronary heart disease and stroke\", section on 'Aspirin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Possible referral for depression evaluation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552805\">",
"    <span class=\"h2\">",
"     For women at high risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women at high risk (Framingham risk score &gt;20 percent (",
"    <a class=\"graphic graphic_table graphicRef76742 \" href=\"UTD.htm?8/17/8478\">",
"     table 1",
"    </a>",
"    ), established CHD, other vascular disease, diabetes mellitus, or chronic kidney disease), we recommend the following additional measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of hypercholesterolemia to secondary prevention targets. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      therapy at a dose of 75 to 162",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of hypertension to achieve goal blood pressure, which is less than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg in all individuals, but lower in women with diabetes, chronic kidney disease, or established CVD. The data and specific goals are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"       \"What is goal blood pressure in the treatment of hypertension?\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      supplementation and antioxidant vitamins should not be used for primary or secondary prevention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"       \"Overview of homocysteine\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"       \"Nutritional antioxidants in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hormone replacement therapy is",
"      <strong>",
"       not",
"      </strong>",
"      recommended for the primary or secondary prevention of CVD. It has no cardioprotective effect and may produce harm (",
"      <a class=\"graphic graphic_figure graphicRef76930 graphicRef62591 \" href=\"UTD.htm?5/30/5615\">",
"       figure 5A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Menopause'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"       \"Postmenopausal hormone therapy and cardiovascular risk\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/1\">",
"      Eaker ED, Chesebro JH, Sacks FM, et al. Cardiovascular disease in women. Circulation 1993; 88:1999.",
"     </a>",
"    </li>",
"    <li>",
"     Higgins M, Thom T. Cardiovascular disease in women as a public health problem. In: Cardiovascular health and disease in women, Wenger NK, Speroff L, Packard B (Eds), Le Jacq Communications, Connecticut 1993. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/3\">",
"      Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation 2011; 123:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/4\">",
"      Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/5\">",
"      Roger VL, Jacobsen SJ, Pellikka PA, et al. Gender differences in use of stress testing and coronary heart disease mortality: a population-based study in Olmsted County, Minnesota. J Am Coll Cardiol 1998; 32:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/6\">",
"      Wang XL, Tam C, McCredie RM, Wilcken DE. Determinants of severity of coronary artery disease in Australian men and women. Circulation 1994; 89:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/7\">",
"      Hu FB, Stampfer MJ, Manson JE, et al. Trends in the incidence of coronary heart disease and changes in diet and lifestyle in women. N Engl J Med 2000; 343:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/8\">",
"      Lee AJ, Price JF, Russell MJ, et al. Improved prediction of fatal myocardial infarction using the ankle brachial index in addition to conventional risk factors: the Edinburgh Artery Study. Circulation 2004; 110:3075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/9\">",
"      Murabito JM, Evans JC, Larson MG, et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study. Arch Intern Med 2003; 163:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/10\">",
"      Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003; 108:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/11\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/12\">",
"      Winkleby MA, Kraemer HC, Ahn DK, Varady AN. Ethnic and socioeconomic differences in cardiovascular disease risk factors: findings for women from the Third National Health and Nutrition Examination Survey, 1988-1994. JAMA 1998; 280:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/13\">",
"      Vittinghoff E, Shlipak MG, Varosy PD, et al. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003; 138:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/14\">",
"      Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE. The primary prevention of coronary heart disease in women. N Engl J Med 1995; 332:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/15\">",
"      Miller VT. Lipids, lipoproteins, women and cardiovascular disease. Atherosclerosis 1994; 108 Suppl:S73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/16\">",
"      Orth-Gom&eacute;r K, Mittleman MA, Schenck-Gustafsson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/17\">",
"      Grundy SM. Guidelines for cholesterol management: recommendations of the National Cholesterol Education Program's Adult Treatment Panel II. Heart Dis Stroke 1994; 3:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/18\">",
"      Criqui MH, Heiss G, Cohn R, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993; 328:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/19\">",
"      Ridker PM, Rifai N, Cook NR, et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/20\">",
"      Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol 2012; 59:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/21\">",
"      Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/22\">",
"      Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/23\">",
"      Miettinen TA, Py&ouml;r&auml;l&auml; K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96:4211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/24\">",
"      Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998; 32:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/25\">",
"      Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/26\">",
"      Sullivan AK, Holdright DR, Wright CA, et al. Chest pain in women: clinical, investigative, and prognostic features. BMJ 1994; 308:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/27\">",
"      Zuanetti G, Latini R, Maggioni AP, et al. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993; 22:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/28\">",
"      Kanaya AM, Herrington D, Vittinghoff E, et al. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Ann Intern Med 2005; 142:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/29\">",
"      Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/30\">",
"      Hu G, Jousilahti P, Qiao Q, et al. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease. J Am Coll Cardiol 2005; 45:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/31\">",
"      Haffner SM, Lehto S, R&ouml;nnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229.",
"     </a>",
"    </li>",
"    <li>",
"     DeSanctis RW. Clinical manifestations of coronary artery disease: chest pain in women. In: Cardiovascular Health and Disease In Women, Wenger NK, Speroff L, Packard B (Eds), Le Jacq Communications, Connecticut 1993. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/33\">",
"      Singer DE, Nathan DM, Anderson KM, et al. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/34\">",
"      Blake GJ, Pradhan AD, Manson JE, et al. Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med 2004; 164:757.",
"     </a>",
"    </li>",
"    <li>",
"     Fried LP, Becker DM. Smoking and cardiovascular disease. In: Cardiovascular Health and Disease in Women, Douglas PS (Ed), Saunders, Philadelphia 1993. p.217.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/36\">",
"      Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/37\">",
"      Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990; 322:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/38\">",
"      Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/39\">",
"      Cornoni-Huntley J, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hypertension in the United States. The National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med 1989; 149:780.",
"     </a>",
"    </li>",
"    <li>",
"     Collin, L, Douglas PS. Acute myocardial infarction in women. In: Acute Myocardial Infarction, Gersh B, Rahimtoola S (Eds), Chapman and Hall, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/41\">",
"      Mason PJ, Manson JE, Sesso HD, et al. Blood pressure and risk of secondary cardiovascular events in women: the Women's Antioxidant Cardiovascular Study (WACS). Circulation 2004; 109:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/42\">",
"      Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995; 273:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/43\">",
"      Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995; 333:677.",
"     </a>",
"    </li>",
"    <li>",
"     Lobo RA. Hormones, hormone replacement therapy, and heart disease. In: Cardiovascular Health and Disease in Women, Douglas PS (Ed), Saunders, Philadelphia 1993. p.153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/45\">",
"      Li TY, Rana JS, Manson JE, et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation 2006; 113:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/46\">",
"      Jousilahti P, Tuomilehto J, Vartiainen E, et al. Body weight, cardiovascular risk factors, and coronary mortality. 15-year follow-up of middle-aged men and women in eastern Finland. Circulation 1996; 93:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/47\">",
"      Yanovski SZ, Bain RP, Williamson DF. Report of a National Institutes of Health--Centers for Disease Control and Prevention workshop on the feasibility of conducting a randomized clinical trial to estimate the long-term health effects of intentional weight loss in obese persons. Am J Clin Nutr 1999; 69:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/48\">",
"      Lissner L, Odell PM, D'Agostino RB, et al. Variability of body weight and health outcomes in the Framingham population. N Engl J Med 1991; 324:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/49\">",
"      Folsom AR, French SA, Zheng W, et al. Weight variability and mortality: the Iowa Women's Health Study. Int J Obes Relat Metab Disord 1996; 20:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/50\">",
"      Olson MB, Kelsey SF, Bittner V, et al. Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect: a report from the NHLBI-sponsored WISE study. Women's Ischemia Syndrome Evaluation Study Group. J Am Coll Cardiol 2000; 36:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/51\">",
"      Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/52\">",
"      Ninomiya JK, L'Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/53\">",
"      Marroquin OC, Kip KE, Kelley DE, et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome Evaluation. Circulation 2004; 109:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/54\">",
"      Kip KE, Marroquin OC, Kelley DE, et al. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004; 109:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/55\">",
"      Barnard ND, Scialli AR, Bertron P, et al. Effectiveness of a low-fat vegetarian diet in altering serum lipids in healthy premenopausal women. Am J Cardiol 2000; 85:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/56\">",
"      Hu FB, Stampfer MJ, Manson JE, et al. Dietary fat intake and the risk of coronary heart disease in women. N Engl J Med 1997; 337:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/57\">",
"      Fung TT, Willett WC, Stampfer MJ, et al. Dietary patterns and the risk of coronary heart disease in women. Arch Intern Med 2001; 161:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/58\">",
"      Liu S, Buring JE, Sesso HD, et al. A prospective study of dietary fiber intake and risk of cardiovascular disease among women. J Am Coll Cardiol 2002; 39:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/59\">",
"      Iso H, Stampfer MJ, Manson JE, et al. Prospective study of fat and protein intake and risk of intraparenchymal hemorrhage in women. Circulation 2001; 103:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/60\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/62\">",
"      Manjunath G, Tighiouart H, Ibrahim H, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/63\">",
"      Shearman AM, Cupples LA, Demissie S, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003; 290:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/64\">",
"      Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999; 159:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/65\">",
"      Mondul AM, Rodriguez C, Jacobs EJ, Calle EE. Age at natural menopause and cause-specific mortality. Am J Epidemiol 2005; 162:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/66\">",
"      Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/67\">",
"      Mack WJ, Slater CC, Xiang M, et al. Elevated subclinical atherosclerosis associated with oophorectomy is related to time since menopause rather than type of menopause. Fertil Steril 2004; 82:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/68\">",
"      Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 2005; 111:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/69\">",
"      Rexrode KM, Manson JE, Lee IM, et al. Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation 2003; 108:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/70\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/71\">",
"      Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/72\">",
"      Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/73\">",
"      Ness RB, Harris T, Cobb J, et al. Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med 1993; 328:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/74\">",
"      Lawlor DA, Emberson JR, Ebrahim S, et al. Is the association between parity and coronary heart disease due to biological effects of pregnancy or adverse lifestyle risk factors associated with child-rearing? Findings from the British Women's Heart and Health Study and the British Regional Heart Study. Circulation 2003; 107:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/75\">",
"      Fuchs CS, Stampfer MJ, Colditz GA, et al. Alcohol consumption and mortality among women. N Engl J Med 1995; 332:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/76\">",
"      Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/77\">",
"      Rifai N, Buring JE, Lee IM, et al. Is C-reactive protein specific for vascular disease in women? Ann Intern Med 2002; 136:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/78\">",
"      Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/79\">",
"      Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/80\">",
"      Margolis KL, Manson JE, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med 2005; 165:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/81\">",
"      Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/82\">",
"      Roest M, Banga JD, Janssen WM, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103:3057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/83\">",
"      Woodward M, Lowe GD, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study. Eur Heart J 1998; 19:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/84\">",
"      Tanis BC, Bloemenkamp DG, van den Bosch MA, et al. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 2003; 122:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/85\">",
"      von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999; 106:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/86\">",
"      Ridker PM, Manson JE, Buring JE, et al. Homocysteine and risk of cardiovascular disease among postmenopausal women. JAMA 1999; 281:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/87\">",
"      Knekt P, Alfthan G, Aromaa A, et al. Homocysteine and major coronary events: a prospective population study amongst women. J Intern Med 2001; 249:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/88\">",
"      Zylberstein DE, Bengtsson C, Bj&ouml;rkelund C, et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation 2004; 109:601.",
"     </a>",
"    </li>",
"    <li>",
"     Haynes SG, Czajkowski SM. Psychosocial and environmental correlates of heart disease. In: Cardiovascular Health and Disease in Women, Douglas PS (Ed), Saunders, Philadelphia 1993. p.269.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/90\">",
"      Wamala SP, Mittleman MA, Schenck-Gustafsson K, Orth-Gom&eacute;r K. Potential explanations for the educational gradient in coronary heart disease: a population-based case-control study of Swedish women. Am J Public Health 1999; 89:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/91\">",
"      D'Agostino RB Sr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/92\">",
"      Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/93\">",
"      Conroy RM, Py&ouml;r&auml;l&auml; K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/57/28570/abstract/94\">",
"      Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28:2375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1468 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28570=[""].join("\n");
var outline_f27_57_28570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CARDIOVASCULAR RISK FACTORS IN WOMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Impaired glucose tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Metabolic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dietary fat intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sedentary lifestyle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Oral contraceptives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Excess alcohol intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Markers of inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Microalbuminuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Hemostatic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Low bone density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Hyperhomocysteinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Psychosocial factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      RISK ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Framingham risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Reynolds risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SCORE risk system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H552797\">",
"      For all women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H552805\">",
"      For women at high risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1468|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/28/33229\" title=\"figure 1\">",
"      Incidence of myocardial infarction in men and women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/54/11118\" title=\"figure 2\">",
"      Pravastatin and MACE rates in men versus women CARE trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/1/34845\" title=\"figure 3\">",
"      Diabetes increases coronary mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/46/19182\" title=\"figure 4\">",
"      Prevalence of HTN in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/38/5742\" title=\"figure 5A\">",
"      Womens health initiative risk of heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/34/23085\" title=\"figure 5B\">",
"      HRT and CHD HERS II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/7/5247\" title=\"figure 6\">",
"      Folate and alcohol intake and CHD risk in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/41/18064\" title=\"figure 7\">",
"      CRP, cholesterol, and future CV event risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/17/8478\" title=\"table 1\">",
"      Framingham ATPIII score women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31641?source=related_link\">",
"      Healthy diet in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20745?source=related_link\">",
"      High albuminuria (microalbuminuria) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11258?source=related_link\">",
"      Management of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34630?source=related_link\">",
"      Obesity and weight reduction in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5576?source=related_link\">",
"      Overview of primary prevention of coronary heart disease and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/54/7012?source=related_link\">",
"      Patient information: Coronary heart disease in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34665?source=related_link\">",
"      Screening for cardiovascular risk with C-reactive protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_57_28571="AS clinical assessment";
var content_f27_57_28571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76447&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment of disease impact in ankylosing spondylitis in clinical practice",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Domain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Instrument",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Function",
"       </td>",
"       <td>",
"        BASFI, file://www.spondylitis.org",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain",
"       </td>",
"       <td>",
"        VAS, last week, spinal pain, at night, caused by AS and VAS, last week, peripheral joint pain caused by AS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal mobility",
"       </td>",
"       <td>",
"        Chest expansion, modified Sch&ouml;ber index, and occiput to wall distance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient global",
"       </td>",
"       <td>",
"        VAS, last week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiffness",
"       </td>",
"       <td>",
"        Duration of morning stiffness, spine, last week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral joints and entheses",
"       </td>",
"       <td>",
"        Number of swollen joints (44 joint count) validated enthesis index*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute phase reactants",
"       </td>",
"       <td>",
"        ESR or CRP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue",
"       </td>",
"       <td>",
"        VAS",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BASFI: Bath ankylosing spondylitis functional index; VAS: visual analog scale (0 - 100 mm); ESR: erythrocyte sedimentation rate; CRP: C reactive protein",
"    </div>",
"    <div class=\"reference\">",
"     * Braun, J, Pham, T, Sieper, J, et al. Ann Rheum Dis 62:127, 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28571=[""].join("\n");
var outline_f27_57_28571=null;
var title_f27_57_28572="HBV immunization management of preterm infants";
var content_f27_57_28572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hepatitis B immunization management of preterm infants weighing &lt;2000 g, by maternal hepatitis B surface antigen (HBsAg) status",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Maternal HBsAg status",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Positive",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Administer HBIG + single-antigen hepatitis B vaccine within 12 hours of birth",
"         </li>",
"         <li>",
"          Do not count the birth dose as part of the vaccine series",
"         </li>",
"         <li>",
"          Administer three additional hepatitis B vaccine doses with",
"          <br/>",
"          - Single-antigen vaccine at ages 1, 2 to 3, and 6 months,",
"          <em>",
"           or",
"          </em>",
"          <br/>",
"          - Hepatitis B-containing combination vaccine at ages 2, 4, and 6 months (Pediarix) or 2, 4, and 12 to 15 months (Comvax)*",
"         </li>",
"         <li>",
"          Test for HBsAg and antibody to HBsAg 1 to 2 months after completion of &gt;3 doses of a licensed hepatitis B vaccine series (ie, at age 9 to 18 months, generally at the next well-child visit). Testing should not be performed before age 9 months nor within four weeks of the most recent vaccine dose.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Unknown",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Administer HBIG + single-antigen hepatitis B vaccine within 12 hours of birth",
"         </li>",
"         <li>",
"          Test mother for HBsAg",
"         </li>",
"         <li>",
"          Do not count the birth dose as part of the vaccine series",
"         </li>",
"         <li>",
"          Administer three additional hepatitis B vaccine doses with",
"          <br/>",
"          - Single-antigen vaccine at ages 1, 2 to 3, and 6 months,",
"          <em>",
"           or",
"          </em>",
"          <br/>",
"          - Hepatitis B-containing combination vaccine at ages 2, 4, and 6 months (Pediarix) or 2, 4, and 12 to 15 months (Comvax)*",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Negative",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Delay first dose of hepatitis B vaccine until age 1 month or hospital discharge",
"         </li>",
"         <li>",
"          Complete the hepatitis B vaccine series with",
"          <br/>",
"          - Single-antigen vaccine at ages 2 months and 6 to 18 months,",
"          <em>",
"           or",
"          </em>",
"          <br/>",
"          - Hepatitis B-containing combination vaccine at ages 2, 4, and 6 months (Pediarix) or 2, 4, and 12 to 15 months (Comvax)*",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HBsAg: hepatitis B surface antigen; HBIG: hepatitis B immune globulin.",
"     <br/>",
"     * The final dose in the vaccine series should not be administered before age 24 weeks (164 days).",
"    </div>",
"    <div class=\"reference\">",
"     This table is a replacement for Table 4 from: Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR 2005; 54:1. A list of the major errata appeared in MMWR on December 7, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28572=[""].join("\n");
var outline_f27_57_28572=null;
var title_f27_57_28573="Upper airway resistance";
var content_f27_57_28573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58289&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upper airway resistance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 243px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Averaged data from a group of non-snorers. Plotted is upper airway resistance versus percent time of inspiration in wakefulness (solid line) and non-REM sleep (dashed line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kay, A, Trinder, J, Kim, Y, J Appl Physiol 1995; 79:411.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28573=[""].join("\n");
var outline_f27_57_28573=null;
var title_f27_57_28574="Lyme cases by age and sex";
var content_f27_57_28574=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    Confirmed Lyme disease cases by age and sex - United States, 2001 to 2010",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 384px; background-image: url(data:image/gif;base64,R0lGODlhZAKAAcQAAP///wAzmQCZZgAAAIiIiERERCIiIjMzM+7u7lVVVZmZmd3d3WZmZru7u3d3dxEREaqqqszMzH9/fx8fHwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABkAoABAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wIgoGAwMFCCIFtQUnurYjvry5u7HFxqkMBAALD8oEBggIBsokz9HTANbSztDbx9/gowUKAAnUBAkl5iLo5efp69np4fT1mBHUBuQACgcl+rL8AeQncF8/ewgTPlrAYMTAgyQeFgwIQGIJCbUyahygsKPHOg2EiYjnYN4IkvCo/5V0J2KlC44fY2baSLOmzZs4c+KMYq1aN2wIBnC7NtSbNmwvZSq1BNNLUye+ahkY9gsAhAELqIoMBozYi6c8ci4dewbsFrNZCIgUgjbHgABw48ZtS7buWTB0rSTYNySvjbdy5fq1S5jKYMOGDs8AHBiu4sKQmzyOMtlO5a+N50befOWp2BoMGuK4TId0C8aNTXNe/cNzZscmGAzYt6BqbNE3VMfRrQJ1YN6sg48m4Vtw7AdTATiwXSK028RAimsWTl2J69dmGSR4AAHBAwa8GmQ8gMs5gmC4YgB3s/6EdNjV4xu5njl7sgLo1P5T5hy/iAPUwNAeGwOW8F4ABcqnoP97xL2G4G3ePdCAfgxlxF9DG+H2FXStOZjggiCKQF9qtwEAXja8JHBAVv45NwAEf3How4EfhrjgiL+VOIJ+BzgAQATY9EdeNgFuWEiNANBo45LPjaBkcxrq18ADAxwQZEML+HJAAzIgaQaSTzIp5mINYkeZjD2EOeaaSTm5ExRelgGmh2zWeRpeaIZFp518ohDnjHnuoGafhCaJ55HR7VlooX+mGagOgy5qZ6NhPeqWopLy6dmbQjjXm6WjYZppnZ4JYOqpp5pFgEZr0eBpCpSGMaeZo2pKHKq4qtrqDa/6CWpuotY6Zqm4pmqCfiOctwsCtR1QCwPODsCleLUMaR7/esT9+lewwjJJbLECqKpRSNQAWJuPq/LnT0QXAuAfAABmi2iHtHa75rfF6kqcRgzUlpV4skxVYS3tZigvIbPWZy+b+OZ67FovkuAvAADzM5WKLBYMI4PzzsjtwiA2jKq+wAxJAAETVzwLvD4C2W4BJhcZ66Ee1wvykiIbWwKyImRZbQMpw7TylFVeuYyWXDqpbQ2R9sbpzR/lbOrMn3ac5sd+Yg11PZvedKbVetrMQtNb20P1cGALqrUJZJdNz9m5LU1D2+6t7fYxcMeYNqR2l6nw3QrlzbTci/XtpOGAvyL43IR3iXiSjyfOik6UV265To2r9zjdknfuR8IkYia2/+ek/wF6jqL/Xfrqnyc6em+Rsy77Gqcbl3ros+dumeuqnxa77sCLUft0L/0e/PFdDA9f8a8j77ycvOPue/PPV0/z1dTXnb313Guh/IO3o979+E5FL/70vZOvPhbfT8b5+vBLZr7tzKcf//1PtC+g8fj3Xym99oPd9vxHwCDoL3z0K6ACi3DA+klvgRCMzvyIh74HRvCCgprg8ip4Pgx6EG01CyCs+PfBEioNgBYUoAhNyMKxaRB8DuxgC2e4ggZyMIE0zKGvUChDFaZQh0A0FA9xWEMSBlGBNhybEY9IwCQWcYBMLKETfdjDKM5wiiOEohWF5QCRUMsrJOCKVrrCHP8XDpGCStTiFiVVG9tU7ARHKQo24mikEP4wa2pco6R49kYTxKMdf0wJO0xiRjtWEY8r1GO3+DierETEIBMhSEUgWUfsJZJtS1SkmHiWrAMQcpIUsYhFSIARr51xg2m8pCYzxckdtQolLFGOIGVZybCp0m93JMtnVokDniVjGfEKihyHmY2fFKmGL3RfJsHxPl6uoI0E4weVBjCPqzhSjO4CIzbvdEoY3hCNhWmmM2/QSgl2U5l59Ig4x1mDvTAwmftLZ0fWyU7vwROB4CQMPevJvnvGkIj6XCY/5XfOeN5SJvscaBXa9zQRCRRvD1VoEtoHrqlhUp6Bi6hEj0DRipr/JaEZxehG4ZTMiobrogeNCT0bOtK+lNSjKM3lWFYq0paS6Zwm/ahGY0HTlNo0bjiFqYF2CoueyvSnkHopuHRaU7NtrqlIbZMhBZPTmB5Sl0/1aVRvOtW5VHWoUPUES6kI0Cwedat666pjvorLq67iPej0KVzRakCl5suqZW3FXPGJyiemZqx0raXasMPWw4W1E3v951xYCtfCBlY9dnUYWLVKisR+c61CbatXM/tYyAZ1qXjNpyssm8rUOBZy9TltZ7mpVgSdFqSiIK1fTctZh6a2tqtlrSVpC9rJnhUVsiXrZnurWcwSN7dS3e1vXkvUSgTXrLy9q2+pilvkVq21/wNg7mE58VxERleyxXVtda27Q+xql7Kj6K72bntc2353ZORNri3fq7PwepOneaTReZc73vgaKLLwnW5eJ5dfD+2Xuu31L8fMi1vYhkK9oTWudMOb3f4qWEQArq9h0RvbAhO2wR9O8IUPplwET3jDvz0FhAU83BO7l78iHjGGP+ti1HL4wdhhrIFBzN4ay3jGDE6wg0HRWB73GLwoNjGSf3zCINd4yJ8ospB3POUjB5jJJJ4vjJ/cXEpImcshBjN9LYrlLA/Wyhp+sVtV8eUl23jMJ2WxeGMs445W+cZEDrOb9WvkLbuZyXYWc4pN0eYrJ1nJhlZzi//840DvucuTKP90mt/s50RTetGWBnSGyWzfxSFC0pw+NKYnDeo4lxnIJR51qBUtWr3q2dJ8vnOlSQ3YqDoa1pCWRKmZiuZVX1rCj96uIm9N6lxHYtcRnrOgEV1sYeuR2L5eqSln8upm99rUolZ2sPHsTGhjm9V9Fe59mVLtaFN52ar+9q8dU+t6epvXg17xI5AtZ23j+trwnrWvFfruZMd1zfMut7pjjW5g3xvfP+13vf894GMLPN/MNjfCF67agSq80wYFuCPo3ekDpxviH0/4pgee1UEvguPZtre19U3yh4ucxtuOt7NN53KK9zniLZ94Sy+ecoa3Wtc17/jNQ25zOrt75CAPN3T/Gw4JlINb5RKHc9Khru6bpac7ZUG6vzPO9NK0O8IVljXLkx72ght80iAjwAN8tvYvaX3hXP+5ZUo+dn97/OxRl/rdPBmBARjgO26H+cFlzu00GLXuRTd72WOO+LL1SAFCccC6yMDzp/tc6Xig0bQpfHe857zxPa+4vRJgAF1AQPKBdzLju55tT0uB4Jl2+rqpTvbO0/5uV/E7vDQkvLdjnK+up8y5Yx/00A/d81NffKZBdvoFLMABEUh9qpG/deADAvZolz32V47z5IveXgqAWQQOwJcxVH72lx+3HrZfde0Pf/Ddt7uFhQX5Wpznk7Lyfc/jjvk7sB8t7ld84KZ8/9wXf25zAAAyAAiAetAjeAUod3IWfHDyfvsWgDrXerZHgPu2MD1yFQigItKnZQb4e4qlfnnwf+sFepbXeRr4eSp4MwzwALqQAEIRgmemd3BnfTRXbgAogOjHghn4fcKCANFSJelBefpnefxngplHge3ng+zngkQndEbXLQhAAA5AAEeIhA6Yd7+xea13fU7Ygxe4gsd3e4nHaAtzdVsIA10URmAEh7aBTdtUSNOHhlT4Z/I2BygIdkF4hi3offNXK2rHdo70Am0kEnTkE0RRTI24iLolglNofD62h3LQhxH4h2I3iWZYhbXCd34HeDLAM4GkDu8QS4B0ivJ1gy+Iif8UJoY8mIIjSImKp4k+xoEOAHlYOHkwwDOj5BCUJEqUtIp8A4VjKIsQWBrH6IdniIcY2IyBeDekZ3oMGAO+OIzAGErBiI0iUEo2kYQ/KGKWuBvLmInQCITnOIijkntTcQC85wKkqBKfBEv0KI+CVYxlGI6VOHPmV46cl46bSH1puHwL03zPF32jqIjGBADC5IhGsZCQaIeSKJB5SHyFhwau+IwBSZEaaXbOuDVY6AAiuTGIqBHUIEbWNEYqmU1lhExdKIWqRoYm9wYZOYC2uHoc2YlP9nU2sioa4SM+UE6tAY41uW4SmD/+2JE4mZNGeZPwx3oLUgAyaAAOMBA94E7/RHB+RTmOcLCVxviVOFiRT5mMINIjz6AcQMmFqjeWeCeTGneJSWmTAFmLc7mUTMgk7ngV0MKLvfeSgriPF1kWcdmUdcmW0TiQD8hu37gkVSkNtZCW5keUg8mVNDmZYBmWSsmWH6mPahgfuPB8x9SXa5mYUOeWUEmOsciMG7mZFoiZOkmQwgGaO+IAhxiZfil/gDmT7GGZ+RiFtVeYpKmBR5kKy0GSVxGa1zORrMmbutkGXtmbTgiTy3mZ+jacqICAJYCdDTiaXhhxpkmWcJma5riah/mP5OmUG0gd2jkC62mb3CmdpYmM/Td34mmeHlmemRmc6Fl11UGDSUMx1GSD/zwplvopjvwoPMzZitH5m+cJnPxJHVfxAAlQElRCku4Zhnw1nb32nfNZB8/pmpy5lPj5mpopnEvikxkBmRc6gEuooWPGoXdJnxsqny6qoNBJnd7JJPiQhQgpoB52ozMKdrAYpON5n+jYoEjamRhEdi06oiGafQcqKwk6iySamE7qm7ippBfEpBl6pVMKnqhJpPZpl14KpCBalFIkpF26nzBqnUzwoTZqplT6pAV6ix/EpSVYozmqpuY3oLRokWe6oKpppA7qpmWDp5elpzFJo4bapU1aXa0Zp5I6qXtKQ2SnYzi6qHyKoD/6ooy6n9JZpnJaqVc0qGTKpowqJ3RXnf+f6qChCqp/qaURxKCEmqSA+pZWcHisaqoleqS1+quwuaS8WqfACqWBuQS6Sqr52Z2cSJi22queOKvDyqxMCaenuVCrqqxy+axWCqtZGqxbOq3wKaqeuqlSmmNgSKdPOKrNGqlziqZ+4qeyQ6unWqipSnmCipjrGqiZqqjVOpk3IYS6Q6/Qyq37iqvY2q/xKa6xKqLeqq9tKrC5Q7DEWq+5ibCGka8EerDvqrHLOq6oyrDjQ7HU6q8LG4GqqrAmKrL6+qqu2rDGCqLOQ7Iga6/mihceW6Uc264566zFWrEx+4Izy7IbW7MXe60Zq7KQqrSA+LAbG7HqODs0C7NAW4H/UcpAPWutPNuv5Eqpmlqksiq1RPunBauHV5uVWful/8q1Tku2VpuPQwu2ZWuxZnus1pG29fmxVEutXduxebutdho8U/utcxu0SDsFWAqxrWqwLsu4ewu10Sq2clu1JbuyKPsV8sqKfiumeku43fqynruzTBm3Y1q4lNumTXq3THu0W8uuJtu3X1u6aIc8g9uyj3uveQo3ifu0i/uzfNu2Ogu5gQs8tVu0t3uz4hajt6m4Y6uzjeu7Rlu3Mku7zauu0XurgoGpdpu7ITu5leurdBu+htuspNu5thu6wkumquu6Jyu739u0oMu83vugglu9u+u2ovu668uvnAu44vu5/46Lvr0btvNqv3jbvz6rvhN1wOU6v3v7vP/7vqw7utTrwKF7veO7tnKVrskLu205wKb7u/HLu9Vbvv4bwhj8tvxLeCy8wrtqwecLw8YrwCVcwe6bwhIsvV7boa+4pjYrw/gLwSh8vEBcPcUbxER8w8m3hOn3ukvLvh7swU5soHBrw+Y7w/KrxNVXgk0sxZarxTEMxlhMwkX8PEfsvEl8xfung9z7w2KMxAa8ujo8pyacwENMw2WcrDwMx1msxmgcx1D8xNN7PGdsvWl8wsHJxI/qxn5syIDswtpqx7NLyI+8w+3byHqsvGOMv+l7x3nMwC/8xmOTubbyyXKMva3bwv+neb/BC8KUK8SvfMiSnJ7uIbGMUsmb28CijH6K7MMG28mxjMupHMqN3Bu2TCiFzMrqCsyV28tt/MuunMMOO8KcHM0DhxPH3CfJDMqR7K5gOo7KrLUaDMnjbMlfjMk92y3bfMoZrL9snKheLMjmDL6eTMa7rMzqLMzl3M0q68zw3L33zM37PMz8HMhRi8z6PMUT7M5cvMjQnNBRDLzLbM0P3KiBA9EAjc6dmr3pGs5qq9B0GcB9jMjSDK6Lss4GvdBezMQSLc4gPc0ibc8aXcW1gtLk/MEQzdLU3MoYDb8xXc09HbkIbcopPccE/c3sfLoUfcE2Pc9UfNObmc9EDdX/50zS46rTP83TU73D8czIVl3RW9PUuUzMX73Fl9XVD73VY33UA43Tak2+wiLWbH3JZZ2DXNzSH43WIQ29suzNFCwTX1QVdKhNcSiRs4zDOMzMVw18eP23hw3Wb93WdP3YTF0YfeSQcwSRC7mKfv3S7bzSjL3TEx3Uex3Bib3UYVwXl12KrK2KkUjZqa3VAY2uNYHamyzbM33Teh3Big3ZdvFFKwJKkiSMFMHZSV3SKuzUKt3YCNzZES3aLr3bJv0RRJgOxD3c3AgA3ljbke3Zyb3WsZvbym3Ukv3cWT3a3e2kdqEf9dgSs+QSr+3cGV3XMk3ffFzfsH3b+X3fQJ3e/9lsD7+0APFCRwS+2fF93KdN2qhc3vO933/s317t4I78EhysCgowTSYx2HNY2C4520W94N6dv9Kt1ApumMyty+JNx35y0JEh1wz+1OMN4iOO3CJ+4uD94sst2rDC4pDh4iHe23js4VQtzzfurzOe4BAu1FUdHz4+40A+0hLu0Y4t3z7N10Ge4nBdy0Ld4iVO4klO3iGO5ELO1TZe0EN+0EteHU3e4FSe4+cd3WWO47775Pq941ve411O43Te32Ne5Eve5qVdz3yO5X/NNjweTnku5oQ+2YDO27bN3/b94Pjd6NOdJIeuT4ne18e955I+6JE+4X0+13+O4B8VsHeO6P9f7uh5zumg7ulRLtBhrukfbuKnjumpHsKsDufQnddxHutX/ulSjuLyseYRTunfLepsTuqZ/uuvzra1bhfEntah7tbT/uOP3unADuuMruzea9HptexQbuw1vutTzu3V7uTX3uok7e2xBe6TvunpHuzC3uyue+SyfuYbmebUEe1zHu+8Tu7Nbe6Lju7uvqzs/mAFj9vZXu6z7uXnTs/BHO4Cv+42wu+qfuvHLucX//BVbtr3HuO0PrysYfG47u8Mj+/9nvD0jvIy3uv6Lhwk7/ADT+TIXuwTv/Ign/G+3u0Vr/K6Lu0zb/MNL8Jv/u9Fj8Bq7vNGn/IYr+cmX++9vu3/Qw/L9BscMe/0q/70LP/ZLh/1oz71JHvwRKb0J5/z4370AQ/2ZJ/2Ww/ABMzlTa/oC8/2Zi/3OH/j9s7s4k71Yh9laz/v4p7r2v71bU/0Vi7xas/zIXL1dh/4Wm/2gu/saA/4Nw9qfS9Wf0/Wdx/ec1/4kQ/1AE/5ie++l49YmW/mkP/4fk7zGh/yh//uo2/wPR/3H7/6MG77QN/5ZB76mr/3YT/7HJ/7m0/tQS/8vn/6nD/8Rn7p0I78xK/7qI/7TB/8gR7xsF/4fK8epDxazi/1nq/6Ne/mr1/800/+MP32ls78b9X9hJ/67M/6O0/9G2/+rl/pIvLf3E/7eg/v/+8PAoI4CgNwosAQsC07kLGZqq4Nx+Ocrvab62g13w9YEvaIuNyORwwsmcgn1HikJW/GprAblXXD4jG5bD6j0+q1mDv0fUnurHY7fcZF7ncdOKfmXWHhWf0R2g0eSt3BFTI2IjopOSZORqLQuQTuZRb5PfYtSkKKngUKsqWqrrK2up4YkpbCAlKOysp5Kc7yheaCtpzG4v7e+gYBe/J2KoNVHiMba9pi1n4mV13S7jpLN0ebUr+Ok5ebow1Pa/eqX3t/6+lauldzg9cT37MHi+/Do+KDFu+ZQID+hGHLRm/bvG7vEBJst8zeQHT9zmHMqJFVOn7rmCmcSNHgwX4gN//Jy1cxYMGOHnmV/GhtYUyaJ03OdMjypciGOmv+hDVgKFGiFzciTaoUCTaI70L+vEkTaNScxR7iHGlQKkxmTnfyrOrzKkOVW63qo0rWH9S1XteVlRh0Kd26GF221ce1p0pOWvHmJflW5t+EKJtmHau3cMSwbtGuBBv4LGOsU9Wmtat5M0fEhBVHZnu48WTAoy3bhBx671rMq1VTNms6cd+ULQ3Tlpt58GXOvn+bwfs1ru7FI/2Cjl3bc+rKkgMjl437823Spad3dU7csfHlzGECDy8ey3exyWdP5c1XYPTqT4eLhqvevHTS8Fk/Pm67+Gvtrve4RtJ4A4YnXG78Kcf/3n7c9Qdaewii15yDC/6TIITl5XcedkHNl2F9qM3VYWYEkriZgdS599xpkt2n2oMMWghjhBz6h193KW5X4YytidjghyzCFSCAJRJJ14kS/pgjdBReZ92KObZYo4tMRqmhfQfKuCGPUnLp3ZVBFhkmUkeud6GT8nXpJZAomvkemla6yaaOWnqoIIY34vhfGD0KKKafd93pY542CpamnV8iOeiUgcY4J6JlZnlmeoa2uSZ4fA75p6bjkEmfovoxumNamNKJJ38vOhpnopGqCuk/qDbZqqcMAkjqpree02mdlSr5pJClFgqnili+SiWxsVrqKrK9vplkfHIuaSyYuFLL/4auprI67KTCMruts4Q2Gu2js2YL5bFVqmkutMvqKW1v1cKLTqjAhuurrbKOSmm5z2bHLb+uovvphPNKumqx7oIXr8JlXCsor/9u6S+hsAb88MQIk5tqshmzezHB+GIr7ritLVxyGx9ra/DBI4cs8sa77usxyw7HrK/G3fb7LWwN1+qfyT8zNXO95zYrcLq/FqysvTZ3zHTFtGIM883tosxwUVcDHWbDQ6+7tMSLCi1qy17rbPPTU8sMIsdn+4p0OO9m/dvWYtO8stpSu6yuyk2DGja9c/8NLMVEQ9v2vcFNG7dvgCe9dtEWg3332ITnbLTlNTv9OOZfD1w1GW0rLv+35+DSPXjXmqO9s+BRT1445UqjzjfnR7uNydVXJx66ZoyDXHfeteNM4+xldy6572y/7ri3l29+qN+Nj6i7iaOrDn1owEOc7/DM2/1y6yqfLfvRhwefseGZwy19XbynDPvykPdtPNd7k829+PBvfyrrxxN7fv5Qq0887Csf3uqHv/Ghj36xCx/yTufAyh2Qe/4jHu0CaJcBZu97wqOg87zHvwdu0H4NVCAII8bBCAKQevGzIGcwSLrVqbB4Hpyf+yDYPAkmr4ALzGHIJijC3LFwTDE8YQrlV7r90VB5Nkyd2Xj4wSXeD4Xdm+ER0XG7ogSxAEMpQBpcWL3emY6EUGT/oBPDWEOAOTGJ2iMiE2lHvgz2yQtHiRsBDIAABBiAAPJ6Xu/UeL03po2KgbNesNgYxTYa0oA3lOLvsBdIoVwRPqFLgB4BQIAE7NGIgwQjEqvIx/YpMYSMPCQpS6lIROLwMoCMnCAtaAAFnEABB8hkK/voSU0S0oyh3OUaf+i6EurwfYscZiNXuUK9JSxrr4zlLFMggUhCM5rSnCY1q2nNa2Izm9rcJje76c1vgjOc4hwnOctpznNqcwK6o+QJHIBJU5QjU2qQZ3BeQU94tuKe+MynK/TJMH72054CBShBV+HPzw1UcXW8Yx5pGdCEquKgY5DoyQramYde1KLWgqhB/zmaCoruCaMZHWnctDgALjpUoxFV6UZFulKPftSlL+2oTGNa0zWA1As3xSlMgxhScuRUpySd6VBbutN5HrWLLOVpUlNq1KIydalI9Wk9gcopqSq1qVXV6lZpitWuehWqUQ0rWW361X1SdaLxvKpYp3rWf/Z0rEQtq1znalez0vWpd9XrXtPKg7XG1al8xWtf60rYwyLWrW3N6lsRylXHNhayfv0pWx9b0ciqFbOZ1axQOUsey252sWjNq2JJW9rJfraynv0raC9r2tMmFraDla1hZ1tb2uJWsLfNrV8lUA7fvgK4qxAuK4g7XFcY97jIXS5zlduK5KYCumyQrhqoW//d5hY3uKjdLne7693vgje84h0vectr3vOiN73qXS972+ve98I3vvKdL33ra9/74je/+t0veE2K0lU0oCj/TYMDBuxfAv83wEQZ8BgUYIAtIuAEBzaDgyEMAAVv8QwNOMBQDrAACWcYDRvu8IcxfNI0FMAAKJgwilV8YQGbwcQoZTEZZPziBaMhAhweQANAfOIc77jHNi6DSYniYwaPochDuXGIyYAAk3r4yGh4MomZ/OMyLGDH7wQAjem7UDxWUhUBVsUCmvzlhmK5yWNWAwP0uIAH6PHMYR5DmwHwZj2uOQ0EcAAAEHAAPssZDXvu859fzAYHPMDFgUYDol2cZw3/c2HRNebCo8/wZj6jQNJkuHQKKp0GBmBS02cAtaE/3cwDhNqOYB71qTHpaSIzwM4NFbV82WnJLafi1Xr+r60vKegEB5XLsOw1rs1QAFjq2gwLMAAEAEDsNSy72ckWQx3reIJnn6HajpZopbE9aRpMOwzupIG3yTDuTue0zB8ut7IHUGKJkhoADog1u8UQ73mXuos9tiQX6x3fZQJAlqzAcJTXQID/Alzg2QZ2ldMQgUomvJlnePgJCP5hNDz4nRFXQ8YrTpSC1/gBC3DwCTYeY5GTnMkgH4PFAWDySVe55WY4wIMHYIAIuByWAZc4GWg+lJur/OJnSECsc85MNRDd/+MNd/IBHsCAAkT45Ux3OtSDfgYDFN0BKpb6fLmuCj8Xe+Eo8Dq1kQz2NCyg6EbfORrSLoSzp8HPeiQ70+cM9zG8uccppzsN8h5wF6Pg7mY4O9+7IHjBj8EAmGbALAufAsWfgPEpQDzL3V1ynSsc0kI/AeW7cHBLNtTxmeZitSeP6onX3ACNxzzP52vrc7vi8wbndSVhXwbZ0wD3ZWjAgF8f9jDwPgy6F7vv2TD84XfBxENZQPF3f7vNI58Mn2/+r3OP5DAUoJJjpj4Zsu9x66OhAGrnPqw9f30hPGDfJCe/GNIfS8CfIPpkSACf2R9fWrPZzQeYc/Xjr2o0mwHu1f9ZlvEftdlRCuCfECxUCgzg/g2dm83a/xWgGLDTsulRA06gGKRcAmqgi2GgGXwgBzKg/l0gCWabAawb6UngCaYgAHzgyQmdCIKbyKHAC/bcjKkgQ2WgEBwADrqgCRIYDcpge3UZGyjAAwzF721aUVRSEYZBmRGFHh1hEoZfUbiYE3aBkqnYFA6AEnoeEnbhijVZAILhO3GhF4ZBynHZGJ5Byp1hG5ahGF4ZGbxhwMUhGiRAw2FhGOThAERZHZoBAEoZxs0ZIJKBjukhG44BIvrhhxkizB0Azg0if1FiJVriJWJiJmriJnJiJ3riJ4JiKIriKJJiKZriKaJiKqriKrL/Yiu64ivCYizK4izSYi3a4i3iYi7q4i7yYi/64i8CYzAK4zASYzEa4zEiYzIq4zIyYzM64zOywZuh4EZokc5B4zXuIgEMxQ6eAYc120YgQKJFGDaS4y2mHoDNoUY4wABwYzm6YyoG2AMg4b4tgEkhoRTWXAFsniUNgM5p4zsh4QJEgEkxm7wRxQPAEgQMgNMNAAQMZBSeQJmd3ztS5CkywAAwwEUWHYfpEUcGGOmloxZJYjg+AAIoQBfikR1FwEKim7spJFFAwIN9YwrIY0Xa5CrOo0I+QJ8tHwBw5EUWxU6mAIeNo7OxoxZBwEleTQREQB8ORQTo5NgNRZ2hQE3e7uRVlqJSFoUCIEBP/iRGioFIokCAPdgW2hwN3GNXDgBUsmREOsCOqZ1VYuVcgqIWFd1FctGDwdKDEYBO4hwEFJs2WqPLbWOf3aOdQd1QNICCsaVQMiBY2lk60uVkYiIU7puCCSSHGYBe7hxEohuuaaNjPiQVaqMfPmVU8iRRJMA4rmM7UuZrbuKbreXMNWQNDgCmkUM4HiBs8qYnlqbNDSbeJdqHheNslkM19mZyKudyMmdzOudzQmd0Sud0Umd1Wud1Ymd2aud2cmd3eud3gmd4iud4kmd5mud5omd6qud6smd7uud7wmd8yid1hgAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reported cases of Lyme disease are most common among boys aged 5 to 9 years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: United States Centers for Disease Control and Prevention. Lyme Disease Data. Available at:",
"     <a href=\"file://www.cdc.gov/lyme/stats/chartstables/incidencebyagesex.html\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://www.cdc.gov/lyme/stats/chartstables/incidencebyagesex.html",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28574=[""].join("\n");
var outline_f27_57_28574=null;
var title_f27_57_28575="Flexural atopic dermatitis";
var content_f27_57_28575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexural atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 218px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical appearance of atopic dermatitis in flexural areas of the legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_57_28575=[""].join("\n");
var outline_f27_57_28575=null;
